



# STIC Search Report

## Biotech-Chem Library

STIC Database Tracking Number: 127078

TO: Terra Gibbs  
Location: REM-2D10/2C18  
Art Unit: 1635  
Tuesday, July 13, 2004  
Case Serial Number: 10/000213

From: Paul Schulwitz  
Location: Biotech-Chem Library  
REM-1A65  
Phone: (571)272-2527

[paul.schulwitz@uspto.gov](mailto:paul.schulwitz@uspto.gov)

### Search Notes

Examiner Gibbs,

See attached results.

If you have any questions about this search feel free to contact me at any time.

Thank you for using STIC search services!

Paul Schulwitz  
Technical Information Specialist  
STIC Biotech/Chem Library  
(571)272-2527



**This Page Blank (uspto)**

Hi 03H

Schulwitz, Paul

---

From: Gibbs, Terra  
Sent: Thursday, July 01, 2004 1:53 PM  
To: Schulwitz, Paul  
Subject: Sequence search request...

Hi David,

I have another request for a score over length search:

I need a length limited nucleotide sequence search of nucleobases 1710 through 1757 of SEQ ID NO:3 in USSN 10/000,213, where the returns are rank ordered based on the score over length/ratio as we've discussed. I need the lengths limited to hits between 8 and 80 nucleotides, and I'll take as many hits as you can import into excel (64,000?), and alignments for anything above .75 on the above ratio. Hope this is clear, please call me if it's not. I also need the interference databases searched.

*Terra Cotta Gibbs, Ph.D.  
Art Unit 1635  
Remsen Building 2D10  
571-272-0758*

***This Page Blank (uspto)***

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: July 13, 2004, 11:01:34 ; Search time 0.001 Seconds  
(without alignments)  
59.424 Million cell updates/sec

Title: us-10-000-213-3

Sequence: 1 ggcgtgctgactgactgttgag.....caggagaatgcattcattc 48

Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 0.5

Searched: 46 seqs, 619 residues

Total number of hits satisfying chosen parameters: 92

Minimum DB seq length: 8  
Maximum DB seq length: 80

Post-processing: Minimum Match 0%  
Maximum Match 100%

Listing first 50 summaries

Database : rgedb:\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	14.8	30.8	18	1	AR075067
2	14.8	30.8	18	1	AR141885
3	14.4	30.0	18	1	AR336915
4	13.4	27.9	16	1	AR328438
5	12.8	26.7	16	1	AR3190
6	12.8	26.7	16	1	AR8951
7	12.8	26.7	16	1	AR202833
8	12.8	26.7	16	1	AR328439
9	12.8	26.7	16	1	BD066464
10	12.8	26.7	17	1	AX673162
11	12.8	26.7	17	1	AX733659
12	12.8	26.7	17	1	AX737062
13	11.8	24.6	15	1	AR009449
14	11.8	24.6	15	1	AR055874
15	11.8	24.6	15	1	AR113632
16	11.8	24.6	15	1	AX632925
17	11.8	24.6	15	1	BD208780
18	11.4	23.7	15	1	AR180533
19	10.4	21.7	12	1	AR013953
20	10.4	21.7	12	1	AR013953
21	10.4	21.7	12	1	AX624126
22	10.4	20.8	11	1	AX625561
23	10.4	20.8	11	1	AX628640
24	10.4	20.8	11	1	AX631547
25	10.4	20.8	13	1	AX631547
26	10.4	20.8	13	1	AR030055
27	9.8	20.4	13	1	AR030055
28	9.8	20.4	13	1	AR12840
29	9.8	20.4	13	1	AR310639
30	9.8	20.4	13	1	AX711140
31	9.4	19.6	11	1	AX470508
32	9.4	19.6	11	1	AX623937
33	9.4	19.6	11	1	AX625659

34	9.4	19.6	11	1	AX625973	ACCESSION:AX625973
35	9.4	19.6	11	1	AX626369	ACCESSION:AX626369
36	9.4	19.6	11	1	AX627679	ACCESSION:AX627679
37	9.4	19.6	11	1	AX628604	ACCESSION:AX628604
38	9.4	19.6	11	1	AX629528	ACCESSION:AX629528
39	9.4	19.6	11	1	AX630375	ACCESSION:AX630375
40	9.4	19.6	11	1	AX631358	ACCESSION:AX631358
41	9.4	19.6	12	1	AX6017	ACCESSION:AX6017
42	9.4	19.6	12	1	BD248202	ACCESSION:BD248202
43	9.4	19.6	12	1	BD248202	ACCESSION:BD248202
44	9.4	19.6	12	1	BD248202	ACCESSION:BD248202
45	9.4	19.6	12	1	BD248202	ACCESSION:BD248202
46	9.4	19.6	12	1	BD248202	ACCESSION:BD248202
47	8.8	18.3	17	1	AX733659	ACCESSION:AX733659
48	7.8	16.3	11	1	AX625561	ACCESSION:AX625561
49	7.4	15.4	15	1	AR180533	ACCESSION:AR180533
50	7.2	15.0	13	1	AX625126	ACCESSION:AX625126

## ALIGNMENTS

RESULT 1	AR075067/c	AR075067	Sequence 27 from patent US 5955306.	18 bp	DNA	linear	PAT 28-AUG-2000
LOCUS	AR075067	AR075067	GI:10001819				
DEFINITION	AR075067	AR075067	GI:10001819				
VERSION	AR075067.1	AR075067.1	GI:10001819				
KEYWORDS	Unknown.	Unknown.					
SOURCE	Unknown.	Unknown.					
ORGANISM	Unknown.	Unknown.					
REFERENCE	1. (bases 1 to 18)						
AUTHORS	Gimeno, C.J. and Errada, P.R.						
TITLE	Gene encoding proteins that interact with the tub protein						
JOURNAL	Patent: US 5955306-A 27 21-SEP-1999;						
FEATURES	Location/Qualifiers						
source	1..18						
	/organism="unknown"						
	/mol_type="unassigned DNA"						

Query Match 30.8%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 3.2;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1714 GCTGACTGATGTTGAGG 1731  
DB 18 GCTGACTGACGCTGAGG 1

RESULT 2  
AR141885/c  
LOCUS AR141885  
DEFINITION Sequence 27 from patent US 6147192.  
ACCESSION AR141885  
VERSION AR141885.1  
KEYWORDS GI:15101401  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1. (bases 1 to 18)  
AUTHORS Gimeno, C.J. and Errada, P.R.  
Tub interactor (TI) polypeptides and uses therefor  
Patent: US 6147192-A 27 14-NOV-2000;  
FEATURES Location/Qualifiers  
1..18  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 30.8%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 3.2;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1714 GCTGACTGATGTTGAGG 1731  
Db 18 GCTGACTGACGCTGAGG 1

RESULT 3  
AR336915/c 18 bp DNA linear PAT 17-AUG-2003  
LOCUS AR336915  
DEFINITION Sequence 23 from patent US 6566131.  
ACCESSION AR336915  
VERSION AR336915.1 GI:33722769  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Cowsett,L.M.  
TITLE Antisense modulation of Smad6 expression  
JOURNAL Patent: US 6566131-A 23 20-MAY-2003;  
FEATURES Location/Qualifiers  
source 1..18  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 30.0%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 3.8;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1723 TGTTCAGCGAACAACAC 1738  
Db 18 TGTTCAGCGAACAACAC 3

RESULT 4  
AR328438 16 bp RNA linear PAT 17-AUG-2003  
LOCUS AR328438  
DEFINITION Sequence 5840 from patent US 6566127.  
ACCESSION AR328438  
VERSION AR328438.1 GI:33714246  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions  
related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6566127-A 5840 20-MAY-2003;  
FEATURES Location/Qualifiers  
source 1..16  
/organism="unknown"  
/mol\_type="unassigned RNA"

Query Match 27.9%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 5.4;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1715 CTGACGTGATGTTGAG 1729  
Db 2 CTGACGTGATGTTGAG 16

RESULT 5  
AA5190/c 16 bp DNA linear PAT 07-MAR-1997  
LOCUS AA5190  
DEFINITION Sequence 67 from Patent WO9517507.  
ACCESSION AA5190  
VERSION AA5190.1 GI:2299685  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1 (bases 1 to 16)

AUTHORS Brysch,W., Schlingensiepen,K., Schlingensiepen,R. and  
Schlingensiepen,G.  
TITLE ANTISENSE NUCLEIC ACIDS FOR THE PREVENTION AND TREATMENT OF  
JOURNAL DISORDERS IN WHICH EXPRESSION OF C-erbB PLAYS A ROLE  
BIOCHEMISTIK GES (DE)  
COMMENT Patent: WO 9517507-A 67 29-JUN-1995;  
Other publication AU 1313095 950710.  
FEATURES Location/Qualifiers  
source 1..16  
/organism="unidentified"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32644"

Query Match 26.7%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 6.9;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1723 TGTTCAGCGAACAACAC 1738  
Db 16 TGTTCAGCGAACAACAC 1

RESULT 6  
A88951/c 16 bp DNA linear PAT 22-JAN-2000  
LOCUS A88951  
DEFINITION Sequence 1099 from Patent WO9833904.  
ACCESSION A88951  
VERSION A88951.1 GI:6737521  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Brysch,W. and Schlingensiepen,K.  
TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD  
JOURNAL Patent: WO 9833904-A 1099 06-AUG-1998;  
BIOCHEMISTIK GES (DE); BRYSCH WOLFGANG (DE)  
FEATURES Location/Qualifiers  
source 1..16  
/organism="unidentified"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32644"

Query Match 26.7%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 6.9;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1723 TGTTCAGCGAACAACAC 1738  
Db 16 TGTTCAGCGAACAACAC 1

RESULT 7  
AR202833/c 16 bp DNA linear PAT 20-JUN-2002  
LOCUS AR202833  
DEFINITION Sequence 67 from patent US 6365345.  
ACCESSION AR202833  
VERSION AR202833.1 GI:21499063  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Brysch,W., Schlingensiepen,K.-H., Schlingensiepen,R. and  
Schlingensiepen,G.-F.  
TITLE Antisense nucleic acids for the prevention and treatment of  
disorders in which expression of c-erbB plays a role  
JOURNAL Patent: US 6365345-A 67 02-APR-2002;  
FEATURES Location/Qualifiers  
source 1..16  
/organism="unknown"  
/mol\_type="unassigned DNA"

```

Query Match      26.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 6.9;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1723 TGTTCAGGGAACAGAC 1738
      |||||
      16 TGTTCAGGGAACAGAC 1

Db

RESULT 8
AR328439      AR328439      16 bp      RNA      linear      PAT 17-AUG-2003
LOCUS      Sequence 5841 from patent US 6566127.
DEFINITION      AR328439
ACCESSION      AR328439
VERSION      AR328439.1 GI:33714247
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unknown.
REFERENCE      Unclassified.
AUTHORS      1 (bases 1 to 16)
Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.
TITLE      Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL      Patent: US 6566127-A 5841 20-MAY-2003;
FEATURES      Location/Qualifiers
source      1..16
/mol_type="unassigned RNA"
/mol_type="unassigned RNA"

Query Match      26.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 6.9;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1717 GACTGATGTTGAGCA 1732
      |||||
      1 GAGTGATGTTGAGCA 16

Db

RESULT 9
BD066464/c      BD066464      16 bp      DNA      linear      PAT 27-AUG-2002
LOCUS      An antisense oligonucleotide preparation method.
DEFINITION      BD066464
ACCESSION      BD066464
VERSION      BD066464.1 GI:22612067
KEYWORDS      JP 2001511000-A/1099.
SOURCE      unidentified
ORGANISM      unidentified
REFERENCE      1 (bases 1 to 16)
Schlingensiepen, K.H. and Brysch, W.
AUTHORS      An antisense oligonucleotide preparation method
TITLE      Patent: JP 2001511000-A 1099 07-AUG-2001;
JOURNAL      BIOLOGISCHES GESAMTSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT      OS Unknown
PN      JP 2001511000-A/1099
PD      07-AUG-2001
PF      30-JAN-1998 JP 199852533
PR      31-JAN-1997 EP 97101531.8
PI      KARL HERMANN SCHLINGENSIEPEN, WOLFGANG BRYSCH
PC      C12N15/11, C07H21/04, A61K31/70
CC      An antisense oligonucleotide preparation method FH Key
FEATURES      Location/Qualifiers
FT      source      1..16
/mol_type="unassigned RNA"
/mol_type="unassigned RNA"

FEATURES      source      1..16
Location/Qualifiers
/mol_type="unassigned RNA"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

Query Match      26.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 6.9;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

Qy      1723 TGTTCAGGGAACAGAC 1738
      |||||
      16 TGTTCAGGGAACAGAC 1

Db

RESULT 10
AX673162/c      AX673162      17 bp      DNA      linear      PAT 27-MAR-2003
LOCUS      Sequence 1607 from Patent WO03004526.
DEFINITION      AX673162
ACCESSION      AX673162
VERSION      AX673162.1 GI:29331510
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM      Homo sapiens
REFERENCE      1
Telerman, A., Amson, R. and Tuijinder, M.
TITLE      Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL      Patent: WO 03004526-A 1607 16-JAN-2003;
FEATURES      Molecular Engines Laboratories (FR)
source      1..17
/mol_type="unassigned DNA"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Qy      1737 ACAGAGAAATGCATC 1752
      |||||
      16 ACAGAGAAATGCATC 1

Db

RESULT 11
AX733659      AX733659      17 bp      DNA      linear      PAT 08-MAY-2003
LOCUS      Sequence 5293 from Patent WO03025175.
DEFINITION      AX733659
ACCESSION      AX733659
VERSION      AX733659.1 GI:30513002
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM      Homo sapiens
REFERENCE      1
Bukayocsa, Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS      Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE      Telerman, A., Amson, R. and Tuijinder, M.
JOURNAL      Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
COMMENT      Patent: WO 03025175-A 5293 27-MAR-2003;
JOURNAL      Molecular Engines Laboratories (FR)
FEATURES      Location/Qualifiers
FT      source      1..17
/mol_type="unassigned DNA"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Qy      1731 GATCAGCAGAGAAA 1746
      |||||
      1 GATCAGCAGAGAAA 16

Db

RESULT 12

```

```

AX737062/c  AX737062 17 bp DNA linear PAT 08-MAY-2003
LOCUS      Sequence 2652 from Patent WO03025177.
DEFINITION AX737062
ACCESSION  AX737062
VERSION    AX737062.1 GI:30516350
KEYWORDS
SOURCE
ORGANISM   Homo sapiens (human)
            Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS    Telerman,A., Ameon,R. and Tuijinder,M.
TITLE      Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
JOURNAL    Patent: WO 03025177-A 2652 27-MAR-2003;
FEATURES
source
            1. .17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      26.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.1;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1737 ACAGGAGAAATGCATC 1752
Db      16 ATAGGAGAAATGCATC 1

RESULT 13
LOCUS      AR009449 15 bp DNA linear PAT 04-DEC-1998
DEFINITION Sequence 5 from patent US 5756294.
ACCESSION  AR009449
VERSION    AR009449.1 GI:3968254
KEYWORDS
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 15)
AUTHORS    White,M.B. and Sadzewicz,L.K.
TITLE      Susceptibility mutation for breast and ovarian cancer
JOURNAL    Patent: US 5756294-A 5 26-MAY-1998;
FEATURES
source
            1. .15
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      24.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 10;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1731 GAACAGACAGAGAGA 1745
Db      1 GAACACAGAGAGAGA 15

RESULT 14
LOCUS      AR055874 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 78 from patent US 5837542.
ACCESSION  AR055874
VERSION    AR055874.1 GI:5981451
KEYWORDS
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 15)
AUTHORS    Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
            Draper,K.G.

```

```

TITLE      Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL    Patent: US 5837542-A 78 17-NOV-1998;
FEATURES
source
            1. .15
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      24.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 10;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1724 GTTGAGGGAACAGAC 1738
Db      15 GTCCAGGGAACAGAC 1

RESULT 15
LOCUS      AR113632 15 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 78 from patent US 6132967.
ACCESSION  AR113632
VERSION    AR113632.1 GI:14093954
KEYWORDS
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 15)
AUTHORS    Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
            Draper,K.G.
TITLE      Ribozyme treatment of diseases or conditions related to levels of
            intercellular adhesion molecule-1 (ICAM-1)
JOURNAL    Patent: US 6132967-A 78 17-OCT-2000;
FEATURES
source
            1. .15
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      24.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 10;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1724 GTTGAGGGAACAGAC 1738
Db      15 GTCCAGGGAACAGAC 1

RESULT 16
LOCUS      AX632925 15 bp RNA linear PAT 21-FEB-2003
DEFINITION Sequence 64 from Patent EP1260586.
ACCESSION  AX632925
VERSION    AX632925.1 GI:28468539
KEYWORDS
SOURCE     unidentified
ORGANISM   unidentified
REFERENCE  1
AUTHORS    Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Dierenzo,A.,
            Karpetsky,A., Draper,K.G., Kisch,K., Matulic-Adamc,J.,
            McSwiggen,J.A., Kodak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Swedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
            Wolf,T.
TITLE      Method and reagent for inhibiting the expression of disease related
            genes
JOURNAL    Patent: EP 1260586-A 64 27-NOV-2002;
FEATURES
source
            1. .15
            /organism="unidentified"
            /mol_type="unassigned RNA"
            /db_xref="taxon:32644"

Query Match      24.6%; Score 11.8; DB 1; Length 15;

```

Best Local Similarity 86.7%; Pred. No. 10;  
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1724 GTTGAGGAAACAGAC 1738  
|||||  
15 GTCACGAGAACAGAC 1

Db 15 GTCACGAGAACAGAC 1

RESULT 17  
BD208780/c 15 bp RNA linear PAT 17-JUN-2003  
LOCUS Enzymatic nucleic acid treatment of diseases or conditions related  
DEFINITION to hepatitis C virus infection.  
ACCESSION BD208780  
VERSION BD208780.1 GI:33018550  
KEYWORDS JP 2002512791-A/2370.  
SOURCE unidentified  
ORGANISM unclassified.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Blatt, L., Meswiggen, J. A., Roberts, E., Pavco, P. A. and Macejak, D.  
TITLE Enzymatic nucleic acid treatment of diseases or conditions related  
JOURNAL to hepatitis C virus infection  
PATENT: JP 2002512791-A 2370 08-MAY-2002;  
RIBOZYME PHARMACEUTICALS INC  
OS Hepatitis virus (hepatitis C virus)  
PN JP 2002512791-A/2370  
PD 08-MAY-2002  
PR 26-APR-1999 JP 2000545991  
PR 27-APR-1998 US 60/083217, 18-SEP-1998 US 60/100842 PR  
25-FEB-1999 US 09/257608, 23-MAR-1999 US 09/274553 PI  
LAWRENCE BLATT, JAMES A MCSWIGGEN, ELISABETH ROBERTS, PAMELA A PI  
PAVCO,  
PI DENNIS MACEJAK  
PC C12N9/00, A61K31/7105, A61K38/21, A61K48/00, A61P31/12, C12N15/09,  
PC A61K37/66,  
PC C12N15/00  
CC Enzymatic nucleic acid treatment of diseases or conditions CC  
CC related to  
FH hepatitis C virus infection.  
FT Key Location/Qualifiers  
FT source 1..15 Location/Qualifiers  
FT virus) /organism="Hepatitis virus (hepatitis C FT

FEATURES  
source Location/Qualifiers  
1..15 /organism="unclassified"  
/mol\_type="genomic RNA"  
/db\_xref="taxon:32644"

Query Match 24.6%; Score 11.8; DB 1; Length 15;  
Best Local Similarity 86.7%; Pred. No. 10;  
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1714 GGTGACTGATGTGA 1728  
|||||  
15 GCTGACTGATGTGA 1

Db 15 GCTGACTGATGTGA 1

RESULT 18  
ARI80533/c 15 bp DNA linear PAT 20-APR-2002  
LOCUS ARI80533  
DEFINITION Sequence 601 from patent US 6333152.  
ACCESSION ARI80533  
VERSION ARI80533.1 GI:20222566  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Vogelstein, B., Kinzler, K. W., Zhang, L. and Zhou, W.  
TITLE Gene expression profiles in normal and cancer cells  
JOURNAL Patent: US 6333152-A 601 25-DEC-2001;

FEATURES  
source Location/Qualifiers  
1..15 /organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 23.7%; Score 11.4; DB 1; Length 15;  
Best Local Similarity 92.3%; Pred. No. 12;  
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1739 AGGAGAAATGCAT 1751  
|||||  
14 AGGAGCAATGCAT 2

Db 14 AGGAGCAATGCAT 2

RESULT 19  
AR013953 12 bp DNA linear PAT 05-DEC-1998  
LOCUS AR013953  
DEFINITION Sequence 8 from patent US 5773226.  
ACCESSION AR013953  
VERSION AR013953.1 GI:3971407  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 12)  
AUTHORS Millan, J. L.  
TITLE Recombinant calf intestinal alkaline phosphatase  
JOURNAL Patent: US 5773226-A 8 30-JUN-1998;  
FEATURES Location/Qualifiers  
source 1..12 /organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 21.7%; Score 10.4; DB 1; Length 12;  
Best Local Similarity 91.7%; Pred. No. 16;  
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1733 ACAGACAGAGAGA 1744  
|||||  
1 ACAGACAGAGAGA 12

Db 1 ACAGACAGAGAGA 12

RESULT 20  
I79681 12 bp DNA linear PAT 10-JUN-1998  
LOCUS I79681  
DEFINITION Sequence 8 from patent US 5707853.  
ACCESSION I79681  
VERSION I79681.1 GI:3207971  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 12)  
AUTHORS Millan, J. L.  
TITLE Nucleic acid encoding calf intestinal alkaline phosphatase  
JOURNAL Patent: US 5707853-A 8 13-JUN-1998;  
FEATURES Location/Qualifiers  
source 1..12 /organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 21.7%; Score 10.4; DB 1; Length 12;  
Best Local Similarity 91.7%; Pred. No. 16;  
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1733 ACAGACAGAGAGA 1744  
|||||  
1 ACAGACAGAGAGA 12

Db 1 ACAGACAGAGAGA 12

RESULT 21  
AX624126 11 bp DNA linear PAT 21-FEB-2003  
LOCUS AX624126

```

DEFINITION Sequence 1167 from Patent WO02053774.
ACCESSION AX624126
VERSION AX624126.1 GI:28452067
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 1167 11-JUL-2002;
          Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
          1. .11
          /organism="Homo sapiens"
          /mol_type="unassigned DNA"
          /db_xref="taxon:9606"

Query Match          20.8%; Score 10; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 18;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1715 CTGACTGATG 1724
Db 1 CTGACTGATG 10

RESULT 22
AX625561/c          11 bp DNA linear PAT 21-FEB-2003
LOCUS Sequence 2602 from Patent WO02053774.
DEFINITION AX625561
ACCESSION AX625561
VERSION AX625561.1 GI:28453502
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 2602 11-JUL-2002;
          Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
          1. .11
          /organism="Homo sapiens"
          /mol_type="unassigned DNA"
          /db_xref="taxon:9606"

Query Match          20.8%; Score 10; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 18;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1747 TGCATCCATT 1756
Db 11 TGCATCCATT 2

RESULT 23
AX628640/c          11 bp DNA linear PAT 21-FEB-2003
LOCUS Sequence 5681 from Patent WO02053774.
DEFINITION AX628640
ACCESSION AX628640
VERSION AX628640.1 GI:28456678
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin

```

```

JOURNAL Patent: WO 02053774-A 5681 11-JUL-2002;
          Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
          1. .11
          /organism="Homo sapiens"
          /mol_type="unassigned DNA"
          /db_xref="taxon:9606"

Query Match          20.8%; Score 10; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 18;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1731 GAACAGACAG 1740
Db 10 GAACAGACAG 1

RESULT 24
AX631547          11 bp DNA linear PAT 21-FEB-2003
LOCUS Sequence 8589 from Patent WO02053774.
DEFINITION AX631547
ACCESSION AX631547
VERSION AX631547.1 GI:28459613
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 8589 11-JUL-2002;
          Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
          1. .11
          /organism="Homo sapiens"
          /mol_type="unassigned DNA"
          /db_xref="taxon:9606"

Query Match          20.8%; Score 10; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 18;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1715 CTGACTGATG 1724
Db 1 CTGACTGATG 10

RESULT 25
A25126          13 bp DNA linear PAT 21-SEP-1995
LOCUS Synthetic EcorI adaptor.
DEFINITION A25126
ACCESSION A25126
VERSION A25126.1 GI:1247054
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
          artificial sequences.
REFERENCE 1 (bases 1 to 13)
AUTHORS
JOURNAL Patent: DE 3925748-A 5 11-APR-1991;
          Location/Qualifiers
FEATURES
source
          1. .13
          /organism="synthetic construct"
          /mol_type="unassigned DNA"
          /db_xref="taxon:32630"

Query Match          20.8%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1746 ATGCATCCAT 1755

```

Db 3 ATGCATCATC 12

RESULT 26  
LOCUS AR030055/c 13 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 244 from patent US 5861244.  
ACCESSION AR030055  
VERSION AR030055.1 GI:5943269  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.

REFERENCE 1 (bases 1 to 13)  
AUTHORS Wang, C.-G. and Hepburn, A.G.  
TITLE Genetic sequence assay using DNA triple strand formation  
JOURNAL Patent: US 5861244-A 244 19-JAN-1999;  
FEATURES  
source  
Location/Qualifiers  
1. .13  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 20.4%; Score 10; DB 1; Length 13;  
Best Local Similarity 100.0%; Pred. No. 19;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1727 GAGGGAACAG 1736  
12 GAGGGAACAG 3

Db 12 GAGGGAACAG 3

RESULT 27  
LOCUS 121833 13 bp DNA linear PAT 07-OCT-1996  
DEFINITION Sequence 10 from patent US 5525468.  
ACCESSION 121833  
VERSION 121833.1 GI:1602187  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.

REFERENCE 1 (bases 1 to 13)  
AUTHORS McSwigen, J.A.  
TITLE Assay for Ribozyme target site  
JOURNAL Patent: US 5525468-A 10 11-JUN-1996;  
FEATURES  
source  
Location/Qualifiers  
1. .13  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 20.4%; Score 9.8; DB 1; Length 13;  
Best Local Similarity 84.6%; Pred. No. 21;  
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1737 ACAGAGAATGC 1749  
1 ACTGAGAAAGGC 13

Db 1 ACTGAGAAAGGC 13

RESULT 28  
LOCUS 121840 13 bp DNA linear PAT 07-OCT-1996  
DEFINITION Sequence 17 from patent US 5525468.  
ACCESSION 121840  
VERSION 121840.1 GI:1602194  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.

REFERENCE 1 (bases 1 to 13)  
AUTHORS McSwigen, J.A.  
TITLE Assay for Ribozyme target site  
JOURNAL Patent: US 5525468-A 17 11-JUN-1996;

FEATURES  
source  
Location/Qualifiers  
1. .13  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 20.4%; Score 9.8; DB 1; Length 13;  
Best Local Similarity 84.6%; Pred. No. 21;  
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1737 ACAGAGAATGC 1749  
13 ACTGAGAAAGGC 1

Db 13 ACTGAGAAAGGC 1

RESULT 29  
LOCUS AR310639/c 13 bp DNA linear PAT 12-JUN-2003  
DEFINITION Sequence 3 from patent US 6559125.  
ACCESSION AR310639  
VERSION AR310639.1 GI:31703742  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.

REFERENCE 1 (bases 1 to 13)  
AUTHORS Deryan, P.B., Wurtz, N. and Chang, A.  
TITLE Polyamide-alkylator conjugates and related products and method  
JOURNAL Patent: US 6559125-A 3 06-MAY-2003;  
FEATURES  
source  
Location/Qualifiers  
1. .13  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 20.4%; Score 9.8; DB 1; Length 13;  
Best Local Similarity 84.6%; Pred. No. 21;  
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1741 GAGAAATGCATCC 1753  
13 GAGAGCTGCATCC 1

Db 13 GAGAGCTGCATCC 1

RESULT 30  
LOCUS AX711140 13 bp DNA linear PAT 11-APR-2003  
DEFINITION Sequence 440 from Patent EP1288296.  
ACCESSION AX711140  
VERSION AX711140.1 GI:29787521  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
artificial sequences.

REFERENCE 1  
AUTHORS Draper, K.G., McSwigen, J.A., Holecsek, J.J., Dudycz, L.W.,  
Macejak, D.G. and Mamone, J.A.  
TITLE Method and reagent for inhibiting HBV viral replication  
JOURNAL Patent: EP 1288296-A 440 05-MAR-2003;  
FEATURES  
source  
Location/Qualifiers  
1. .13  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="Nucleic Acid"

Query Match 20.4%; Score 9.8; DB 1; Length 13;  
Best Local Similarity 84.6%; Pred. No. 21;  
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1737 ACAGAGAATGC 1749  
1 ACTGAGAAAGGC 13

Db 1 ACTGAGAAAGGC 13

```
RESULT 31
AX470508      11 bp   DNA      linear   PAT 09-AUG-2002
LOCUS         Sequence 85 from Patent WO02053773.
DEFINITION    AX470508
ACCESSION     AX470508
VERSION       AX470508.1  GI:22205633
KEYWORDS
SOURCE        Homo sapiens (human)
ORGANISM      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE     1
AUTHORS      Hofmann,K., Conradt,M. and Petersohn,D.
TITLE        Method for determining skin stress or skin ageing in vitro
JOURNAL      Patent: WO 02053773-A 85 11-JUL-2002;
              HENKEL KGAA (DE)
FEATURES
  source      Location/Qualifiers
              1..11
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"
Query Match   19.6%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 23;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1712 CTGCTGACTGA 1722
Db 1 CTGCTGACTGA 11

RESULT 32
AX623937/c    11 bp   DNA      linear   PAT 21-FEB-2003
LOCUS         Sequence 978 from Patent WO02053774.
DEFINITION    AX623937
ACCESSION     AX623937
VERSION       AX623937.1  GI:28451878
KEYWORDS
SOURCE        Homo sapiens (human)
ORGANISM      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE     1
AUTHORS      Petersohn,D., Conradt,M. and Hofmann,K.
TITLE        Method for determining homeostasis of the skin
JOURNAL      Patent: WO 02053774-A 978 11-JUL-2002;
              Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
  source      Location/Qualifiers
              1..11
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"
Query Match   19.6%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 23;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1747 TGCATTCATTC 1757
Db 11 TGCATTCATTC 1

RESULT 33
AX625659      11 bp   DNA      linear   PAT 21-FEB-2003
LOCUS         Sequence 2700 from Patent WO02053774.
DEFINITION    AX625659
ACCESSION     AX625659
VERSION       AX625659.1  GI:28453600
KEYWORDS
SOURCE        Homo sapiens (human)
ORGANISM      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
```

```
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE     1
AUTHORS      Petersohn,D., Conradt,M. and Hofmann,K.
TITLE        Method for determining homeostasis of the skin
JOURNAL      Patent: WO 02053774-A 2700 11-JUL-2002;
              Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
  source      Location/Qualifiers
              1..11
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"
Query Match   19.6%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 23;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1743 GAAATGCATCC 1753
Db 1 GAAATGCATCC 11

RESULT 34
AX625973      11 bp   DNA      linear   PAT 21-FEB-2003
LOCUS         Sequence 3014 from Patent WO02053774.
DEFINITION    AX625973
ACCESSION     AX625973
VERSION       AX625973.1  GI:28454011
KEYWORDS
SOURCE        Homo sapiens (human)
ORGANISM      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE     1
AUTHORS      Petersohn,D., Conradt,M. and Hofmann,K.
TITLE        Method for determining homeostasis of the skin
JOURNAL      Patent: WO 02053774-A 3014 11-JUL-2002;
              Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
  source      Location/Qualifiers
              1..11
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"
Query Match   19.6%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 23;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1718 ACTGATCTTGA 1728
Db 1 ACTGATCTTGA 11

RESULT 35
AX626369      11 bp   DNA      linear   PAT 21-FEB-2003
LOCUS         Sequence 3410 from Patent WO02053774.
DEFINITION    AX626369
ACCESSION     AX626369
VERSION       AX626369.1  GI:28454407
KEYWORDS
SOURCE        Homo sapiens (human)
ORGANISM      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE     1
AUTHORS      Petersohn,D., Conradt,M. and Hofmann,K.
TITLE        Method for determining homeostasis of the skin
JOURNAL      Patent: WO 02053774-A 3410 11-JUL-2002;
              Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
  source      Location/Qualifiers
              1..11
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"
```

```

Query Match      19.6%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 23;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1720 TGATGTTGAGG 1730
      ||| ||| ||| ||| |||
Db      1 TGGTGTTGAGG 11

RESULT 36
LOCUS      AX627679
DEFINITION Sequence 4720 from Patent WO02053774.
ACCESSION  AX627679
VERSION     AX627679.1 GI:28455717
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS     Petersohn,D., Conradt,M. and Hofmann,K.
TITLE        Method for determining homeostasis of the skin
JOURNAL      Patent: WO 02053774-A 4720 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
            1..11
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      19.6%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 23;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1738 CAGGAGAAATG 1748
      ||| ||| ||| ||| |||
Db      1 CAGGAGAAATG 11

RESULT 37
LOCUS      AX628604
DEFINITION Sequence 5645 from Patent WO02053774.
ACCESSION  AX628604
VERSION     AX628604.1 GI:28456642
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS     Petersohn,D., Conradt,M. and Hofmann,K.
TITLE        Method for determining homeostasis of the skin
JOURNAL      Patent: WO 02053774-A 5645 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
            1..11
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      19.6%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 23;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1712 CTGCTGACTGA 1722
      ||| ||| ||| ||| |||
Db      1 CTGCTGACTGA 11

RESULT 38

```

```

AX629528/c
LOCUS      AX629528
DEFINITION Sequence 6569 from Patent WO02053774.
ACCESSION  AX629528
VERSION     AX629528.1 GI:28457566
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS     Petersohn,D., Conradt,M. and Hofmann,K.
TITLE        Method for determining homeostasis of the skin
JOURNAL      Patent: WO 02053774-A 6569 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
            1..11
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      19.6%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 23;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1745 AATGCATCCAT 1755
      ||| ||| ||| ||| |||
Db      11 AATGCATCCAT 11

RESULT 39
LOCUS      AX630375
DEFINITION Sequence 7416 from Patent WO02053774.
ACCESSION  AX630375
VERSION     AX630375.1 GI:28458413
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS     Petersohn,D., Conradt,M. and Hofmann,K.
TITLE        Method for determining homeostasis of the skin
JOURNAL      Patent: WO 02053774-A 7416 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
            1..11
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      19.6%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 23;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1730 GGAACAGACAG 1740
      ||| ||| ||| ||| |||
Db      1 GGAACAGACAG 11

RESULT 40
LOCUS      AX631358/c
DEFINITION Sequence 8400 from Patent WO02053774.
ACCESSION  AX631358
VERSION     AX631358.1 GI:28459404
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE

```

AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.  
TITLE Method for determining homeostasis of the skin  
JOURNAL Patent: WO 02053774-A 8400 11-JUL-2002;  
Henkel Kommanditgesellschaft auf Aktien (DE)

FEATURES  
source  
1. .11  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 19.6%; Score 9.4; DB 1; Length 11;  
Best Local Similarity 90.9%; Pred. No. 23;  
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1747 TGCATCCATTC 1757  
Db 11 TGCATTCATTC 1

RESULT 41  
LOCUS A36017 12 bp DNA linear PAT 04-MAR-1997  
DEFINITION Sequence 16 from Patent EP0564801.  
ACCESSION A36017  
VERSION A36017.1 GI:2293645  
KEYWORDS  
SOURCE .  
ORGANISM unidentified  
unclassified.

REFERENCE 1 (bases 1 to 12)  
AUTHORS Sommergruber,W.D., Auer,H., Blaas,D.D., Frasel,L., Hartmuth,K.D.,  
Kuechler,E.P., Kowalski,H., Liebig,H.D., Skern,T.D. and  
Ziegler,G.S.  
TITLE Analysis of host cell shut-off  
JOURNAL Patent: BP 0564801-A 16 13-OCT-1993;  
BOEHRINGER INGELHEIM INT (DE)  
COMMENT Other publication DE 4206769 930909  
Other publication JP 6197799 940719  
Other publication CA 2090834 930905  
Other publication DE 4217929 931202.

FEATURES  
source  
1. .12  
/organism="unidentified"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32644"

Query Match 19.6%; Score 9.4; DB 1; Length 12;  
Best Local Similarity 90.9%; Pred. No. 23;  
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1747 TGCATCCATTC 1757  
Db 11 TTCATCCATTC 1

RESULT 42  
LOCUS BD248202 12 bp DNA linear PAT 17-JUL-2003  
DEFINITION Short-chain oligonucleotide for inhibiting VEGF expression.  
ACCESSION BD248202  
VERSION BD248202.1 GI:33057972  
KEYWORDS JP 2002524038-A/21.  
SOURCE synthetic construct  
ORGANISM artificial sequences.

REFERENCE 1 (bases 1 to 12)  
AUTHORS Uhlmann,E., Peyman,A., Bitonti,A. and Woessner,R.  
TITLE Short-chain oligonucleotide for inhibiting VEGF expression  
JOURNAL Patent: JP 2002524038-A 21 06-AUG-2002;  
AVENTIS PHARMA DEUTSCHLAND GMBH  
COMMENT OS Artificial Sequence  
PN JP 2002524038-A/21  
PD 06-AUG-2002

PF 29-JUL-1999 JP 2000563768  
PI 07-AUG-1998 EP 98114853.9  
PR EUDEN UHLMANN,ANUSCHIRMAN PEYMAN,ALAN BITONTI,RICHARD WOESSNER  
PC C12N15/09,A61K31/711,A61K31/715,A61K31/712,A61K31/7125 PC  
A61K48/00,A61P9/00  
PC A61P13/12,A61P17/16,A61P27/02,A61P29/00,A61P35/00,A61P43/00,  
PC C12N15/00  
CC Description of Artificial Sequence: Antisense FH Key  
Location/Qualifiers  
FT source 1. .12  
/organism='Artificial Sequence'.  
Location/Qualifiers  
1. .12  
/organism="synthetic construct"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32630"

FEATURES  
source  
1. .12  
/organism="synthetic construct"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32630"

Query Match 19.6%; Score 9.4; DB 1; Length 12;  
Best Local Similarity 90.9%; Pred. No. 23;  
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1736 GACAGAGAAA 1746  
Db 1 GACAGCAGAAA 11

RESULT 43  
LOCUS E07501 12 bp DNA linear PAT 29-SEP-1997  
DEFINITION Synthetic DNA for probe.  
ACCESSION E07501  
VERSION E07501.1 GI:2175639  
KEYWORDS JP 1994133799-A/10.  
SOURCE unidentified  
unclassified.

REFERENCE 1 (bases 1 to 12)  
AUTHORS Yamashita,K., Yamamoto,T. and Mori,H.  
TITLE ANALYSIS OF HUMAN HERPES VIRUS 6 TYPE @ (3754/24) HHV-6) DNA AND  
DISCRIMINATION OF SUB-TYPE  
JOURNAL Patent: JP 1994133799-A 10 17-MAY-1994;  
INTERNATL REAGENTS CORP  
COMMENT OS None  
OC Artificial sequences.  
PN JP 1994133799-A/10  
PD 17-MAY-1994  
PF 27-OCT-1992 JP 1992311416  
PI YAMASHITA KOICHI, YAMAMOTO TAKESHI, MORI HIROYUKI PC  
C12Q1/68,C12Q1/68,C12N15/11,C12N15/38;  
CC strandedness: Single;  
CC topology: linear;  
CC hypothetical: No;  
CC anti-sense: No;  
FH Key  
FT source 1. .12  
/organism='Artificial sequences'.  
Location/Qualifiers  
1. .12  
/organism="unidentified"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32644"

FEATURES  
source  
1. .12  
/organism="unidentified"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32644"

Query Match 19.6%; Score 9.4; DB 1; Length 12;  
Best Local Similarity 90.9%; Pred. No. 23;  
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1744 AATGATATCA 1754  
Db 2 AATGATATCA 12

RESULT 44

```

E07516/c
LOCUS      E07516      12 bp      DNA      linear      PAT 29-SEP-1997
DEFINITION Synthetic DNA for probe.
ACCESSION E07516
VERSION   E07516.1 GI:2175653
KEYWORDS  JP 1994133799-A/25.
SOURCE    unidentified
ORGANISM  unidentified
REFERENCE 1 (bases 1 to 12)
AUTHORS   Yamaniishi,K., Yamamoto,T. and Mori,H.
TITLE     ANALYSIS OF HUMAN HERPES VIRUS 6 TYPE @ (3754/24) HHV-6) DNA AND
          DISCRIMINATION OF SUB-TYPE
          Patent: JP 1994133799-A 25 17-MAY-1994;
JOURNAL   INTERNATL REAGENTS CORP
COMMENT   OS None
          OC Artificial sequences.
          PN JP 1994133799-A/25
          PD 17-MAY-1994
          PP 27-OCT-1992 JP 1992311416
          PI YAMANISHI KOICHI, YAMAMOTO TAKESHI, MORI HIROYUKI PC
          CI2Q1/68, CI2Q1/68, CI2N15/11, CI2N15/38;
          CC strandedness: Single;
          CC topology: linear;
          CC hypothetical: No;
          CC anti-sense: Yes;
          FH Key
          FT source
          Location/Qualifiers
          source
            1..12
            /organism='Artificial sequences'
            /mol_type='genomic DNA'
            /db_xref='taxon:32644'

Query Match      19.6%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 23;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1744 AAATGCATCCA 1754
Db      11 AAATGATATCCA 1

RESULT 45
LOCUS      I24583      12 bp      DNA      linear      PAT 07-OCT-1996
DEFINITION Sequence 11 from patent US 5545526.
ACCESSION  I24583
VERSION    I24583.1 GI:1604453
KEYWORDS
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 12)
AUTHORS    Baxter-Lowe,L,Ann.
TITLE      Method for HLA Typing
JOURNAL    Patent: US 5545526-A 11 13-AUG-1996;
FEATURES   Location/Qualifiers
            1..12
            /organism='unknown'
            /mol_type='unassigned DNA'

Query Match      19.6%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 23;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1730 GGAACGACGAG 1740
Db      12 GGAACGACGAG 2

```

```

RESULT 46
LOCUS      BD064791      12 bp      DNA      linear      PAT 27-AUG-2002
DEFINITION Method for detecting the extent of binding of transcriptional
ACCESSION  BD064791
VERSION    BD064791.1 GI:22610394
KEYWORDS   JP 2001275678-A/3
SOURCE     synthetic construct
ORGANISM   synthetic construct
REFERENCE  1 (bases 1 to 12)
AUTHORS    Kishimoto,T., Niwa,S., Mori,Y., Sachiyo, Minaki, Fukushima,R. and
          Nishikawa,K.
TITLE      Method for detecting the extent of binding of transcriptional
          regulatory protein to oligoDNA
          Patent: JP 2001275678-A 3 09-OCT-2001;
          SUMITOMO ELECTRIC INDUSTRIES LTD
JOURNAL    OS Artificial Sequence
COMMENT    PN JP 2001275678-A/3
          PD 09-OCT-2001 JP 2000096306
          PP 31-MAR-2000 JP 2000096306
          PI TOSHIHIKO KISHIMOTO,SHINICHIRO NIWA,YUKO MORI,SACHIYO PI
          MIMAKI,REI FUKUSHIMA,
          PI KAZUKO NISHIKAWA
          PC CI2N15/09, CI2N5/10, CI2Q1/00, CI2Q1/68, CI2N15/00, CI2N5/00 CC
          Synthetic DNA
          FH Key
          FT source
          Location/Qualifiers
          source
            1..12
            /organism='Artificial Sequence'
            /mol_type='genomic DNA'
            /db_xref='taxon:32630'

Query Match      19.6%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 23;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1726 TGAAGGACGAG 1736
Db      2 TGAAGGACGAG 12

RESULT 47
LOCUS      AX733659/c      17 bp      DNA      linear      PAT 08-MAY-2003
DEFINITION Sequence 5293 from Patent WO03025175.
ACCESSION  AX733659
VERSION    AX733659.1 GI:30513002
KEYWORDS
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
REFERENCE  1
AUTHORS    Telerman,A., Amson,R. and Tuijinder,M.
TITLE      Sequences involved in phenomena of tumour suppression, tumour
          reversion, apoptosis and/or virus resistance and their use as
          medicines
JOURNAL    Patent: WO 03025175-A 5293 27-MAR-2003;
FEATURES   Molecular Engines Laboratories (FR)
            Location/Qualifiers
            1..17
            /organism='Homo sapiens'
            /mol_type='unassigned DNA'
            /db_xref='taxon:9606'

Query Match      18.3%; Score 8.8; DB 1; Length 17;
Best Local Similarity 83.3%; Pred. No. 31;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

QY 1712 CTCCTGACTGAT 1723  
Db 13 CTCCTGCTGAT 2

RESULT 48  
AX625561 11 bp DNA linear PAT 21-FEB-2003  
LOCUS AX625561  
DEFINITION Sequence 2602 from Patent WO02053774.  
ACCESSION AX625561  
VERSION AX625561.1 GI:28453502  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE 1  
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.  
TITLE Method for determining homeostasis of the skin  
JOURNAL Patent: WO 02053774-A 2602.11-JUL-2002;  
Henkel Kommanditgesellschaft auf Aktien (DE)  
FEATURES location/Qualifiers  
source 1..11  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 16.3%; Score 7.8; DB 1; Length 11;  
Best Local Similarity 81.8%; Pred. No. 40;  
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1744 AAATGCATCCA 1754  
Db 1 AAATGCATGCA 11

RESULT 49  
ARI80533 15 bp DNA linear PAT 20-APR-2002  
LOCUS ARI80533  
DEFINITION Sequence 601 from patent US 6333152.  
ACCESSION ARI80533  
VERSION ARI80533.1 GI:20222566  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.  
TITLE Gene expression profiles in normal and cancer cells  
JOURNAL Patent: US 6333152-A 601 25-DEC-2001;  
location/Qualifiers  
FEATURES 1..15  
source /organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 15.4%; Score 7.4; DB 1; Length 15;  
Best Local Similarity 88.9%; Pred. No. 47;  
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1749 CATGCATTC 1757  
Db 1 CATGCATTC 9

RESULT 50  
A25126/c 13 bp DNA linear PAT 21-SEP-1995  
LOCUS A25126  
DEFINITION Synthetic EcoRI adaptor.  
ACCESSION A25126  
VERSION A25126.1 GI:1247054  
KEYWORDS  
SOURCE Synthetic construct  
ORGANISM Synthetic construct

artificial sequences.  
REFERENCE 1 (bases 1 to 13)  
AUTHORS  
JOURNAL Patent: DE 3925748-A 5 11-APR-1991;  
FEATURES location/Qualifiers  
source 1..13  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"

Query Match 15.0%; Score 7.2; DB 1; Length 13;  
Best Local Similarity 75.0%; Pred. No. 49;  
Matches 9; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1746 ATGCATCATTC 1757  
Db 12 ATGCATCATGC 1

Search completed: July 13, 2004, 11:01:34  
Job time : 0.001 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

## OM nucleic - nucleic search, using sw model

Run on: July 13, 2004, 11:03:42 ; Search time 0.001 Seconds

(without alignments)  
218.208 Million cell updates/sec

Title: us-10-000-213-3

Perfect score: 48  
Sequence: 1 ggcctcgtactgactgtgag.....caggagaatgcatcattcc 48Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 0.5

Searched: 169 seqs, 2273 residues

Total number of hits satisfying chosen parameters: 338

Minimum DB seq length: 8

Maximum DB seq length: 80

Post-processing: Minimum Match 0%

Maximum Match 100%  
Listing first 170 summaries

Database : rngdb:\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	* Query Match Length	DB ID	Description
1	20	41.7	20 1 ADB99915	Vitamin D nuclear
2	20	41.7	20 1 ADB99916	Vitamin D nuclear
3	20	41.7	20 1 ADB99914	Vitamin D nuclear
4	20	41.7	20 1 ADB99917	Vitamin D nuclear
5	14.8	30.8	18 1 AAV11884	Homo sapiens tub 1
6	14.4	30.0	18 1 AAD36184	Human Smad6 antisense
7	13.8	28.7	17 1 ACD62830	HCV minus strand D
8	13	27.1	17 1 ABN08350	Human GMLP-1 17-m
9	13	27.1	17 1 ABN08352	Human GMLP-1 17-m
10	13	27.1	17 1 ABN08351	Human GMLP-1 17-m
11	13	27.1	17 1 ABN08349	Human GMLP-1 17-m
12	13	27.1	17 1 ABN08353	Human GMLP-1 17-m
13	12.8	26.7	16 1 AAC92724	c-erbB-2 antisense
14	12.8	26.7	17 1 ACC52840	Human tumour suppress
15	12.8	26.7	17 1 ACD59656	Tumour suppression
16	12.8	26.7	17 1 ACD59656	HCV DNAzyme subseq
17	12	25.0	13 1 ABF92692	Oligonucleotide SE
18	12	25.0	13 1 ABF92693	Oligonucleotide SE
19	11.8	24.6	15 1 AAT51864	Human ICM hammeth
20	11.8	24.6	15 1 AAZ64202	Substrate for ham
21	11.8	24.6	15 1 AAF68891	IGFBP3 oligonucleo
22	11.8	24.6	15 1 AAF68892	IGFBP3 oligonucleo
23	11.8	24.6	15 1 AAF68891	IGFBP3 oligonucleo
24	11.8	24.6	15 1 AAF68892	IGFBP3 oligonucleo
25	11.6	24.2	15 1 AAT48035	ASO probe #7 for d
26	11.4	23.7	13 1 ABC12425	Hepatitis C virus
27	11.4	23.7	13 1 ABC12425	Oligonucleotide SE
28	11.4	23.7	13 1 ABC12424	Oligonucleotide SE
29	11.4	23.7	15 1 AAX31546	Tag sequence of a
30	11.4	23.7	15 1 AAF68891	IGFBP3 oligonucleo
31	11.4	23.7	15 1 AAF68890	IGFBP3 oligonucleo
32	11.4	23.7	15 1 AAS98675	Colony stimulating
33	11.4	23.7	15 1 ABK32500	Human PLAU gene, a
				Human pancreatic c

34	11	22.9	12 1	ABT55463	Oligonucleotide pr
35	11	22.9	13 1	ABF42717	Oligonucleotide SE
36	11	22.9	13 1	ABH51281	Oligonucleotide SE
37	11	22.9	13 1	ABH51281	Oligonucleotide SE
38	11	22.9	13 1	ABF28165	Oligonucleotide SE
39	11	22.9	13 1	ABH51280	Oligonucleotide SE
40	11	22.9	13 1	ABH52406	Oligonucleotide SE
41	11	22.9	13 1	ABH52406	Oligonucleotide SE
42	11	22.9	13 1	ABH52406	Oligonucleotide SE
43	11	22.9	13 1	ABH52406	Oligonucleotide SE
44	11	22.9	13 1	ABH52406	Oligonucleotide SE
45	10.8	22.5	14 1	AAZ6214	Oestrogen receptor
46	10.6	22.1	13 1	ABC68262	Oligonucleotide SE
47	10.6	22.1	13 1	ABC68263	Oligonucleotide SE
48	10.4	21.7	12 1	ABH5801	Oligonucleotide pr
49	10.4	21.7	12 1	ABH5801	Oligonucleotide pr
50	10.4	21.7	12 1	ABH5801	Oligonucleotide pr
51	10.4	21.7	12 1	ABH5801	Oligonucleotide pr
52	10.4	21.7	12 1	ABH5801	Oligonucleotide pr
53	10.4	21.7	13 1	ABC94621	Oligonucleotide SE
54	10.4	21.7	13 1	ABC94621	Oligonucleotide SE
55	10.4	21.7	13 1	ABF18905	Oligonucleotide SE
56	10.4	21.7	13 1	ABF18905	Oligonucleotide SE
57	10.4	21.7	13 1	ABF18905	Oligonucleotide SE
58	10.4	21.7	13 1	ABF18905	Oligonucleotide SE
59	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
60	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
61	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
62	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
63	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
64	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
65	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
66	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
67	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
68	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
69	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
70	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
71	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
72	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
73	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
74	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
75	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
76	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
77	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
78	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
79	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
80	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
81	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
82	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
83	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
84	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
85	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
86	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
87	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
88	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
89	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
90	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
91	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
92	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
93	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
94	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
95	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
96	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
97	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
98	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
99	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
100	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
101	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
102	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
103	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
104	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
105	10.4	21.7	13 1	ABH43430	Oligonucleotide SE
106	10.4	21.7	13 1	ABH43430	Oligonucleotide SE

C 107	9.8	20.4	13	1	ABC20825	Oligonucleotide SE
C 108	9.8	20.4	13	1	ABC07406	Oligonucleotide SE
C 109	9.8	20.4	13	1	ABF07048	Oligonucleotide SE
C 110	9.8	20.4	13	1	ABC87934	Oligonucleotide SE
C 111	9.8	20.4	13	1	ABF21698	Oligonucleotide SE
C 112	9.8	20.4	13	1	ABH20206	Oligonucleotide SE
C 113	9.8	20.4	13	1	ABH34096	Oligonucleotide SE
C 114	9.8	20.4	13	1	ABH42048	Oligonucleotide SE
C 115	9.8	20.4	13	1	ABC48762	Oligonucleotide SE
C 116	9.8	20.4	13	1	ABC12427	Oligonucleotide SE
C 117	9.8	20.4	13	1	ABC87935	Oligonucleotide SE
C 118	9.8	20.4	13	1	ABC41627	Oligonucleotide SE
C 119	9.8	20.4	13	1	ABH24244	Oligonucleotide SE
C 120	9.8	20.4	13	1	ABF68806	Oligonucleotide SE
C 121	9.8	20.4	13	1	ABC83525	Oligonucleotide SE
C 122	9.8	20.4	13	1	ABH24245	Oligonucleotide SE
C 123	9.8	20.4	13	1	ABH42049	Oligonucleotide SE
C 124	9.8	20.4	13	1	ABH50272	Oligonucleotide SE
C 125	9.8	20.4	13	1	ABC74874	Oligonucleotide SE
C 126	9.8	20.4	13	1	ABC10734	Oligonucleotide SE
C 127	9.8	20.4	13	1	ABH20207	Oligonucleotide SE
C 128	9.8	20.4	13	1	ABH10408	Oligonucleotide SE
C 129	9.8	20.4	13	1	ABF68807	Oligonucleotide SE
C 130	9.8	20.4	13	1	ABF68831	Oligonucleotide SE
C 131	9.8	20.4	13	1	ABF68833	Oligonucleotide SE
C 132	9.8	20.4	13	1	ABH64891	Oligonucleotide SE
C 133	9.8	20.4	13	1	ABC20824	Oligonucleotide SE
C 134	9.8	20.4	13	1	ABC97855	Oligonucleotide SE
C 135	9.8	20.4	13	1	ABC48763	Oligonucleotide SE
C 136	9.8	20.4	13	1	ABC07407	Oligonucleotide SE
C 137	9.8	20.4	13	1	ABF18398	Oligonucleotide SE
C 138	9.8	20.4	13	1	ABF21699	Oligonucleotide SE
C 139	9.8	20.4	13	1	ABF46516	Oligonucleotide SE
C 140	9.8	20.4	13	1	ABF51962	Oligonucleotide SE
C 141	9.8	20.4	13	1	ABF51963	Oligonucleotide SE
C 142	9.8	20.4	13	1	ABF02354	Oligonucleotide SE
C 143	9.8	20.4	13	1	ABC41626	Oligonucleotide SE
C 144	9.8	20.4	13	1	ABC97854	Oligonucleotide SE
C 145	9.8	20.4	13	1	ABF14030	Oligonucleotide SE
C 146	9.8	20.4	13	1	ABF68830	Oligonucleotide SE
C 147	9.8	20.4	13	1	ABH44534	Oligonucleotide SE
C 148	9.8	20.4	13	1	ABC35910	Oligonucleotide SE
C 149	9.8	20.4	13	1	ABF07049	Oligonucleotide SE
C 150	9.8	20.4	13	1	ABF18399	Oligonucleotide SE
C 151	9.8	20.4	13	1	ABF68832	Oligonucleotide SE
C 152	9.8	20.4	13	1	ABH64890	Oligonucleotide SE
C 153	9.8	20.4	13	1	ABC22258	Oligonucleotide SE
C 154	9.8	20.4	13	1	ABC35911	Oligonucleotide SE
C 155	9.8	20.4	13	1	ABC83524	Oligonucleotide SE
C 156	9.8	20.4	13	1	ABF11986	Oligonucleotide SE
C 157	9.8	20.4	13	1	ABF11987	Oligonucleotide SE
C 158	9.8	20.4	13	1	ABH10409	Oligonucleotide SE
C 159	9.8	20.4	13	1	ABH44535	Oligonucleotide SE
C 160	9.8	20.4	13	1	ABH50273	Oligonucleotide SE
C 161	9.8	20.4	13	1	ABC72954	Oligonucleotide SE
C 162	9.8	20.4	13	1	ABC72955	Oligonucleotide SE
C 163	9.8	20.4	13	1	ABC74875	Oligonucleotide SE
C 164	9.8	20.4	13	1	ABC10735	Oligonucleotide SE
C 165	9.8	20.4	13	1	ABC12426	Oligonucleotide SE
C 166	9.8	20.4	13	1	ABF02355	Oligonucleotide SE
C 167	9.8	20.4	13	1	ABF14031	Oligonucleotide SE
C 168	9.8	20.4	13	1	ABF46517	Oligonucleotide SE
C 169	9.8	20.4	13	1	ADD15389	Plasmid pHIY-LTR E
C 170	8.8	18.3	17	1	ABT39656	Tumour suppression

## ALIGNMENTS

RESULT 1  
ADB99915/c  
ID ADB99915 standard; DNA; 20 BP.  
XX

AC	ADB99915;	Location/Qualifiers
XX	04-DEC-2003 (first entry)	
DT	Vitamin D nuclear receptor antisense oligonucleotide, SEQ ID 54.	
XX		
DE	Cytostatic; gene therapy; antisense oligonucleotide; human;	
XX	Vitamin D nuclear receptor; cancer; developmental disorder;	
KM	phosphorothioate; ss.	
XX		
OS	Synthetic.	
XX		
PH	Key	
FT	modified_base 1..20	
FT	/tag= a	
FT	/mod_base= OTHER	
FT	/note="This oligonucleotide has a phosphorothioate	
FT	backbone and 2'-methoxyethyl (2'-MOE) wings at the 5'	
FT	and 3' ends, which are 5 nucleotides in length. Also all	
XX	cytidine residues are 5-methylcytidines"	
XX		
PN	W02003041657-A2.	
XX		
PD	22-MAY-2003.	
XX		
PF	13-NOV-2002; 2002WO-US036692.	
XX		
PR	14-NOV-2001; 2001US-00000213.	
XX	(ISIS-) ISIS PHARM INC.	
PA		
XX		
PI	Baker BF, Dobie K, Roach MP;	
XX		
DR	WPI; 2003-468578/44.	
XX		
PT	New antisense oligonucleotides for modulating vitamin D nuclear receptor	
PT	gene expression, particularly useful for treating or preventing cancer or	
XX	developmental disorder, or as diagnostics or research reagents.	
PT		
PS	Claim 3; SEQ ID NO 54; 122bp; English.	
XX		
CC	The present invention relates to novel antisense oligonucleotides	
CC	(ADB99875-ADB99952) which are targeted to a human vitamin D nuclear	
CC	receptor coding sequence (ADB99864), and specifically hybridizes with and	
CC	inhibits the expression of vitamin D nuclear receptor. The antisense	
CC	oligonucleotides are useful for treating an animal having a disease or	
CC	condition associated with vitamin D nuclear receptor, e.g. cancer or	
CC	developmental disorder.	
XX		
SQ	Sequence 20 BP; 3 A; 8 C; 2 G; 7 T; 0 U; 0 Other;	
XX		
Query Match	41.7%; Score 20; DB 1; Length 20;	
Best Local Similarity	100.0%; Pred. No. 4.2;	
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
QY	1722 ATGTTGAGGGAACGACGACG 1741	
Db	20 ATGTTGAGGGAACGACGACG 1	
XX		
RESULT 2		
ADB99916/c		
ID ADB99916 standard; DNA; 20 BP.		
XX		
AC	ADB99916;	
XX		
DT	04-DEC-2003 (first entry)	
XX		
DE	Vitamin D nuclear receptor antisense oligonucleotide, SEQ ID 55.	
XX		
KM	Cytostatic; gene therapy; antisense oligonucleotide; human;	
KM	Vitamin D nuclear receptor; cancer; developmental disorder;	
KM	phosphorothioate; ss.	

```
XX OS Synthetic.
XX FH Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note="This oligonucleotide has a phosphorothioate
FT backbone and 2'-methoxyethyl (2'-MOE) wings at the 5'
FT and 3' ends, which are 5 nucleotides in length. Also all
FT cytidine residues are 5-methylcytidines"
XX PN
XX MO2003041657-A2.
XX PD
XX 22-MAY-2003.
XX PF 13-NOV-2002; 2002MO-US036692.
XX PR 14-NOV-2001; 2001US-00000213.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Baker BF, Dobie K, Roach MP;
XX DR WPI; 2003-468578/44.
XX PT New antisense oligonucleotides for modulating vitamin D nuclear receptor
XX gene expression, particularly useful for treating or preventing cancer or
XX developmental disorder, or as diagnostics or research reagents.
XX PS Claim 3; SEQ ID NO 55; 122bp; English.
XX SQ Sequence 20 BP; 1 A; 7 C; 3 G; 9 T; 0 U; 0 Other;
XX
XX Query Match 41.7%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 4.2;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1730 GGAACAGACAGAGAAATGC 1749
XX DB 20 GGAACAGACAGAGAAATGC 1
XX
XX RESULT 3
XX ADB99914/c
XX ID ADB99914 standard; DNA; 20 BP.
XX XX
XX AC ADB99914;
XX XX
XX 04-DEC-2003 (first entry)
XX DE Vitamin D nuclear receptor antisense oligonucleotide, SEQ ID 53.
XX XX
XX KM Cytostatic; gene therapy; antisense oligonucleotide; human;
XX vitamin D nuclear receptor; cancer; developmental disorder;
XX phosphorothioate; ss.
XX OS Synthetic.
XX FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note="This oligonucleotide has a phosphorothioate
FT backbone and 2'-methoxyethyl (2'-MOE) wings at the 5'
```

```
FT and 3' ends, which are 5 nucleotides in length. Also all
FT cytidine residues are 5-methylcytidines"
XX PN
XX MO2003041657-A2.
XX PD
XX 22-MAY-2003.
XX PF 13-NOV-2002; 2002MO-US036692.
XX PR 14-NOV-2001; 2001US-00000213.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Baker BF, Dobie K, Roach MP;
XX DR WPI; 2003-468578/44.
XX PT New antisense oligonucleotides for modulating vitamin D nuclear receptor
XX gene expression, particularly useful for treating or preventing cancer or
XX developmental disorder, or as diagnostics or research reagents.
XX PS Claim 3; SEQ ID NO 53; 122bp; English.
XX SQ Sequence 20 BP; 6 A; 8 C; 3 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 41.7%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 4.2;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1710 GGCTGCTGACTGATGTTGAG 1729
XX DB 20 GGCTGCTGACTGATGTTGAG 1
XX
XX RESULT 4
XX ADB99917/c
XX ID ADB99917 standard; DNA; 20 BP.
XX XX
XX AC ADB99917;
XX XX
XX 04-DEC-2003 (first entry)
XX DE Vitamin D nuclear receptor antisense oligonucleotide, SEQ ID 56.
XX XX
XX KM Cytostatic; gene therapy; antisense oligonucleotide; human;
XX vitamin D nuclear receptor; cancer; developmental disorder;
XX phosphorothioate; ss.
XX OS Synthetic.
XX FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note="This oligonucleotide has a phosphorothioate
FT backbone and 2'-methoxyethyl (2'-MOE) wings at the 5'
FT and 3' ends, which are 5 nucleotides in length. Also all
FT cytidine residues are 5-methylcytidines"
XX PN
XX MO2003041657-A2.
XX PD
XX 22-MAY-2003.
XX PF 13-NOV-2002; 2002MO-US036692.
```

PR 14-NOV-2001; 2001US-00000213.  
XX  
XX (ISIS-) ISIS PHARM INC.  
XX  
XX Baker BF, Dobie K, Roach MP;  
XX WPI; 2003-468578/44.  
XX  
PT New antisense oligonucleotides for modulating vitamin D nuclear receptor  
PT gene expression, particularly useful for treating or preventing cancer or  
PT developmental disorder, or as diagnostics or research reagents.  
XX  
PS Claim 3; SEQ ID NO 56; 122pp; English.  
XX  
CC The present invention relates to novel antisense oligonucleotides  
CC (ADB9875-ADB9952) which are targeted to a human vitamin D nuclear  
CC receptor coding sequence (ADB9964), and specifically hybridizes with and  
CC inhibits the expression of vitamin D nuclear receptor. The antisense  
CC oligonucleotides are useful for treating an animal having a disease or  
CC condition associated with vitamin D nuclear receptor, e.g. cancer or  
CC developmental disorder.  
XX  
SQ Sequence 20 BP; 4 A; 4 C; 5 G; 7 T; 0 U; 0 Other;  
  
Query Match 41.7%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 4.2;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1738 CAGGAGAAATGCATCCATTC 1757  
Db 20 CAGGAGAAATGCATCCATTC 1  
  
RESULT 5  
AAV11884/c  
ID AAV11884 standard; cDNA; 18 BP.  
XX  
AC AAV11884;  
XX  
DT 11-SEP-1998 (first entry)  
XX  
DE Homo sapiens Tub Interactor gene antisense sequence.  
XX  
XX antisense; tub interactor; treatment; obesity; cachexia;  
XX anorexia nervosa; diabetes; cell cycle progression; apoptosis;  
XX neurodegenerative disease; Alzheimer's disease; drug screening;  
XX Parkinson's disease; Huntington's chorea; detection; diagnosis;  
XX amyotrophic lateral sclerosis; spinocerebellar degeneration; ss.  
XX  
OS Synthetic.  
OS Homo sapiens.  
XX  
PN WO9812302-A1.  
XX  
PD 26-MAR-1998.  
XX  
PF 05-SEP-1997; 97MO-US015627.  
XX  
XX 17-SEP-1996; 96US-00715032.  
PR 21-JUL-1997; 97US-00897340.  
XX  
XX (MILL-) MILLENNIUM PHARM INC.  
XX  
XX Gimeno CJ, Errada PR;  
XX WPI; 1998-217246/19.  
XX  
XX Tub interactor genes - used to develop products for the treatment of  
PT obesity, cachexia, anorexia nervosa or related disorders e.g. diabetes.  
XX  
PS Disclosure; Page 85; 120pp; English.  
XX  
CC The sequence is that of a Tub Interactor (TI) gene antisense sequence

XX  
SQ Sequence 18 BP; 3 A; 8 C; 4 G; 3 T; 0 U; 0 Other;  
  
Query Match 30.8%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 23;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1714 GCTGACTGATGTTGAGGG 1731  
Db 18 GCTGACTGACGCTGAGGG 1  
  
RESULT 6  
AAD36184/c  
ID AAD36184 standard; DNA; 18 BP.  
XX  
AC AAD36184;  
XX  
DT 09-AUG-2002 (first entry)  
XX  
XX  
DE Human Smad6 antisense oligonucleotide, ISIS #28552.  
XX  
XX  
XX Human; Smad6 protein; antisense; cardiovascular disease; infection;  
KW inflammation; cancer; therapy; phosphorothioate backbone; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
FH Key  
FT modified\_base 1..18 Location/Qualifiers  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER = Phosphorothioate backbone"  
FT 1..4  
FT /\*tag= b  
FT /note= "2'methoxyethyl nucleotides"  
FT 5..6  
FT /\*tag= d  
FT /mod\_base= m5c  
FT 10..12  
FT /\*tag= e  
FT /mod\_base= m5c  
FT modified\_base 14  
FT /\*tag= f  
FT /mod\_base= m5c  
FT modified\_base 15..18  
FT /\*tag= c  
FT /note= "2'methoxyethyl nucleotides"  
FT 17  
FT /\*tag= g  
FT /mod\_base= m5c  
XX  
PN WO200228878-A1.  
XX  
PD 11-APR-2002.  
XX  
PF 01-OCT-2001; 2001WO-US030645.  
XX  
XX 04-OCT-2000; 2000US-00679298.  
PR  
XX (ISIS-) ISIS PHARM INC.  
XX  
XX Monia BP, Cowsett LM;  
XX WPI; 2002-394345/42.  
XX  
XX Oligonucleotides, useful for the modulation of Smad6 expression in the  
PT treatment or prophylaxis of e.g. cardiovascular disease, are targeted to  
PT nucleic acid molecule encoding Smad6.  
XX  
PS Example 16; Page 90; 110pp; English.  
XX  
CC The invention relates to an antisense oligonucleotide targeted to a

CC nucleic acid molecule encoding human Smad6 protein, which specifically  
 CC hybridizes with the nucleic acid and inhibits its expression. Antisense  
 CC compound of the invention are used for inhibiting the expression of  
 CC Smad6 in cells and tissues in the treatment of a disease or condition  
 CC associated with Smad6 such as cardiovascular disease, cancer, infection  
 CC and inflammation. They are also useful in the diagnostics, as research  
 CC reagents, in kits and in antisense therapy. The present sequence is an  
 CC antisense oligonucleotide targeted to human Smad6

XX  
 SQ Sequence 18 BP, 3 A, 7 C, 4 G, 4 T, 0 U, 0 Other;

Query Match 30.0%; Score 14.4; DB 1; Length 18;  
 Best Local Similarity 93.8%; Pred. No. 26;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1723 TGTGTGAGGGAACGAC 1738  
 DB 18 TGTGTGAGGGAACGAC 3

RESULT 7  
 ID ACD62830 standard; RNA; 17 BP.  
 XX  
 AC ACD62830;  
 XX  
 DT 24-SEP-2003 (first entry)  
 XX  
 DE HCV minus strand DNAzyme substrate sequence #749.  
 XX  
 Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;  
 KM enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinczyme;  
 KM enzyme; G-cleaver ribozyme; decoy molecule; aptamer;  
 KM HBV reverse transcriptase; Enhancer I region; viral replication;  
 KM degenerative; disease state; HBV infection; HCV infection; cirrhosis;  
 KM liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;  
 KM virucide; antiinflammatory; substrate; ss.

XX  
 OS Hepatitis C virus.  
 XX  
 PN WO200281494-A1.  
 XX  
 PD 17-OCT-2002.  
 XX  
 PF 26-MAR-2002; 2002WO-US009187.  
 XX  
 PR 26-MAR-2001; 2001US-00817879.  
 PR 08-JUN-2001; 2001US-00877478.  
 PR 08-JUN-2001; 2001US-0296876P.  
 PR 24-OCT-2001; 2001US-0335059P.  
 PR 05-DEC-2001; 2001US-0337055P.  
 XX  
 PA (RIBO-) RIBOZYME PHARM INC.  
 PA (BLAT/) BLATT L.  
 PA (MACE/) MACEJAK D.  
 PA (MCSW/) MCSWIGEN J.  
 PA (MORR/) MORRISSEY D.  
 PA (PVC/) PAVCO P.  
 PA (LEEP/) LEE P.  
 PA (DRAP/) DRAPER K.  
 PA (ROBE/) ROBERTS E.

PI Blatt L, Macejak D, Mcswigen J, Morrissey D, Pavco P, Lee P,  
 PI Draper K, Roberts E;  
 DR WPI; 2003-229207/22.  
 XX  
 PT Novel compound useful for treating cirrhosis, liver failure,  
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus  
 PT infection.  
 XX  
 PS Claim 1; Page 288; 387bp; English.

XX  
 CC The present invention relates to nucleic acid molecules which modulate  
 CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or  
 CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense  
 CC and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,  
 CC inozymes, zinczymes, amberzymes, and G-cleaver ribozymes. Also disclosed  
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse  
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well  
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV  
 CC DNA. The nucleic acids may be used to modulate the expression of HBV  
 CC genes and HBV viral replication. Also disclosed is a method for screening  
 CC compounds and/or potential therapies directed against HBV, and compounds  
 CC that modulate the expression and/or replication of HCV. The compounds and  
 CC methods of the invention are useful for the treatment of degenerative and  
 CC disease states related to HBV and HCV infection, replication and gene  
 CC expression such as cirrhosis, liver failure, and hepatocellular  
 CC carcinoma. The present sequence represents a substrate for one of the HCV  
 CC DNAzyme or minus strand DNAzyme sequences disclosed in the present  
 CC invention

XX  
 SQ Sequence 17 BP, 3 A, 1 C, 9 G, 0 T, 4 U, 0 Other;

Query Match 28.7%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 64.7%; Pred. No. 30;  
 Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

OY 1714 GCTGACTGATGTTGAGG 1730  
 DB 1 GCTGAGUGAGUGGAGG 17

RESULT 8  
 ID ABN08350/C  
 XX  
 AC ABN08350;  
 XX  
 DT 29-MAY-2002 (first entry)  
 XX  
 DE Human GDMLP-1 17-mer scanning SBQ ID NO:5 sequence SBQ ID NO:8342.  
 XX  
 KM Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;  
 KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
 KM skeletal muscle disorder; amplicon; screening; ss.

XX  
 OS Homo sapiens.  
 XX  
 PN WO200192524-A2.  
 XX  
 PD 06-DEC-2001.  
 XX  
 PF 25-MAY-2001; 2001WO-US016981.  
 XX  
 PR 26-MAY-2000; 2000US-0207456P.  
 PR 21-SEP-2000; 2000US-0234687P.  
 PR 27-SEP-2000; 2000US-0236359P.  
 PR 04-OCT-2000; 2000GB-00024263.  
 PR 30-JAN-2001; 2001WO-US000661.  
 PR 30-JAN-2001; 2001WO-US000662.  
 PR 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.  
 PR 30-JAN-2001; 2001WO-US000666.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.  
 PR 30-JAN-2001; 2001WO-US000669.  
 PR 30-JAN-2001; 2001WO-US000670.  
 PR 05-FEB-2001; 2001US-0266860P.

XX  
 PA (AEON-) AEONICA INC.  
 PA  
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
 XX

DR WPI; 2002-179446/23.  
 XX New polypeptide, for raising antibodies that recognise hGDMLP-1 proteins,  
 PT or as specific biomolecule capture probes for surface-enhanced laser  
 PT desorption ionization, comprises human myosin-like protein hGDMLP-1.  
 XX  
 PS Disclosure; SEQ ID NO 8342; 214pp; English.  
 XX  
 CC The present invention describes a human genome-derived myosin-like  
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-  
 CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
 CC nucleic acids can be used as probes to detect, characterise and quantify  
 CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to  
 CC provide initial substrates for the recombinant engineering of hGDMLP-1  
 CC protein variants having desired phenotypic improvements, and for  
 CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
 CC used as immunogens to raise antibodies that specifically recognise hGDMLP  
 CC -1 proteins, as standards in assays used to determine the concentration  
 CC and/or amount specifically of hGDMLP proteins, as specific biomolecule  
 CC capture probes for surface-enhanced laser desorption ionisation, as  
 CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
 CC production, and in vaccines or for replacement therapy. The  
 CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
 CC disorder associated with the expression of hGDMLP-1, in particular heart  
 CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
 CC The present sequence represents an oligomer used in the screening of the  
 CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
 CC The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/published\_pct\_sequence  
 CC  
 SQ Sequence 17 BP; 8 A; 4 C; 3 G; 2 T; 0 U; 0 Other;  
 XX  
 QY 1713 TGCTGACTGATGT 1725  
 Db 16 TGCTGACTGATGT 4  
 Query Match 27.1%; Score 13; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 39;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 9  
 ABN08352/c  
 ID ABN08352 standard; DNA; 17 BP.  
 XX  
 AC ABN08352;  
 XX  
 DT 29-MAY-2002 (first entry)  
 DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8344.  
 XX  
 KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;  
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
 KW skeletal muscle disorder; amplicon; screening; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200192524-A2.  
 PD 06-DEC-2001.  
 XX  
 PF 25-MAY-2001; 2001WO-US016981.  
 XX  
 PR 26-MAY-2000; 2000US-0207456P.  
 PR 21-SEP-2000; 2000US-0234687P.  
 PR 27-SEP-2000; 2000US-0236359P.  
 PR 04-OCT-2000; 2000GB-00024263.  
 PR 30-JAN-2001; 2001WO-US000661.  
 PR 30-JAN-2001; 2001WO-US000662.  
 PR 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.

PR 30-JAN-2001; 2001WO-US000666.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.  
 PR 30-JAN-2001; 2001WO-US000669.  
 PR 30-JAN-2001; 2001WO-US000670.  
 PR 05-FEB-2001; 2001US-0266860P.  
 XX  
 PA (AEOM-) AEOMICA INC.  
 XX  
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
 XX  
 DR WPI; 2002-179446/23.  
 XX  
 XX New polypeptide, for raising antibodies that recognise hGDMLP-1 proteins,  
 PT or as specific biomolecule capture probes for surface-enhanced laser  
 PT desorption ionization, comprises human myosin-like protein hGDMLP-1.  
 XX  
 PS Disclosure; SEQ ID NO 8344; 214pp; English.  
 XX  
 CC The present invention describes a human genome-derived myosin-like  
 CC protein 1 (hGDMLP-1). The protein and vaccine production. The hGDMLP-1  
 CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
 CC nucleic acids can be used as probes to detect, characterise and quantify  
 CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to  
 CC provide initial substrates for the recombinant engineering of hGDMLP-1  
 CC protein variants having desired phenotypic improvements, and for  
 CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
 CC used as immunogens to raise antibodies that specifically recognise hGDMLP  
 CC -1 proteins, as standards in assays used to determine the concentration  
 CC and/or amount specifically of hGDMLP proteins, as specific biomolecule  
 CC capture probes for surface-enhanced laser desorption ionisation, as  
 CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
 CC production, and in vaccines or for replacement therapy. The  
 CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
 CC disorder associated with the expression of hGDMLP-1, in particular heart  
 CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
 CC The present sequence represents an oligomer used in the screening of the  
 CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
 CC The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/published\_pct\_sequence  
 CC  
 SQ Sequence 17 BP; 6 A; 4 C; 5 G; 2 T; 0 U; 0 Other;  
 XX  
 QY 1713 TGCTGACTGATGT 1725  
 Db 14 TGCTGACTGATGT 2  
 Query Match 27.1%; Score 13; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 39;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 10  
 ABN08351/c  
 ID ABN08351 standard; DNA; 17 BP.  
 XX  
 AC ABN08351;  
 XX  
 DT 29-MAY-2002 (first entry)  
 DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8343.  
 XX  
 KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;  
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
 KW skeletal muscle disorder; amplicon; screening; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200192524-A2.  
 PD 06-DEC-2001.  
 XX

PF 25-MAY-2001; 2001WO-US016981.  
XX  
XX 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
XX  
XX (AEOM-) AEOMICA INC.  
XX  
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX WPI; 2002-179446/23.  
XX  
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.  
XX  
XX Disclosure; SEQ ID NO 8343; 214pp; English.  
XX  
XX The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption/ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
SQ Sequence 17 BP; 7 A; 4 C; 4 G; 2 T; 0 U; 0 Other;  
XX  
XX Query Match 27.1%; Score 13; DB 1; Length 17;  
XX Best Local Similarity 100.0%; Pred. No. 39;  
XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
XX  
Qy 1713 TGCTGACTGATGT 1725  
XX |||||  
Db 15 TGCTGACTGATGT 3

XX Human, genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;  
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
XX skeletal muscle disorder; amplicon; screening; ss.  
XX Homo sapiens.  
XX WO200192524-A2.  
XX  
XX 06-DEC-2001.  
XX  
XX 25-MAY-2001; 2001WO-US016981.  
XX  
XX 25-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
XX  
XX (AEOM-) AEOMICA INC.  
XX  
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX WPI; 2002-179446/23.  
XX  
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.  
XX  
XX Disclosure; SEQ ID NO 8341; 214pp; English.  
XX  
XX The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption/ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
SQ Sequence 17 BP; 7 A; 5 C; 3 G; 2 T; 0 U; 0 Other;  
XX  
XX Query Match 27.1%; Score 13; DB 1; Length 17;  
XX Best Local Similarity 100.0%; Pred. No. 39;  
XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
XX  
Qy 1713 TGCTGACTGATGT 1725  
XX |||||  
Db 17 TGCTGACTGATGT 5

RESULT 12  
 ABN08353/c  
 ID ABN08353 standard; DNA; 17 BP.  
 XX  
 AC ABN08353;  
 XX  
 DT 29-MAY-2002 (first entry)  
 XX  
 DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8345.  
 XX  
 KM Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;  
 KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
 KM skeletal muscle disorder; amplicon; screening; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200192524-A2.  
 XX  
 PD 06-DEC-2001.  
 XX  
 PE 25-MAY-2001; 2001WO-US016981.  
 XX  
 PR 26-MAY-2000; 2000US-0207456P.  
 XX  
 PR 21-SEP-2000; 2000US-0234687P.  
 XX  
 PR 27-SEP-2000; 2000US-0236359P.  
 XX  
 PR 04-OCT-2000; 2000GB-00024263.  
 XX  
 PR 30-JAN-2001; 2001WO-US000661.  
 XX  
 PR 30-JAN-2001; 2001WO-US000662.  
 XX  
 PR 30-JAN-2001; 2001WO-US000663.  
 XX  
 PR 30-JAN-2001; 2001WO-US000664.  
 XX  
 PR 30-JAN-2001; 2001WO-US000665.  
 XX  
 PR 30-JAN-2001; 2001WO-US000666.  
 XX  
 PR 30-JAN-2001; 2001WO-US000667.  
 XX  
 PR 30-JAN-2001; 2001WO-US000668.  
 XX  
 PR 30-JAN-2001; 2001WO-US000669.  
 XX  
 PR 30-JAN-2001; 2001WO-US000670.  
 XX  
 PR 05-FEB-2001; 2001US-0266860P.  
 XX  
 PA (AEOM-) AEOMICA INC.  
 XX  
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
 XX  
 DR WPI; 2002-179446/23.  
 XX  
 PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,  
 PT or as specific biomolecule capture probes for surface-enhanced laser  
 PT desorption ionization, comprises human myosin-like protein hGDMLP-1.  
 XX  
 PS Disclosure; SEQ ID NO 8345; 214pp; English.  
 XX  
 CC The present invention describes a human genome-derived myosin-like  
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-  
 CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
 CC nucleic acids can be used as probes to detect, characterize and quantify  
 CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to  
 CC provide initial substrates for the recombinant engineering of hGDMLP-1  
 CC protein variants having desired phenotypic improvements, and for  
 CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
 CC used as immunogens to raise antibodies that specifically recognise hGDMLP  
 CC -1 proteins, as standards in assays used to determine the concentration  
 CC and/or amount specifically of hGDMLP proteins, as specific biomolecule  
 CC capture probes for surface-enhanced laser desorption ionisation, as  
 CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
 CC production, and in vaccines or for replacement therapy. The  
 CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
 CC disorder associated with the expression of hGDMLP-1, in particular heart  
 CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
 CC The present sequence represents an oligomer used in the screening of the  
 CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
 CC The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO

CC at ftp.wipo.int/pub/published\_pct\_sequence  
 XX  
 SQ Sequence 17 BP; 7 A; 4 C; 4 G; 2 T; 0 U; 0 Other;  
 XX  
 QY Query Match 27.1%; Score 13; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 39;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1713 TGCTGACTGATGT 1725  
 DB 13 TGCTGACTGATGT 1  
 XX  
 AC AAQ92724;  
 XX  
 DT 13-FEB-1996 (first entry)  
 XX  
 DE c-erbB-2 antisense nucleic acid #67.  
 XX  
 KM Antisense nucleic acid; c-erbB-2; inhibition; fibroblast; neoplasm;  
 KM p185-erbB-2 protein tyrosine kinase; tumour; breast cancer; detection;  
 KM immune disease; angiogenesis; ss.  
 XX  
 OS Synthetic.  
 XX  
 PN WO9517507-A1.  
 XX  
 PD 29-JUN-1995.  
 XX  
 PR 09-DEC-1994; 94WO-EP004094.  
 XX  
 PR 23-DEC-1993; 93EP-00120710.  
 XX  
 PA (BIOG-) BIOGNOSTIK GBS BIOMOLEKULARE DIAGNOSTIK.  
 XX  
 PI Bysch W, Schlingensiepen K, Schlingensiepen R, Schlingensiepen G;  
 XX  
 DR WPI; 1995-240669/31.  
 XX  
 PT New anti:sense nucleic acid against C-erbB-2 - for treating or preventing  
 PT neoplasms, immune disease and angiogenesis, also for diagnosis.  
 XX  
 PS Claim 1; Page 35; 55pp; English.  
 XX  
 CC The sequences given in AAQ92658-762 are antisense nucleic acids which  
 CC hybridise with part of the mRNA and/or DNA encoding c-erbB-2. These  
 CC antisense nucleic acids are able to inhibit the expression of the p185-  
 CC erbB-2 protein tyrosine kinase activity and cell growth in a number of  
 CC tumour cells including breast cancer cells. Untransformed normal  
 CC fibroblasts are not growth inhibited by anti-c-erbB-2 antisense compounds  
 CC suggesting that p185-erbB-2 plays a pathogenic role in the growth of the  
 CC above mentioned tumours. These antisense oligonucleotides may be used in  
 CC the prevention and treatment of neoplasms, immune diseases and/or  
 CC diseases involving pathological angiogenesis when associated with c-erbB-  
 CC 2 expression. They may also be used to detect expression of the relevant  
 CC genes  
 XX  
 SQ Sequence 16 BP; 3 A; 5 C; 2 G; 6 T; 0 U; 0 Other;  
 XX  
 QY Query Match 26.7%; Score 12.8; DB 1; Length 16;  
 Best Local Similarity 87.5%; Pred. No. 40;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1723 TGTGAGGACAGAC 1738  
 DB 16 TGTGAGGACAAACAC 1  
 XX  
 RESULT 14

ACC52840/c  
 ID ACC52840 standard; DNA: 17 BP.  
 XX  
 AC ACC52840;  
 XX  
 DT 27-JUN-2003 (first entry)  
 XX  
 DE Human tumour suppressor sequence #1607.  
 XX  
 KW ss; tumour suppressor; antitumour; cytostatic; tumour suppression;  
 KM tumour regression; apoptosis; virus resistance; diagnosis;  
 KM cellular degeneration.  
 XX  
 OS Homo sapiens.  
 XX  
 PN FR2826373-A1.  
 XX  
 PD 27-DEC-2002.  
 XX  
 PF 20-JUN-2001; 2001FR-00008139.  
 XX  
 PR 20-JUN-2001; 2001FR-00008139.  
 XX  
 PA (MOLE-) MOLECULAR ENGINES LAB SA.  
 XX  
 PI Tuijnder M, Telerman A, Amson R;  
 XX  
 DR WPI; 2003-250498/25.  
 XX  
 PT New nucleic acid sequences associated with tumor suppression, regression,  
 PT apoptosis or virus resistance are useful to diagnose and treat viral  
 PT disease, development of tumor cells and cell degeneration.  
 XX  
 PS Claim 1; Page 411; 798bp; French.  
 XX  
 CC This sequence represents an isolated nucleic acid sequence associated  
 CC with tumour suppression or regression, apoptosis or virus resistance. The  
 CC invention relates to these sequences or sequences having at least 80%  
 CC identity to them, and polypeptides encoded by the sequences or  
 CC polypeptides having 80% identity to the polypeptide sequences. The  
 CC invention is used to diagnose or treat viral disease or disease  
 CC characterized by development of tumour cells or cellular degeneration  
 XX  
 SQ Sequence 17 BP; 1 A; 6 C; 2 G; 8 T; 0 U; 0 Other;  
 XX  
 QY Query Match 26.7%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 42;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 XX  
 DB 1737 ACAGGAGAAATGCATC 1752  
 16 ACAGGAGAAAGGATC 1  
 XX  
 RESULT 15  
 ID ABT39656 standard; DNA: 17 BP.  
 XX  
 AC ABT39656;  
 XX  
 DT 12-JUN-2003 (first entry)  
 XX  
 DE Tumour suppression related human fukutin oligo SEQ ID No 5293.  
 XX  
 KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;  
 KM antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;  
 KM schizophrenia; protein chip; gene therapy; tumour suppression;  
 KM human fukutin; ds.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO2003025175-A2.  
 XX

PD 27-MAR-2003.  
 XX  
 PF 17-SEP-2002; 2002WO-1B004208.  
 XX  
 PR 17-SEP-2001; 2001FR-00011978.  
 XX  
 PA (MOLE-) MOLECULAR ENGINES LAB.  
 XX  
 PI Telerman A, Amson R, Tuijnder M;  
 XX  
 DR WPI; 2003-313353/30.  
 XX  
 PT New isolated nucleic acid, useful for treating viral diseases associated  
 PT with tumors and cell degeneration, also related polypeptides, antibodies  
 PT and transfected cells.  
 XX  
 PS disclosure; Page 652; 720bp; French.  
 XX  
 CC The invention relates to a novel isolated 17 mer nucleic acid sequence,  
 CC given in the specification, a sequence containing at least 15 consecutive  
 CC nucleotides from the 17 mer sequence, a sequence with, after optimal  
 CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that  
 CC hybridizes to them under highly stringent conditions, or the complement  
 CC of any of them, or the corresponding RNA. The novel isolated nucleic  
 CC acids of the invention are useful as probes and primers for detecting,  
 CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one  
 CC component of a gene chip, in vitro as (anti)sense reagents, and for  
 CC production of recombinant polypeptides. Any of the nucleic acids,  
 CC polypeptides, vectors containing the nucleic acids, cells containing the  
 CC vector or antibodies directed against the polypeptides are useful for  
 CC preparation of pharmaceuticals for prevention and/or treatment of viral  
 CC diseases that are characterized by development of tumours or cell  
 CC degeneration, specifically cancer but also Alzheimer's disease and  
 CC schizophrenia. Analyses of the expression and/or prognosis of these  
 CC patient samples is useful for diagnosis and/or prognosis of these  
 CC diseases. The polypeptides can also be used to generate antibodies, and  
 CC both the polypeptide and antibodies are useful as components of protein  
 CC chips. The nucleic acid sequences of the invention can be used in gene  
 CC therapy. This polynucleotide sequence represents a tumour suppression  
 CC related human fukutin oligonucleotide of the invention  
 XX  
 SQ Sequence 17 BP; 8 A; 2 C; 6 G; 1 T; 0 U; 0 Other;  
 XX  
 QY Query Match 26.7%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 42;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 XX  
 DB 1731 GAACAGACAGAGAAA 1746  
 1 GATCAGCAGAGAGAAA 16  
 XX  
 RESULT 16  
 ID ACD59839/c  
 XX  
 AC ACD59839 standard; RNA: 17 BP.  
 XX  
 DT 24-SEP-2003 (first entry)  
 XX  
 DE HCV DNAzyme substrate sequence #1529.  
 XX  
 KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;  
 KM RNA stability; RNA expression; RNA synthesis; antisense;  
 KM enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; zinzyme;  
 KM amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;  
 KM HBV reverse transcriptase; Enhancer I region; viral replication;  
 KM degenerative; disease state; HBV infection; HCV infection; cirrhosis;  
 KM liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;  
 KM virucide; antiinflammatory; substrate; ss.  
 XX  
 OS Hepatitis C virus.  
 XX



XX (EPIC-) EPIGENOMICS AG.  
 PA 16-MAY-1994; 94US-00245736  
 XX Olek A, Piepenbrock C, Berlin K;  
 PI 15-AUG-1994; 94US-00291932.  
 XX WPI; 2001-657177/75.  
 DR 17-AUG-1994; 94US-00291433.  
 XX 16-AUG-1994; 94US-00292620.  
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is  
 PT designed to detect single-nucleotide polymorphisms and cytosine  
 PT methylation status.  
 PS Claim 1; SEQ ID NO 192690; 29pp + Sequence listing; German.  
 XX  
 CC This invention describes novel oligonucleotide primers or peptide nucleic  
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
 CC and cytosine methylation status in chemically pretreated genomic DNA. The  
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
 CC range of diseases including immune system, gastrointestinal, respiratory,  
 CC central nervous system, cardiovascular and metabolic disorders. The  
 CC oligomers are also used for detecting cell type differentiation. ABC00010  
 CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073  
 CC represent the oligomers described in the invention. NOTE: The sequence  
 CC data for this patent did not form part of the printed specification, but  
 CC was obtained in electronic format from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences  
 XX  
 SQ Sequence 13 BP; 4 A; 6 C; 0 G; 2 T; 0 U; 1 Other;  
 Query Match 25.0%; Score 12; DB 1; Length 13;  
 Best Local Similarity 100.0%; Pred. No. 45;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1720 TGATGTTGAGCG 1731  
 Db 13 TGATGTTGAGCG 2  
 XX  
 RESULT 19  
 ID AAT51864/c  
 XX AAT51864 standard; RNA; 15 BP.  
 XX  
 AC AAT51864;  
 XX  
 DT 25-MAR-2003 (revised)  
 DT 09-MAR-1997 (first entry)  
 DE Human ICAM hammerhead ribozyme target sequence (nt. position 770).  
 XX  
 KW Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;  
 KW gene expression; downregulation; interleukin-5; IL-5; ICAM-1;  
 KW intercellular adhesion molecule; rel A; tumour necrosis factor;  
 KW TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;  
 KW Philadelphia chromosome; myelogenous leukaemia; CML; cancer;  
 KW Philadelphia chromosome; inflammation; autoimmune disease;  
 KW atherosclerosis; myocardial infarction; stroke; restenosis;  
 KW transplant rejection; rheumatoid arthritis; psoriasis;  
 KW myocardial ischaemia; Kawasaki disease; septic shock; HIV;  
 KW human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;  
 KW ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN W09523225-A2.  
 XX  
 PD 31-AUG-1995.  
 XX  
 PF 23-FEB-1995; 95WO-IB000156.  
 XX  
 PR 23-FEB-1994; 94US-00201109.  
 PR 23-MAR-1994; 94US-0018934.  
 PR 04-APR-1994; 94US-00222795.  
 PR 07-APR-1994; 94US-00224483.  
 PR 15-APR-1994; 94US-00227958.

PR 15-APR-1994; 94US-00228041.  
 PR 16-MAY-1994; 94US-00245736.  
 PR 06-JUL-1994; 94US-00271280.  
 PR 15-AUG-1994; 94US-00291932.  
 PR 16-AUG-1994; 94US-00291433.  
 PR 17-AUG-1994; 94US-00292620.  
 PR 19-AUG-1994; 94US-00293520.  
 PR 02-SEP-1994; 94US-00300000.  
 PR 08-SEP-1994; 94US-00303039.  
 PR 23-SEP-1994; 94US-00311486.  
 PR 23-SEP-1994; 94US-00311486.  
 PR 28-SEP-1994; 94US-00314397.  
 PR 03-OCT-1994; 94US-00316771.  
 PR 07-OCT-1994; 94US-00319492.  
 PR 11-OCT-1994; 94US-00321993.  
 PR 04-NOV-1994; 94US-00334847.  
 PR 10-NOV-1994; 94US-00337608.  
 PR 28-NOV-1994; 94US-00345516.  
 PR 16-DEC-1994; 94US-00357577.  
 PR 23-DEC-1994; 94US-00363233.  
 PR 30-JAN-1995; 95US-00380734.  
 XX  
 PA (RIBO-) RIBOZYME PHARM INC.  
 XX  
 PI Stinchcomb DT, Chowrira B, Dizenzo A, Draper KG, Dudycz LM;  
 PI Grimm S, Karpelsky A, Kitch K, Matulis-Adamic J, Mcswiggen JA;  
 PI Modak A, Pavco P, Beigleman U, Sullivan SM, Sweedler D, Thompson JD,  
 PI Tracz D, Ueman N, Wincott FE, Woolf T;  
 DR WPI; 1995-351090/45.  
 XX  
 PT Ribozymes having modified bases and methods for producing them - for use  
 PT in inhibiting disease related genes.  
 PS  
 XX Claim 2; Page 172; 407pp; English.  
 XX  
 CC The present sequence represents a preferred target sequence for an  
 CC enzymatic nucleic acid (i.e. a ribozyme) which cleaves ICAM-1 mRNA.  
 CC Regions of the mRNA that do not form secondary folding structures and  
 CC that contain potential hammerhead and hairpin ribozyme cleavage sites  
 CC were identified by computer analysis. Ribozymes directed against these  
 CC mRNA sequences were designed and synthesised with modifications that  
 CC improve their nuclease resistance. The ribozymes cleave the ICAM-1 target  
 CC sequences and thereby inhibit ICAM-1 expression, making them useful for  
 CC reducing transplant rejection and alleviating symptoms in patients with  
 CC rheumatoid arthritis, asthma and other inflammatory disorders. (Updated  
 CC on 25-MAR-2003 to correct PI field.)  
 XX  
 SQ Sequence 15 BP; 1 A; 5 C; 4 G; 0 T; 5 U; 0 Other;  
 Query Match 24.6%; Score 11.8; DB 1; Length 15;  
 Best Local Similarity 86.7%; Pred. No. 53;  
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1724 GTTGAGGAACAGAC 1738  
 Db 15 GTTGAGGAACAGAC 1  
 XX  
 RESULT 20  
 ID AA264202/c  
 XX AA264202 standard; RNA; 15 BP.  
 XX  
 AC AA264202;  
 XX  
 DT 28-MAR-2000 (first entry)  
 DT  
 XX  
 DE Substrate for hammerhead ribozyme which cleaves HCV RNA at nt. 6200.  
 XX  
 KW Enzymatic nucleic acid; hammerhead ribozyme; virus replication; cleavage;  
 KW cirrhosis; liver failure; hepatocellular carcinoma; interferon; cancer;  
 KW autoimmune disease; ss.  
 XX

OS Hepatitis C virus.  
 XX  
 PN MO955847-A2.  
 XX  
 PD 04-NOV-1999.  
 XX  
 PF 26-APR-1999; 99MO-US009027.  
 XX  
 PR 27-APR-1998; 98US-0083217P.  
 PR 18-SEP-1998; 98US-0100842P.  
 PR 25-FEB-1999; 99US-00257608.  
 PR 23-MAR-1999; 99US-00274553.  
 XX  
 PA (RIBO-) RIBOZYME PHARM INC.  
 XX  
 PI Blatt L, Meswigen JA, Roberts E, Pavco PA, Macejak D;  
 XX WPI; 2000-062023/05.  
 XX  
 PT Novel ribozymes for the treatment of diseases and conditions related to  
 PT hepatitis C infection.  
 XX  
 PS Claim 1; Page 84; 123pp; English.  
 XX  
 CC The present sequence represents the preferred target sequence of an  
 CC enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves  
 CC the Hepatitis C virus (HCV) RNA sequence at the base position given in  
 CC the descriptor line. The HCV sequence was screened for optimal ribozyme  
 CC target sites using a computer folding algorithm and regions of the mRNA  
 CC which did not form secondary folding structures and contained potential  
 CC ribozyme cleavage sites were identified. Ribozymes were synthesized to  
 CC target these sites and their activities optimized by either varying the  
 CC length of the binding arms or by modification to prevent degradation by  
 CC nucleases. The ribozymes of the invention inhibit gene expression and/or  
 CC viral replication, and are used to treat diseases associated with  
 CC Hepatitis C virus (HCV) infection, e.g. cirrhosis, liver failure and  
 CC hepatocellular carcinoma. The ribozymes may be used in combination with  
 CC interferon to treat HCV infection, other infectious diseases, autoimmune  
 CC diseases, and cancer  
 XX  
 SQ Sequence 15 BP; 4 A; 7 C; 1 G; 0 T; 3 U; 0 Other;  
 QY  
 DB 1714 GCTGACTGATGTTGA 1728  
 15 GCTGAGTGATGTTGA 1  
 RESULT 21  
 ID AAF46891 standard; DNA; 15 BP.  
 XX  
 AC AAF46891;  
 XX  
 DT 30-MAR-2001 (first entry)  
 XX  
 DE IGFBP3 oligonucleotide #311.  
 XX  
 KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;  
 KW cytostatic; dermatological; cardiant; virocidic; ophthalmological; keloid;  
 KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;  
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;  
 KW growth factor mediated cell proliferation; ichthyosis; serbortnoea; ruba;  
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;  
 KW hyperneovascular condition; hyperplasia; kidney disease;  
 KW neovascular condition of the retina; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200078341-A1.

XX  
 PD 28-DEC-2000.  
 XX  
 PF 21-JUN-2000; 2000MO-AU000693.  
 XX  
 PR 21-JUN-1999; 99US-0140345P.  
 XX  
 PA (MURD-) MURDOCH CHILDRENS RES INST.  
 XX  
 PI Wright CJ, Werther GA, Edmondson SR;  
 XX WPI; 2001-041421/05.  
 XX  
 DR  
 XX  
 PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering  
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that  
 PT inhibits or reduces growth factor mediated cell proliferation and/or  
 PT inflammation.  
 XX  
 PS Example 7; Page 46; 201pp; English.  
 XX  
 CC The present invention relates to a method for ameliorating the effects of  
 CC skin disorders. The method comprises contacting the skin with an  
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1  
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of  
 CC inhibiting or reducing growth factor mediated cell proliferation,  
 CC inflammation and/or other disorders. The present sequence is an  
 CC oligonucleotide which can be used to design the antisense  
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-  
 CC P45151). The method is useful for ameliorating the effects of psoriasis,  
 CC ichthyosis, pityriasis, ruba, pilaris, serbortnoea, keloids, keratosis,  
 CC neoplasia, scleroderma, warts, benign growths, cancers of the skin, a  
 CC hyperneovascular condition such as a neovascular condition of the retina,  
 CC brain or skin, growth factor-mediated malignancies, other sclerotic  
 CC disease, kidney disease, hyperproliferation of the inside of blood  
 CC vessels or any other hyperplasia  
 XX  
 SQ Sequence 15 BP; 1 A; 5 C; 6 G; 3 T; 0 U; 0 Other;  
 QY  
 DB 1710 GGCTGCTGACTGATG 1724  
 1 GGCTGCTGCTGACG 15  
 RESULT 22  
 ID AAF46892 standard; DNA; 15 BP.  
 XX  
 AC AAF46892;  
 XX  
 DT 30-MAR-2001 (first entry)  
 XX  
 DE IGFBP3 oligonucleotide #312.  
 XX  
 KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;  
 KW cytostatic; dermatological; cardiant; virocidic; ophthalmological; keloid;  
 KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;  
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;  
 KW growth factor mediated cell proliferation; ichthyosis; serbortnoea; ruba;  
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;  
 KW hyperneovascular condition; hyperplasia; kidney disease;  
 KW neovascular condition of the retina; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200078341-A1.  
 XX  
 PD 28-DEC-2000.  
 XX  
 PF 21-JUN-2000; 2000MO-AU000693.

```

XX 21-JUN-1999; 99US-0140345P.
PR (MURD-) MURDOCH CHILDRENS RES INST.
PA Wraight CJ, Werther GA, Edmondson SR,
PI WPI; 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
XX inflammation.
XX
XX Example 7; Page 46; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, seborrhea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
XX Sequence 15 BP, 1 A; 5 C; 5 G; 4 T; 0 U; 0 Other;
SQ
Query Match 24.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 53;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1711 GCTGCTGACGTGAT 1725
DB 1 GCTGCTGCTGACGT 15
XX
RESULT 23
ABN81214/C
ID ABN81214 standard; DNA; 15 BP.
XX
XX ABN81214;
AC
XX
XX 16-AUG-2002 (first entry)
DT
XX
XX ASO probe #7 for detecting CYP1B1 gene polymorphisms.
DE
XX
XX Cytochrome P450; dioxin-inducible; glaucoma 3; CYP1B1; cytostatic;
KM ophthalmological; gene therapy; polymorphism; breast cancer; ASO;
KM primary congenital glaucoma; allele-specific oligonucleotide; probe; ss.
XX
XX Homo sapiens.
OS
XX
XX MO200230951-A2.
PN
XX
XX 18-APR-2002.
PD
XX
XX 15-OCT-2001; 2001WO-US042726.
PF
XX
XX 13-OCT-2000; 2000US-0240211P.
PR
XX
XX (GENA-) GENAISSANCE PHARM INC.
PA
XX
XX Han J, Klem SE, Sanchis A;
PI
XX
XX WPI; 2002-426265/45.
DR
XX

```

```

PT New genetic variants of cytochrome P450, subfamily I dioxin-inducible,
PT polypeptide 1, glaucoma 3, primary infantile gene, CYP1B1 for treatment
PT and expressing CYP1B1 protein for use in identifying drugs to breast
XX cancer.
XX
XX Claim 15; Page 15; 96pp; English.
XX
XX The present invention relates to a novel isolated polynucleotide
CC comprising a nucleotide sequence which is a polymorphic variant of a
CC reference sequence for cytochrome P450, subfamily I (dioxin-inducible),
CC polypeptide 1 (glaucoma 3, primary infantile), (CYP1B1) gene or its
CC fragment, or a polymorphic variant of a reference sequence for a CYP1B1
CC cDNA or its fragment. The polypeptide of the invention has cytostatic and
CC ophthalmological activity. The polynucleotide may have a use in gene
CC therapy, and antisense gene therapy. The polymorphism and haplotype data
CC of the invention are useful for validating whether CYP1B1 is a suitable
CC target for drugs to treat breast cancer and primary congenital glaucoma,
CC screening for such drugs and reducing bias in clinical trials of such
CC drugs. The sequence represents an allele-specific oligonucleotide (ASO)
CC probe, used in the invention to detect polymorphisms in the CYP1B1 gene
XX
XX Sequence 15 BP, 0 A; 6 C; 1 G; 7 T; 0 U; 1 Other;
SQ
Query Match 24.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 53;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1731 GAACAGACAGAGAGAA 1745
DB 15 GGACAGARAGAGAGAA 1
XX
RESULT 24
ABX01255/C
ID ABX01255 standard; RNA; 15 BP.
XX
XX ABX01255;
AC
XX
XX 23-DEC-2002 (first entry)
DT
XX
XX Hepatitis C virus substrate #1037 for HCV hammerhead ribozyme #1037.
DE
XX
XX Enzymatic nucleic acid; RNA cleavage; Hepatitis C virus infection;
KM HCV ribozyme; HCV expression; HCV replication; cirrhosis; vincine;
KM liver failure; hepatocellular carcinoma; HCV infection; drug therapy;
KM type I interferon; interferon alpha; interferon beta; cytostatic;
KM interferon gamma; consensus interferon; hepatotropic; antiinflammatory;
KM substrate; hammerhead ribozyme; HH ribozyme; ss.
XX
XX Hepatitis C virus.
OS
XX
XX US2002082225-A1.
PN
XX
XX 27-JUN-2002.
PD
XX
XX 23-MAR-1999; 99US-00274553.
PF
XX
XX 23-MAR-1999; 99US-00274553.
PR
XX
XX (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
PA (ROBE/) ROBERTS B.
PA (PACV/) PACCO P A.
PA (MACE/) MACEJACK D.
XX
XX Blatt L, Mcswigen JA, Roberts B, Pavco PA, Macejack D;
PI
XX
XX WPI; 2002-617759/66.
DR
XX
XX New ribozymes targeting RNA derived from hepatitis C virus inhibit viral
PT replication and are useful to treat hepatitis C virus infections and
PT cirrhosis, liver failure or hepatocellular carcinoma.
PT
XX

```

PS Claim 1; Page 51; 80pp; English.

XX The present invention relates to enzymatic nucleic acids which  
CC specifically cleave RNA derived from Hepatitis C virus (HCV). The  
CC enzymatic nucleic acid or ribozyme is in a hammerhead (HH) or hairpin  
CC (HP) motif where the binding arms comprise sequences complementary to one  
CC of the substrate sequences defined in the specification. The HCV  
CC ribozymes are useful for modulating the expression and/or replication of  
CC HCV. They can be used to treat cirrhosis, liver failure and/or  
CC hepatocellular carcinoma. The HCV ribozymes are also useful for treating  
CC a condition associated with HCV infection in conjunction with one or more  
CC other drug therapies, particularly type I interferon, especially  
CC interferon alpha, beta or gamma or consensus interferon. The present  
CC sequence represents a substrate for a HCV hammerhead (HH) ribozyme. Note:  
CC Some of the sequence data for this patent did not form part of the  
CC printed specification. The complete sequence data for this patent was  
CC obtained in electronic format directly from the USPTO web site at  
CC seqdata.uspto.gov/psipdb/entry.html

XX Sequence 15 BP; 4 A; 7 C; 1 G; 0 T; 3 U; 0 Other;

SQ

Query Match 24.6%; Score 11.8; DB 1; Length 15;  
Best Local Similarity 86.7%; Pred. No. 53;  
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1714 GCTGACTGATGTTGA 1728  
Db 15 GCTGACTGATGTTGA 1

RESULT 25  
AAL48035/c  
ID AAL48035 standard; DNA; 15 BP.

XX AAL48035;

AC 27-SEP-2002 (first entry)

XX Human CSF3 gene allele specific probe SEQ ID NO: 13.

DE Human CSF3 gene allele specific probe SEQ ID NO: 13.

XX Human, colony stimulating factor 3 (granulocyte); CSF3; SNP; isogene;  
KM chromosome 17q11-12; single nucleotide polymorphism; immunostimulant;  
KW neutropenia; promyelocytic leukaemia; haematological disorder;  
KW gene therapy; probe; ss.

XX Homo sapiens.

OS WO200194364-A2.

XX 13-DEC-2001.

PD 11-JUN-2001; 2001WO-US018813.

PF 09-JUN-2000; 2000US-0210380P.

PR (GENA-) GENAISSANCE PHARM INC.

PA Duda A, Kazemi A, Messer C, Saueker EA;  
PI WPI; 2002-566435/60.

DR

XX New variants of colony stimulating factor 3 (CSF3) isogenes, useful for  
PT improving efficiency and reliability in the development of drugs for  
PT treating diseases associated with CSF3 activity e.g. neutropenia.

PS Claim 17; Page 13; 68pp; English.

XX The present invention provides the protein, gene and cDNA sequences of  
CC human colony stimulating factor 3 (granulocyte) CSF3. Also described are  
CC single nucleotide polymorphisms (SNPs) identified within these sequences.  
CC The sequences can be used in the treatment of neutropenia, promyelocytic  
CC leukaemia and haematological disorders. The present sequence is an allele  
CC specific probe used to isolate the coding sequences of the invention

XX Sequence 15 BP; 1 A; 5 C; 3 G; 5 T; 0 U; 1 Other;

SQ

Query Match 24.2%; Score 11.6; DB 1; Length 15;  
Best Local Similarity 91.7%; Pred. No. 56;  
Matches 11; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1733 ACAGACGAGGAGA 1744  
Db 12 ACAGACGAGGAGA 1

RESULT 26  
ABC12425/c  
ID ABC12425 standard; DNA; 13 BP.

XX ABC12425;

AC 20-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 12432 for detecting SNP TSC0002943.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KM peptidic nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

OS WO200177384-A2.

XX 18-OCT-2001.

PD 06-APR-2001; 2001WO-IB000713.

PF 07-APR-2000; 2000DE-01019173.

PR (EPIC-) EPIDENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;  
PI WPI; 2001-657177/75.

DR

XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.

PS Claim 1; SEQ ID NO 12432; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences

XX

SQ Sequence 13 BP; 4 A; 5 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 23.7%; Score 11.4; DB 1; Length 13;  
Best Local Similarity 92.3%; Pred. No. 55;  
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1721 GATGTTGAGGGA 1733  
Db 13 GATGTTGAGGGA 1

RESULT 27

ABC12424  
ID ABC12424 standard; DNA; 13 BP.  
XX  
AC ABC12424;  
XX  
DT 20-FEB-2002 (first entry)  
XX  
DE Oligonucleotide SEQ ID NO 12431 for detecting SNP TSC0002943.  
XX  
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
OS Homo sapiens.  
XX  
PN WO200177384-A2.  
XX  
PD 18-OCT-2001.  
XX  
PF 06-APR-2001; 2001WO-IB000713.  
XX  
PR 07-APR-2000; 2000DE-01019173.  
XX  
PA (EPIC-) EPICENOMICS AG.  
XX  
PI Olek A, Piepenbrock C, Berlin K;  
DR WPI; 2001-657177/75.  
XX  
XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX  
PS Claim 1; SEQ ID NO 12431; 29pp + Sequence Listing; German.  
XX  
XX This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 4 A; 0 C; 5 G; 4 T; 0 U; 0 Other;  
XX  
Query Match 23.7%; Score 11.4; DB 1; Length 13;  
Best Local Similarity 92.3%; Pred. No. 55;  
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
XX  
OY 1721 GATGTTGAGGAA 1733  
DB 1 GATGTTGATGAA 13  
XX  
RESULT 28  
AAK31546/c  
ID AAK31546 standard; DNA; 15 BP.  
XX  
AC AAK31546;  
XX  
XX 21-MAY-1999 (first entry)  
XX  
DE Tag sequence of a transcript increased in pancreatic cancer.  
XX  
KW Tag sequence; colorectal cancer; pancreatic cancer; colon cancer;  
KW diagnosis; prognosis; treatment; ss.  
XX  
OS Homo sapiens.

XX  
PN WO9853319-A2.  
XX  
PD 26-NOV-1998.  
XX  
PF 20-MAY-1998; 98WO-US010277.  
XX  
PR 21-MAY-1997; 97US-0047352P.  
XX  
PA (UYJO ) UNIV JOHNS HOPKINS.  
XX  
PI Vogelstein B, Kinzler KW;  
XX  
DR WPI; 1999-070161/06.  
XX  
PT Use of isolated gene transcripts - useful for developing products for the  
PT diagnosis, prognosis and treatment of cancers, particularly colon and  
PT pancreatic cancer.  
XX  
PS Claim 13; Page 60; 120pp; English.  
XX  
XX AAK30947-31815 represent tag sequences of transcripts that are  
CC differentially expressed in colorectal cancer, in pancreatic cancer, or  
CC in both. The tag sequences can be used to identify genes by matching the  
CC tag to a gen data base member, or by using the tag sequences as probes to  
CC isolate unidentified genes from cDNA libraries. The tag sequences can  
CC also be used in a method for diagnosing colon or pancreatic cancer in a  
CC sample suspected of being neoplastic. The method comprises comparing the  
CC level of at least one transcript in a first sample of a tissue to a  
CC second sample, where the first sample is a colonic tissue suspected of  
CC being neoplastic and the second sample is a normal human colonic tissue.  
CC The transcript is identified by a tag selected from AAK30947-31815. The  
CC methods of the invention can be used in the diagnosis, prognosis and  
CC treatment of cancer  
XX  
SQ Sequence 15 BP; 2 A; 6 C; 1 G; 6 T; 0 U; 0 Other;  
XX  
Query Match 23.7%; Score 11.4; DB 1; Length 15;  
Best Local Similarity 92.3%; Pred. No. 60;  
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
XX  
OY 1739 AGGAGAAATGCAT 1751  
DB 14 AGGAGCAATGCAT 2  
XX  
RESULT 29  
AAF46889  
ID AAF46889 standard; DNA; 15 BP.  
XX  
AC AAF46889;  
XX  
DT 30-MAR-2001 (first entry)  
XX  
DE IGFBP3 oligonucleotide #309.  
XX  
XX Anticancer therapy; antiproliferative; antiinflammatory; antiproliferative;  
KW cytostatic; dermatological; cardiac; virucide; ophthalmological; keloid;  
KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pterygia;  
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;  
KW growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;  
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;  
KW hyperneovascular condition; hyperplasia; kidney disease;  
KW neovascular condition of the retina; ss.  
XX  
XX Homo sapiens.  
XX  
PN WO200078341-A1.  
XX  
PD 28-DEC-2000.  
XX  
PF 21-JUN-2000; 2000WO-AU000693.  
XX

```

PR 21-JUN-1999; 99US-0140345P.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
PA
XX
XX Wright CJ, Werther GA, Edmondson SR;
PI
XX WPI; 2001-041421/05.
DR
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
XX Example 7; Page 46; 201pp; English.
PS
XX
XX The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F5161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
XX Sequence 15 BP; 1 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
SQ
XX
XX Query Match 23.7%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 60;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1710 GGCTGCTGACTGA 1722
Db 3 GGCTGCTGCTGCTGA 15
XX
XX RESULT 30
AAF46890
ID AAF46890 standard; DNA; 15 BP.
XX
XX AAF46890;
AC
XX
XX 30-MAR-2001 (first entry)
DT
XX
XX IGFBP3 oligonucleotide #310.
DE
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KM cytostatic; dermatological; cardiac; virucide; ophthalmological; keloid;
XX skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.
XX
XX Homo sapiens.
OS
XX
XX MO200078341-A1.
PN
XX
XX 28-DEC-2000.
PD
XX
XX 21-JUN-2000; 2000MO-AU000693.
PF
XX
XX 21-JUN-1999; 99US-0140345P.
PR
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
PA
XX
XX

```

```

PI Wright CJ, Werther GA, Edmondson SR;
XX
XX WPI; 2001-041421/05.
DR
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
XX Example 7; Page 46; 201pp; English.
PS
XX
XX The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F5161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
XX Sequence 15 BP; 1 A; 6 C; 5 G; 3 T; 0 U; 0 Other;
SQ
XX
XX Query Match 23.7%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 60;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1710 GGCTGCTGACTGA 1722
Db 2 GGCTGCTGCTGCTGA 14
XX
XX RESULT 31
AAS98675/c
ID AAS98675 standard; DNA; 15 BP.
XX
XX AAS98675;
AC
XX
XX 26-MAR-2002 (first entry)
DT
XX
XX Colony stimulating factor 1 receptor (CSF1R) oligonucleotide #41.
DE
XX
XX Colony stimulating factor 1 receptor; CSF1R; polymorphic variant;
XX cytostatic; gene therapy; malignant histiocytosis; isogene;
XX myeloid malignancy; inflammatory disorder; transgenic animal; haplotype;
XX genotype; human; allele specific oligonucleotide; ASO; probe; ss.
XX
XX Homo sapiens.
OS
XX
XX MO200179225-A2.
PN
XX
XX 25-OCT-2001.
PD
XX
XX 12-APR-2001; 2001MO-US012044.
PF
XX
XX 12-APR-2000; 2000US-0196411P.
PR
XX
XX (GENA-) GENAISSANCE PHARM INC.
PA
XX
XX Chew A, Choi JY, Koehn B;
PI
XX
XX WPI; 2002-075058/10.
DR
XX
XX Novel polymorphic variants of colony stimulating factor 1 receptor useful
PT in studying expression and function of the protein, useful for screening
PT candidate drugs to treat diseases e.g. inflammatory disorders.
XX
XX

```

PS Claim 15; Page 15; 164pp; English.

XX The invention describes a novel isolated polynucleotide (I) comprising a  
 CC sequence which is a polymorphic variant (PV) of a reference sequence for  
 CC colony stimulating factor 1 receptor (CSF1R) gene, found on the  
 CC polypeptide are useful for improving the discovery and development of  
 CC drugs for treating diseases associated with CSF1R activity, e.g.,  
 CC malignant histiocytosis, myeloid malignancies, and inflammatory disorders  
 CC and the haplotypes can be used to validate CSF1R as a candidate target  
 CC for treating a specific condition or disease predicted to be associated  
 CC with CSF1R activity. Genotyping the CSF1R gene of an individual can also  
 CC be used in developing diagnostic tests and therapeutic treatments. (I) is  
 CC useful in studying the expression and function of CSF1R, and in  
 CC expressing CSF1R protein for use in screening for candidate drugs to  
 CC treat diseases related to CSF1R activity and in studying the effect of  
 CC the variation on the biological activity of CSF1R as well as on the  
 CC binding affinity of candidate drugs targeting CSF1R. Antibodies are  
 CC useful in a variety of diagnostic and prognostic formats and therapeutic  
 CC methods. A transgenic animal is useful in studying expression of the  
 CC CSF1R isogenes in vivo, for in vivo screening and testing of drugs  
 CC targeted against CSF1R protein, and for testing the efficacy of  
 CC therapeutic agents and compounds. Allele specific oligonucleotides (ASO)  
 CC are useful as probes and primers, and for assaying a polymorphism in the  
 CC target region. Without requiring any a priori knowledge of the phenotypic  
 CC effect of any particular CSF1R or haplotype the invention provides a  
 CC method for identifying lead compounds that are more likely to show  
 CC efficacy in clinical trials. This sequence is an allele specific  
 CC oligonucleotide probe used for detecting CSF1R gene polymorphisms,  
 CC described in the method of the invention

XX Sequence 15 BP; 4 A; 4 C; 4 G; 2 T; 0 U; 1 Other;

SO Query Match 23.7%; Score 11.4; DB 1; Length 15;  
 Best Local Similarity 80.0%; Pred. No. 60;  
 Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1711 GCTGCTGACTGATGT 1725  
 DB 15 GCAGCTGCTCATCT 1  
 |||||  
 |||||

RESULT 32  
 ABK96525  
 ID ABK96525 standard; DNA; 15 BP.  
 AC ABK96525;  
 XX  
 XX 24-SEP-2002 (first entry)  
 DT  
 XX  
 DE Human PLAU gene, allele specific primer #34.  
 KW Human; ss; primer; Plasminogen activator; urokinase; PLAU; cancer;  
 KW cytostatic; serine protease; thrombolytic disorder; isogenes; PCR;  
 KW pulmonary embolism; chromosome 10q24-qter; haplotype; genotype; SNP;  
 KW single nucleotide polymorphism; thrombolytic; gene therapy.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200240503-A2.  
 XX  
 PD 23-MAY-2002.  
 XX  
 PF 14-NOV-2001; 2001WO-US044001.  
 XX  
 PR 17-NOV-2000; 2000US-0249703P.  
 XX  
 PA (GENA-) GENAISSANCE PHARM INC.  
 XX  
 PI Anastasio AE, Bentivegna SC, Koshy B;  
 XX WPI; 2002-519370/55.  
 DR  
 XX Genetic variants of Plasminogen activator, Urokinase (PLAU) isogenes,  
 PT

PT useful for improving efficiency and reliability in drug development for  
 PT treating thrombolytic disorders and cancer.

XX Claim 14; Page 14; 92pp; English.

PS The invention relates to a polynucleotide comprising a first nucleotide  
 CC sequence (N81) comprising a PLAU (plasminogen activator, urokinase, a  
 CC serine protease) isogene selected from isogenes 1-9 and 11-20 given in  
 CC the specification, where each isogene comprises the regions of the PLAU  
 CC gene or cDNA and is further defined by the corresponding sequence of  
 CC polymorphisms (defining single nucleotide polymorphisms, SNP). Also  
 CC included are methods of haplotyping/genotyping (and predicting the  
 CC haplotype/genotype of the PLAU gene of an individual, identifying an  
 CC association between a trait and at least one haplotype or haplotype pair  
 CC of the PLAU gene, an isolated oligonucleotide for detecting a  
 CC polymorphism in the PLAU gene, a recombinant non-human organism  
 CC transformed or transfected with the gene or cDNA, fragments of the  
 CC polynucleotides of at least 10 base pairs encompassing a polymorphic  
 CC site, an isolated polymorphic variant PLAU protein or fragment, an  
 CC isolated monoclonal antibody specific for PLAU, a computer system for  
 CC storing and analysing polymorphism data for the PLAU gene and a genome  
 CC anthology for the PLAU gene. PLAU is useful in screening for drugs  
 CC targeting PLAU that are useful for treating thrombolytic disorders and  
 CC cancers. The methods are useful for improving the efficiency and  
 CC reliability of the discovery and development of drugs for treating  
 CC diseases associated with PLAU activity, in validating PLAU as a drug  
 CC target and in the design of clinical trials for treating a specific  
 CC condition of disease associated with PLAU activity. The antibody is  
 CC useful in diagnostic, prognostic and therapeutic methods. PLAU  
 CC polynucleotides are useful in studying the expression and function of  
 CC PLAU, and in expressing PLAU protein for use in screening for candidate  
 CC drugs to treat diseases related to PLAU activity. The gene for PLAU is  
 CC located on chromosome 10q24-qter. The present sequence is an allele  
 CC specific primer used to amplify PLAU polynucleotides with a specific  
 CC polymorphism

XX Sequence 15 BP; 5 A; 2 C; 7 G; 0 T; 0 U; 1 Other;

SO Query Match 23.7%; Score 11.4; DB 1; Length 15;  
 Best Local Similarity 80.0%; Pred. No. 60;  
 Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1729 GGGACAGACAGGAG 1743  
 DB 1 GGGACAGACAGGAG 15  
 |||||  
 |||||

RESULT 33  
 ABK32500/C  
 ID ABK32500 standard; DNA; 15 BP.  
 AC ABK32500;  
 XX  
 XX 23-APR-2002 (first entry)  
 DT  
 XX  
 DE Human pancreatic cancer SAGE tag #52.  
 KW Human; colon cancer; colorectal cancer; pancreatic cancer; SAGE tag;  
 KW serial analysis of gene expression; diagnostic; prognostic; probe;  
 KW cancer marker; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US6333152-B1.  
 XX  
 PD 25-DEC-2001.  
 XX  
 PF 20-MAY-1998; 98US-00081646.  
 XX  
 PR 20-MAY-1998; 98US-00081646.  
 XX  
 PA (UYJO) UNIV JOHNS HOPKINS.  
 XX



```

RESULT 36
ABH51281/C
ID ABH51281 standard; DNA; 13 BP.
XX
AC ABH51281;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 251258 for detecting SNP TSC0061330.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 251258; 299p + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 5 C; 0 G; 3 T; 0 U; 0 Other;
XX
Query Match 22.9%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 62;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1723 TGTGTAGGGAA 1733
| | | | | | | | | |
| | | | | | | | | |
Db 12 TGTGTAGGGAA 2
XX
RESULT 37
ABC88045/C
ID ABC88045 standard; DNA; 13 BP.
XX
AC ABC88045;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 88062 for detecting SNP TSC0022137.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

```

```

KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 88062; 299p + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 5 C; 0 G; 3 T; 0 U; 0 Other;
XX
Query Match 22.9%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 62;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1720 TGTGTGTAGG 1730
| | | | | | | | | |
| | | | | | | | | |
Db 11 TGTGTGTAGG 1
XX
RESULT 38
ABF28165/C
ID ABF28165 standard; DNA; 13 BP.
XX
AC ABF28165;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 128162 for detecting SNP TSC0032096.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX

```

PA (EPIC-) EPIGENOMICS AG.  
XX  
PI Olek A, Piepenbrock C, Berlin K;  
XX  
XX WPI; 2001-657177/75.  
DR  
XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX  
PS Claim 1; SEQ ID NO 128162; 29pp + Sequence Listing; German.  
XX  
CC This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, cardiovascular, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 6 A; 5 C; 0 G; 2 T; 0 U; 0 Other;  
XX  
Query Match 22.9%; Score 11; DB 1; Length 13;  
Best Local Similarity 100.0%; Pred. No. 62;  
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
XX  
QY 1720 TGATGTTGAGG 1730  
DB 13 TGATGTTGAGG 3  
XX  
RESULT 39  
ID ABH51280 standard; DNA; 13 BP.  
XX  
AC ABH51280;  
XX  
DT 22-FEB-2002 (first entry)  
XX  
DE Oligonucleotide SEQ ID NO 251257 for detecting SNP TSC0061330.  
XX  
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
OS Homo sapiens.  
XX  
XX WO200177384-A2.  
XX  
XX 18-OCT-2001.  
XX  
PD 06-APR-2001; 2001WO-IB000713.  
XX  
PF 07-APR-2000; 2000DE-01019173.  
XX  
PR (EPIC-) EPIGENOMICS AG.  
XX  
PA (EPIC-) EPIGENOMICS AG.  
XX  
PI Olek A, Piepenbrock C, Berlin K;  
XX  
XX WPI; 2001-657177/75.  
XX  
XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX  
PS Claim 1; SEQ ID NO 251257; 29pp + Sequence Listing; German.  
XX  
CC This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 U; 0 Other;  
XX  
Query Match 22.9%; Score 11; DB 1; Length 13;  
Best Local Similarity 100.0%; Pred. No. 62;  
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
XX  
QY 1723 TGTTGAGGGAA 1733  
DB 2 TGTTGAGGGAA 12  
XX  
RESULT 40  
ID ABH52406/C  
XX  
AC ABH52406 standard; DNA; 13 BP.  
XX  
AC ABH52406;  
XX  
DT 22-FEB-2002 (first entry)  
XX  
DE Oligonucleotide SEQ ID NO 252383 for detecting SNP TSC0061567.  
XX  
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
OS Homo sapiens.  
XX  
XX WO200177384-A2.  
XX  
XX 18-OCT-2001.  
XX  
PD 06-APR-2001; 2001WO-IB000713.  
XX  
PF 07-APR-2000; 2000DE-01019173.  
XX  
PR (EPIC-) EPIGENOMICS AG.  
XX  
PA (EPIC-) EPIGENOMICS AG.  
XX  
PI Olek A, Piepenbrock C, Berlin K;  
XX  
XX WPI; 2001-657177/75.  
XX  
XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX  
PS Claim 1; SEQ ID NO 252383; 29pp + Sequence Listing; German.  
XX  
XX This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 3 A; 0 C; 4 G; 5 T; 0 U; 1 Other;

```

Query Match      22.9%; Score 11; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 62;
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY      1743 GAATGATCCAT 1755
      :|||||
      13 RAAATCATCCAT 1

RESULT 41
ID      ABC88044
      ABC88044 standard; DNA; 13 BP.
AC
XX
XX      ABC88044;
AC
XX
XX      21-FEB-2002 (first entry)
DT
XX
XX      oligonucleotide SEQ ID NO 88061 for detecting SNP TSC0022137.
DE
XX
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX      Homo sapiens.
OS
XX
XX      WO200177384-A2.
PN
XX
XX      18-OCT-2001.
PD
XX
XX      06-APR-2001; 2001WO-IB000713.
PF
XX
XX      07-APR-2000; 2000DE-01019173.
PR
XX
XX      (EPIC-) EPIGENOMICS AG.
PA
XX
XX      Olek A, Piepenbrock C, Berlin K;
PI
XX
XX      WPI; 2001-657177/75.
DR
XX
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
XX      Claim 1; SEQ ID NO 88061; 29pp + Sequence Listing; German.
XX
XX      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
CC
XX
SQ      Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 U; 0 Other;

Query Match      22.9%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 62;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1720 TGATGTTGAGG 1730
      :|||||
      3 TGATGTTGAGG 13

RESULT 42
ID      ABF28164
      ABF28164 standard; DNA; 13 BP.
AC
XX
XX      ABF28164 standard; DNA; 13 BP.
AC
XX

```

```

XX      ABF28164;
AC
XX
XX      21-FEB-2002 (first entry)
DT
XX
XX      oligonucleotide SEQ ID NO 128161 for detecting SNP TSC0032096.
DE
XX
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX      Homo sapiens.
OS
XX
XX      WO200177384-A2.
PN
XX
XX      18-OCT-2001.
PD
XX
XX      06-APR-2001; 2001WO-IB000713.
PF
XX
XX      07-APR-2000; 2000DE-01019173.
PR
XX
XX      (EPIC-) EPIGENOMICS AG.
PA
XX
XX      Olek A, Piepenbrock C, Berlin K;
PI
XX
XX      WPI; 2001-657177/75.
DR
XX
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
XX      Claim 1; SEQ ID NO 128161; 29pp + Sequence Listing; German.
XX
XX      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
CC
XX
SQ      Sequence 13 BP; 2 A; 0 C; 5 G; 6 T; 0 U; 0 Other;

Query Match      22.9%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 62;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1720 TGATGTTGAGG 1730
      :|||||
      1 TGATGTTGAGG 11

RESULT 43
ID      ABF42716
      ABF42716 standard; DNA; 13 BP.
AC
XX
XX      ABF42716;
AC
XX
XX      21-FEB-2002 (first entry)
DT
XX
XX      oligonucleotide SEQ ID NO 142713 for detecting SNP TSC0035797.
DE
XX
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX      Homo sapiens.
OS
XX

```

```

PN MO200177384-A2.
PD 18-OCT-2001.
PP 06-APR-2001; 2001WO-IB000713.
PR 07-APR-2000; 2000DE-01019173.
PA (EPIC-) EPIGENOMICS AG.
PI Olek A, Piepenbrock C, Berlin K;
DR WPI; 2001-657177/75.
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 142713; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 7 G; 3 T; 0 U; 1 Other;
XX
XX Query Match 22.9%; Score 11; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 62;
XX Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1721 GATGTTGAGG 1731
Db 2 GATGTTGAGG 12
RESULT 44
ABHS2407
ID ABHS2407 standard; DNA; 13 BP.
AC ABHS2407;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 252384 for detecting SNP TSC0061567.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
PD 18-OCT-2001.
PP 06-APR-2001; 2001WO-IB000713.
PR 07-APR-2000; 2000DE-01019173.
PA (EPIC-) EPIGENOMICS AG.
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.

```

```

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 252384; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC09989, ABR00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 4 C; 0 G; 3 T; 0 U; 1 Other;
XX
Query Match 22.9%; Score 11; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 62;
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0
Oy 1743 GAAATGCATCCAT 1755
Db 1 AAATTCATCCAT 13
XX
RESULT 45
AA526214/C
XX ID AAA526214 standard; DNA; 14 BP.
XX
XX AAA526214;
AC
XX 19-JUN-2000 (first entry)
DT
XX
DE Oestrogen receptor hairpin ribozyme target sequence SEQ ID NO:2712.
XX
XX Oestrogen receptor; C-raf; k-ras; bcl-2; ribozyme; cleavage;
KM hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;
KW gene expression modification; cancer; phosphorothioate; endonuclease;
XX anticancer; breast cancer; endometrium cancer; ss.
XX
XX Homo sapiens.
OS
XX
XX WO9954459-A2.
PN
XX 28-OCT-1999.
PD
XX 19-APR-1999; 99WO-US008547.
PE
XX 20-APR-1998; 98US-0082404P.
XX 23-JUN-1998; 98US-00103636.
PR
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX Thompson JD, Beigelman L, Meswigen UA, Karpeisky A, Bellon L;
P1 Reynolds M, Zwick M, Jarvis T, Woolf T, Haeblerl P;
P1 Matulic-Adamic J;
XX
XX WPI; 2000-013246/01.
DR
XX
XX Claim 79; Page 103; 148pp; English.
PS
XX The present invention describes nucleic acids (A) that interact stably
CC with a target sequence and contain at least one phosphoro(dithioate
CC link, having endonuclease activity (A), and more generally any catalytic

```

CC nucleic acid (A') that modulates expression of the oestrogen receptor  
 CC gene, are used to treat cancer (particularly of breast or endometrium),  
 CC in vivo or by transforming cells ex vivo and implanting treated cells, or  
 CC for other conditions associated with levels of oestrogen receptor.  
 CC Because of the high selectivity for targeted RNA, (A) can also be used to  
 CC correlate inhibition of gene expression with alterations in phenotype,  
 CC particularly for identification of therapeutic targets, and as research  
 CC reagents (for RNA, in the same way that restriction endonucleases are  
 CC used with DNA). The combination of modifications in (A) improves  
 CC resistance to nucleases, binding affinity and/or activity. AAA23503 to  
 CC AAA24747 represent oestrogen receptor hammerhead ribozyme sequences, and  
 CC AAA24748 to AAA25992 represent their corresponding target sequences.  
 CC AAA25993 to AAA26105 represent oestrogen receptor hairpin ribozyme  
 CC sequences, and AAA26107 to AAA26218 represent their corresponding target  
 CC sequences. AAA26219 to AAA26271 represent other ribozyme sequences and  
 CC antisense oligonucleotides used in the exemplification of the present  
 CC invention  
 CC  
 SQ Sequence 14 BP; 1 A; 4 C; 1 G; 8 T; 0 U; 0 Other;

Query Match 22.5%; Score 10.8; DB 1; Length 14;  
 Best Local Similarity 85.7%; Pred. No. 69;  
 Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1726 TGAGGAAACAGCA 1739  
 DB 14 TGAGGAAACAGCAA 1

RESULT 46  
 ABC68262  
 ID ABC68262 standard; DNA; 13 BP.

AC ABC68262;  
 XX 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 68279 for detecting SNP TSC0017813.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PA (EPIC-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

XX WPI, 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is  
 PT designed to detect single-nucleotide polymorphisms and cytosine  
 PT methylation status.

PS Claim 1; SEQ ID NO 68279; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic  
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
 CC and cytosine methylation status in chemically pretreated genomic DNA. The  
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
 CC range of diseases including immune system, gastrointestinal, respiratory,  
 CC central nervous system, cardiovascular and metabolic disorders. The  
 CC oligomers are also used for detecting cell type differentiation. ABC00010  
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence  
 CC data for this patent did not form part of the printed specification, but  
 CC was obtained in electronic format from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences

SQ Sequence 13 BP; 5 A; 0 C; 5 G; 2 T; 0 U; 1 Other;

Query Match 22.1%; Score 10.6; DB 1; Length 13;  
 Best Local Similarity 90.9%; Pred. No. 70;  
 Matches 10; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 1739 AGGAGAAATGC 1749  
 DB 3 AGGAGAAATGCY 13

RESULT 47  
 ABC68263/c  
 ID ABC68263 standard; DNA; 13 BP.

AC ABC68263;  
 XX 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 68280 for detecting SNP TSC0017813.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PA (EPIC-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

XX WPI, 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is  
 PT designed to detect single-nucleotide polymorphisms and cytosine  
 PT methylation status.

PS Claim 1; SEQ ID NO 68280; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic  
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
 CC and cytosine methylation status in chemically pretreated genomic DNA. The  
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
 CC range of diseases including immune system, gastrointestinal, respiratory,  
 CC central nervous system, cardiovascular and metabolic disorders. The  
 CC oligomers are also used for detecting cell type differentiation. ABC00010  
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
 CC represent the oligomers described in the invention. NOTE: The sequence  
 CC data for this patent did not form part of the printed specification, but  
 CC was obtained in electronic format from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences

SQ Sequence 13 BP; 2 A; 5 C; 0 G; 5 T; 0 U; 1 Other;

Query Match 22.1%; Score 10.6; DB 1; Length 13;  
 Best Local Similarity 90.9%; Pred. No. 70;  
 Matches 10; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 1739 AGGAGAAATGC 1749  
 |||||

Db 11 AGGAGAAATGY 1

RESULT 48

ABH85801 standard; DNA; 12 BP.

XX ABH85801;

XX 22-FEB-2002 (first entry)

DT Oligonucleotide primer SEQ ID NO 285794 for detecting SNP TSC0012441.

XX

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

PD 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

PR (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.

PS Claim 1; SEQ ID NO 285794; 29pp + Sequence Listing; German.

XX

XX This invention describes novel oligonucleotide primers or peptide nucleic

XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

XX and cytosine methylation status in chemically pretreated genomic DNA. The

XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a

XX range of diseases including immune system, gastrointestinal, respiratory,

XX central nervous system, cardiovascular and metabolic disorders. The

XX oligomers are also used for detecting cell type differentiation. ABC00010

XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

XX represent the oligomers described in the invention. NOTE: The sequence

XX data for this patent did not form part of the printed specification, but

XX was obtained in electronic format from WIPO at

XX ftp.wipo.int/pub/published\_pct\_sequences

XX

SQ Sequence 12 BP; 7 A; 0 C; 4 G; 1 T; 0 U; 0 Other;

Query Match 21.7%; Score 10.4; DB 1; Length 12;

Best Local Similarity 91.7%; Pred. No. 71;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1737 ACAGGAGAATG 1748

Db 1 AAAGGAGAAATG 12

RESULT 49

AB141640 standard; DNA; 12 BP.

XX AB141640;

XX 22-FEB-2002 (first entry)

DT Oligonucleotide primer SEQ ID NO 341613 for detecting SNP TSC0042137.

XX

KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

PD 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

PR (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.

PS Claim 1; SEQ ID NO 341613; 29pp + Sequence Listing; German.

XX

XX This invention describes novel oligonucleotide primers or peptide nucleic

XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

XX and cytosine methylation status in chemically pretreated genomic DNA. The

XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a

XX range of diseases including immune system, gastrointestinal, respiratory,

XX central nervous system, cardiovascular and metabolic disorders. The

XX oligomers are also used for detecting cell type differentiation. ABC00010

XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

XX represent the oligomers described in the invention. NOTE: The sequence

XX data for this patent did not form part of the printed specification, but

XX was obtained in electronic format from WIPO at

XX ftp.wipo.int/pub/published\_pct\_sequences

XX

SQ Sequence 12 BP; 5 A; 0 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 21.7%; Score 10.4; DB 1; Length 12;

Best Local Similarity 91.7%; Pred. No. 71;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1726 TGAGGAGACAGA 1737

Db 1 TGAGGAGAGAGA 12

RESULT 50

AB149018/C

ID AB149018 standard; DNA; 12 BP.

XX AB149018;

XX 22-FEB-2002 (first entry)

DT Oligonucleotide primer SEQ ID NO 348991 for detecting SNP TSC0045849.

XX

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

PD 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

```

XX (EPIC-) EPIGENOMICS AG.
PA Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 348991; 29bp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT92073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 4 A; 5 C; 0 G; 3 T; 0 U; 0 Other;
XX
Query Match 21.7%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 71;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1721 GATGTTGAGCGA 1732
Db 12 GATGTTGAGCGA 1
XX
RESULT 51
AB162513/C
ID AB162513 standard; DNA; 12 BP.
XX
AC AB162513;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 362486 for detecting SNP TSC0053258.
XX
SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 362486; 29bp + Sequence Listing; German.
XX

```

```

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT92073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 6 C; 0 G; 5 T; 0 U; 0 Other;
XX
Query Match 21.7%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 71;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1726 TGAGGAGACGA 1737
Db 12 TGAGGAGACGA 1
XX
RESULT 52
ABH69285/C
ID ABH69285 standard; DNA; 12 BP.
XX
AC ABH69285;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 269262 for detecting SNP TSC0001682.
XX
SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 269262; 29bp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT92073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

```

SQ Sequence 12 BP; 4 A; 4 C; 1 G; 3 T; 0 U; 0 Other;  
Query Match 21.7%; Score 10.4; DB 1; Length 12;  
Best Local Similarity 91.7%; Pred. No. 71;  
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1723 TGTTCAGCGAAC 1734  
12 TGTTCAGCGTAAC 1  
RESULT 53  
ABC94621/c  
ID ABC94621 standard; DNA; 13 BP.  
XX  
AC ABC94621;  
XX  
DT 21-FEB-2002 (first entry)  
XX  
DE Oligonucleotide SEQ ID NO 94638 for detecting SNP TSC0023588.  
XX  
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
OS Homo sapiens.  
XX  
PN WO200177384-A2.  
XX  
PD 18-OCT-2001.  
XX  
PF 06-APR-2001; 2001WO-IB000713.  
XX  
PR 07-APR-2000; 2000DE-01019173.  
XX  
PA (EPIC-) EPIGENOMICS AG.  
XX  
PI Olek A, Piepenbrock C, Berlin K;  
XX  
DR WPI; 2001-657177/75.  
XX  
XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX  
PS Claim 1; SEQ ID NO 94638; 29pp + Sequence Listing; German.  
XX  
CC This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 4 A; 5 C; 0 G; 4 T; 0 U; 0 Other;  
Query Match 21.7%; Score 10.4; DB 1; Length 13;  
Best Local Similarity 91.7%; Pred. No. 75;  
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1721 GATGTTGAGGGA 1732  
12 GATTTGAGGGA 1  
RESULT 54  
ABC6414  
ABC6414

ID ABC6414 standard; DNA; 13 BP.  
XX  
AC ABC6414;  
XX  
DT 20-FEB-2002 (first entry)  
XX  
DE Oligonucleotide SEQ ID NO 36431 for detecting SNP TSC0011440.  
XX  
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
OS Homo sapiens.  
XX  
PN WO200177384-A2.  
XX  
PD 18-OCT-2001.  
XX  
PF 06-APR-2001; 2001WO-IB000713.  
XX  
PR 07-APR-2000; 2000DE-01019173.  
XX  
PA (EPIC-) EPIGENOMICS AG.  
XX  
PI Olek A, Piepenbrock C, Berlin K;  
XX  
DR WPI; 2001-657177/75.  
XX  
XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX  
PS Claim 1; SEQ ID NO 36431; 29pp + Sequence Listing; German.  
XX  
CC This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 6 A; 0 C; 5 G; 2 T; 0 U; 0 Other;  
Query Match 21.7%; Score 10.4; DB 1; Length 13;  
Best Local Similarity 91.7%; Pred. No. 75;  
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1722 ATGTTGAGGGA 1733  
2 ATGATGAGGGA 13  
RESULT 55  
ABF18905/c  
ID ABF18905 standard; DNA; 13 BP.  
XX  
AC ABF18905;  
XX  
DT 21-FEB-2002 (first entry)  
XX  
DE Oligonucleotide SEQ ID NO 118902 for detecting SNP TSC0023684.  
XX  
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
OS Homo sapiens.

```

XX  XX  WO200177384-A2.
XX  XX  18-OCT-2001.
XX  XX  06-APR-2001; 2001WO-IB000713.
XX  XX  07-APR-2000; 2000DE-01019173.
XX  XX  (EPIC-) EPIGENOMICS AG.
XX  XX  Olek A, Piepenbrock C, Berlin K;
XX  XX  WPI; 2001-657177/75.
XX  XX  Set of oligonucleotides, useful for diagnosis and cell typing, is
XX  XX  designed to detect single-nucleotide polymorphisms and cytosine
XX  XX  methylation status.
XX  XX  Claim 1; SEQ ID NO 118902; 29pp + Sequence Listing; German.
XX  XX  This invention describes novel oligonucleotide primers or peptide nucleic
XX  XX  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX  XX  and cytosine methylation status in chemically pretreated genomic DNA. The
XX  XX  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX  XX  range of diseases including immune system, gastrointestinal, respiratory,
XX  XX  central nervous system, cardiovascular and metabolic disorders. The
XX  XX  oligomers are also used for detecting cell type differentiation. ABC00010
XX  XX  -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX  XX  represent the oligomers described in the invention. NOTE: The sequence
XX  XX  data for this patent did not form part of the printed specification, but
XX  XX  was obtained in electronic format from WIPO at
XX  XX  ftp.wipo.int/pub/published_pct_sequences

SQ  Sequence 13 BP; 2 A; 7 C; 0 G; 4 T; 0 U; 0 Other;

Query Match      21.7%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 75;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY  1721 GATGTTGAGGGA 1732
    |||||
    12 GATGTGAGGGA 1

DE  12 GATGTGAGGGA 1

AC  ABC36415 standard; DNA; 13 BP.
XX  XX  ABC36415;
XX  XX  20-FEB-2002 (first entry)
XX  XX  Oligonucleotide SEQ ID NO 36432 for detecting SNP TSC0011440.
XX  XX  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX  XX  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX  XX  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX  XX  Homo sapiens.
XX  XX  WO200177384-A2.
XX  XX  18-OCT-2001.
XX  XX  06-APR-2001; 2001WO-IB000713.
XX  XX  07-APR-2000; 2000DE-01019173.
XX  XX  (EPIC-) EPIGENOMICS AG.
XX  XX  Olek A, Piepenbrock C, Berlin K;
XX  XX

```

```

DR  WPI; 2001-657177/75.
XX  XX  Set of oligonucleotides, useful for diagnosis and cell typing, is
XX  XX  designed to detect single-nucleotide polymorphisms and cytosine
XX  XX  methylation status.
XX  XX  Claim 1; SEQ ID NO 36432; 29pp + Sequence Listing; German.
XX  XX  This invention describes novel oligonucleotide primers or peptide nucleic
XX  XX  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX  XX  and cytosine methylation status in chemically pretreated genomic DNA. The
XX  XX  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX  XX  range of diseases including immune system, gastrointestinal, respiratory,
XX  XX  central nervous system, cardiovascular and metabolic disorders. The
XX  XX  oligomers are also used for detecting cell type differentiation. ABC00010
XX  XX  -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX  XX  represent the oligomers described in the invention. NOTE: The sequence
XX  XX  data for this patent did not form part of the printed specification, but
XX  XX  was obtained in electronic format from WIPO at
XX  XX  ftp.wipo.int/pub/published_pct_sequences

SQ  Sequence 13 BP; 2 A; 5 C; 0 G; 6 T; 0 U; 0 Other;

Query Match      21.7%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 75;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY  1722 ATGTTGAGGGA 1733
    |||||
    12 ATGATGAGGGA 1

DE  12 ATGATGAGGGA 1

AC  ABF92694 standard; DNA; 13 BP.
XX  XX  ABF92694;
XX  XX  22-FEB-2002 (first entry)
XX  XX  Oligonucleotide SEQ ID NO 192691 for detecting SNP TSC0047415.
XX  XX  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX  XX  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX  XX  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX  XX  Homo sapiens.
XX  XX  WO200177384-A2.
XX  XX  18-OCT-2001.
XX  XX  06-APR-2001; 2001WO-IB000713.
XX  XX  07-APR-2000; 2000DE-01019173.
XX  XX  (EPIC-) EPIGENOMICS AG.
XX  XX  Olek A, Piepenbrock C, Berlin K;
XX  XX  WPI; 2001-657177/75.
XX  XX  Set of oligonucleotides, useful for diagnosis and cell typing, is
XX  XX  designed to detect single-nucleotide polymorphisms and cytosine
XX  XX  methylation status.
XX  XX  Claim 1; SEQ ID NO 192691; 29pp + Sequence Listing; German.
XX  XX  This invention describes novel oligonucleotide primers or peptide nucleic
XX  XX  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX  XX  and cytosine methylation status in chemically pretreated genomic DNA. The
XX  XX  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX  XX  range of diseases including immune system, gastrointestinal, respiratory,

```

CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
CC  
SQ Sequence 13 BP; 2 A; 1 C; 6 G; 3 T; 0 U; 1 Other;  
Query Match 21.7%; Score 10.4; DB 1; Length 13;  
Best Local Similarity 91.7%; Pred. No. 75;  
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 1720 TGATGTTGAGG 1731  
Db 1 TGACGTTGAGG 12  
RESULT 58  
ABF18904  
ID ABF18904 standard; DNA; 13 BP.  
AC ABF18904;  
XX  
XX 21-FEB-2002 (first entry)  
DT  
XX  
DE Oligonucleotide SEQ ID NO 118901 for detecting SNP TSC0029684.  
XX  
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
XX Homo sapiens.  
XX  
XX WO200177384-A2.  
XX  
XX 18-OCT-2001.  
XX  
XX 06-APR-2001; 2001WO-IB000713.  
XX  
XX 07-APR-2000; 2000DE-01019173.  
XX  
XX (EPIC-) EPIGENOMICS AG.  
XX  
XX Olek A, Piepenbrock C, Berlin K;  
XX  
XX WPI; 2001-657177/75.  
XX  
XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
XX PT designed to detect single-nucleotide polymorphisms and cytosine  
XX PT methylation status.  
XX  
XX  
PS Claim 1; SEQ ID NO 118901; 29pp + Sequence Listing; German.  
XX  
XX This invention describes novel oligonucleotide primers or peptide nucleic  
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The  
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
XX CC range of diseases including immune system, gastrointestinal, respiratory,  
XX CC central nervous system, cardiovascular and metabolic disorders. The  
XX CC oligomers are also used for detecting cell type differentiation. ABC00010  
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
XX CC represent the oligomers described in the invention. NOTE: The sequence  
XX CC data for this patent did not form part of the printed specification, but  
XX CC was obtained in electronic format from WIPO at  
XX CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 4 A; 0 C; 7 G; 2 T; 0 U; 0 Other;  
Query Match 21.7%; Score 10.4; DB 1; Length 13;  
Best Local Similarity 91.7%; Pred. No. 75;  
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1721 GATGTTGAGGGA 1732  
Db 2 GATGTTGAGGGA 13  
RESULT 59  
ABH43430  
ID ABH43430 standard; DNA; 13 BP.  
AC ABH43430;  
XX  
XX 22-FEB-2002 (first entry)  
DT  
XX  
DE Oligonucleotide SEQ ID NO 243407 for detecting SNP TSC0010229.  
XX  
XX  
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
XX Homo sapiens.  
XX  
XX WO200177384-A2.  
XX  
XX 18-OCT-2001.  
XX  
XX 06-APR-2001; 2001WO-IB000713.  
XX  
XX 07-APR-2000; 2000DE-01019173.  
XX  
XX (EPIC-) EPIGENOMICS AG.  
XX  
XX Olek A, Piepenbrock C, Berlin K;  
XX  
XX WPI; 2001-657177/75.  
XX  
XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
XX PT designed to detect single-nucleotide polymorphisms and cytosine  
XX PT methylation status.  
XX  
XX  
PS Claim 1; SEQ ID NO 243407; 29pp + Sequence Listing; German.  
XX  
XX This invention describes novel oligonucleotide primers or peptide nucleic  
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The  
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
XX CC range of diseases including immune system, gastrointestinal, respiratory,  
XX CC central nervous system, cardiovascular and metabolic disorders. The  
XX CC oligomers are also used for detecting cell type differentiation. ABC00010  
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
XX CC represent the oligomers described in the invention. NOTE: The sequence  
XX CC data for this patent did not form part of the printed specification, but  
XX CC was obtained in electronic format from WIPO at  
XX CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 U; 0 Other;  
Query Match 21.7%; Score 10.4; DB 1; Length 13;  
Best Local Similarity 91.7%; Pred. No. 75;  
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 1718 ACTGATGTTGAG 1729  
Db 2 ACTGATGTTGAG 13  
RESULT 60  
ABH14879/c  
ID ABH14879 standard; DNA; 13 BP.  
AC ABH14879;  
XX  
XX 22-FEB-2002 (first entry)  
DT

```

XX  oligonucleotide SEQ ID NO 214856 for detecting SNP TSC0052286.
DE
XX
XX  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX  Homo sapiens.
XX
XX  WO200177384-A2.
XX
XX  18-OCT-2001.
XX
XX
XX  06-APR-2001; 2001WO-IB000713.
XX
XX  07-APR-2000; 2000DE-01019173.
XX
XX  (EPIC-) EPIGENOMICS AG.
XX
XX  Olek A, Piepenbrock C, Berlin K;
XX
XX  WPI; 2001-657177/75.
XX
XX  Set of oligonucleotides, useful for diagnosis and cell typing, is
XX  designed to detect single-nucleotide polymorphisms and cytosine
XX  methylation status.
XX
XX  Claim 1; SEQ ID NO 214856; 29pp + Sequence Listing; German.
XX
XX  This invention describes novel oligonucleotide primers or peptide nucleic
XX  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX  and cytosine methylation status in chemically pretreated genomic DNA. The
XX  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX  range of diseases including immune system, gastrointestinal, respiratory,
XX  central nervous system, cardiovascular and metabolic disorders. The
XX  oligomers are also used for detecting cell type differentiation. ABC00010
XX  -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX  represent the oligomers described in the invention. NOTE: The sequence
XX  data for this patent did not form part of the printed specification, but
XX  was obtained in electronic format from WIPO at
XX  ftp.wipo.int/pub/published_pct_sequences
XX
XX  Sequence 13 BP; 2 A; 5 C; 0 G; 5 T; 0 U; 1 Other;
SQ
XX
XX  Query Match 21.7%; Score 10.4; DB 1; Length 13;
XX  Best Local Similarity 91.7%; Pred. No. 75;
XX  Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1725 TTGAGGGAACAG 1736
XX  |||||
XX  13 TTGAGGGAACAG 2
DB
XX
XX  RESULT 61
XX  ABH58053/c
XX  ID ABH58053 standard; DNA; 13 BP.
XX
XX  ABH58053;
XX
XX  22-FEB-2002 (first entry)
XX
XX  Oligonucleotide SEQ ID NO 258030 for detecting SNP TSC0062747.
DE
XX
XX  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX  Homo sapiens.
XX
XX  WO200177384-A2.
XX
XX  18-OCT-2001.
XX

```

```

PF 06-APR-2001; 2001WO-IB000713.
XX
XX  07-APR-2000; 2000DE-01019173.
XX
XX  (EPIC-) EPIGENOMICS AG.
XX
XX  Olek A, Piepenbrock C, Berlin K;
XX
XX  WPI; 2001-657177/75.
XX
XX  Set of oligonucleotides, useful for diagnosis and cell typing, is
XX  designed to detect single-nucleotide polymorphisms and cytosine
XX  methylation status.
XX
XX  Claim 1; SEQ ID NO 258030; 29pp + Sequence Listing; German.
XX
XX  This invention describes novel oligonucleotide primers or peptide nucleic
XX  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX  and cytosine methylation status in chemically pretreated genomic DNA. The
XX  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX  range of diseases including immune system, gastrointestinal, respiratory,
XX  central nervous system, cardiovascular and metabolic disorders. The
XX  oligomers are also used for detecting cell type differentiation. ABC00010
XX  -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX  represent the oligomers described in the invention. NOTE: The sequence
XX  data for this patent did not form part of the printed specification, but
XX  was obtained in electronic format from WIPO at
XX  ftp.wipo.int/pub/published_pct_sequences
XX
XX  Sequence 13 BP; 6 A; 5 C; 0 G; 2 T; 0 U; 0 Other;
SQ
XX
XX  Query Match 21.7%; Score 10.4; DB 1; Length 13;
XX  Best Local Similarity 91.7%; Pred. No. 75;
XX  Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1720 TCAATGTTGACG 1731
XX  |||||
XX  12 TTAATGTTGACG 1
DB
XX
XX  RESULT 62
XX  ABF11938
XX  ID ABF11938 standard; DNA; 13 BP.
XX
XX  ABF11938;
XX
XX  21-FEB-2002 (first entry)
XX
XX  Oligonucleotide SEQ ID NO 111935 for detecting SNP TSC0027936.
DE
XX
XX  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX  Homo sapiens.
XX
XX  WO200177384-A2.
XX
XX  18-OCT-2001.
XX
XX  06-APR-2001; 2001WO-IB000713.
XX
XX  07-APR-2000; 2000DE-01019173.
XX
XX  (EPIC-) EPIGENOMICS AG.
XX
XX  Olek A, Piepenbrock C, Berlin K;
XX
XX  WPI; 2001-657177/75.
XX
XX  Set of oligonucleotides, useful for diagnosis and cell typing, is
XX  designed to detect single-nucleotide polymorphisms and cytosine
XX  methylation status.
XX

```

XX Claim 1; SEQ ID NO 111935; 29pp + Sequence Listing; German.  
 XX  
 CC This invention describes novel oligonucleotide primers or peptide nucleic  
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
 CC and cytosine methylation status in chemically pretreated genomic DNA. The  
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
 CC range of diseases including immune system, gastrointestinal, respiratory,  
 CC central nervous system, cardiovascular and metabolic disorders. The  
 CC oligomers are also used for detecting cell type differentiation. ABC00010  
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073  
 CC represent the oligomers described in the invention. NOTE: The sequence  
 CC data for this patent did not form part of the printed specification, but  
 CC was obtained in electronic format from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences  
 XX  
 SQ Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 U; 0 Other;  
 Query Match 21.7%; Score 10.4; DB 1; Length 13;  
 Best Local Similarity 91.7%; Pred. No. 75;  
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 1721 GATGTTGAGGA 1732  
 Db |||||  
 2 GATGTTGAGGA 13  
 RESULT 63  
 ABC78923/C  
 ID ABC78923 standard; DNA; 13 BP.  
 AC ABC78923;  
 XX  
 DT 21-FEB-2002 (first entry)  
 XX  
 DE Oligonucleotide SEQ ID NO 78940 for detecting SNP TSC0020091.  
 XX  
 SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200177384-A2.  
 XX  
 PD 18-OCT-2001.  
 XX  
 PF 06-APR-2001; 2001WO-IB000713.  
 XX  
 PR 07-APR-2000; 2000DE-01019173.  
 XX  
 PA (EPig-) EPIGENOMICS AG.  
 XX  
 PI Olek A, Piepenbrock C, Berlin K;  
 XX  
 DR WPI; 2001-657177/75.  
 XX  
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is  
 PT designed to detect single-nucleotide polymorphisms and cytosine  
 PT methylation status.  
 XX  
 PS Claim 1; SEQ ID NO 78940; 29pp + Sequence Listing; German.  
 XX  
 CC This invention describes novel oligonucleotide primers or peptide nucleic  
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
 CC and cytosine methylation status in chemically pretreated genomic DNA. The  
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
 CC range of diseases including immune system, gastrointestinal, respiratory,  
 CC central nervous system, cardiovascular and metabolic disorders. The  
 CC oligomers are also used for detecting cell type differentiation. ABC00010  
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073  
 CC represent the oligomers described in the invention. NOTE: The sequence  
 CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences  
 XX  
 SQ Sequence 13 BP; 1 A; 4 C; 0 G; 8 T; 0 U; 0 Other;  
 Query Match 21.7%; Score 10.4; DB 1; Length 13;  
 Best Local Similarity 91.7%; Pred. No. 75;  
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 1736 GACGAGGAAT 1747  
 Db |||||  
 13 GACGAGGAAT 2  
 RESULT 64  
 ABF92695/C  
 ID ABF92695 standard; DNA; 13 BP.  
 AC ABF92695;  
 XX  
 DT 22-FEB-2002 (first entry)  
 XX  
 DE Oligonucleotide SEQ ID NO 192692 for detecting SNP TSC0047415.  
 XX  
 SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200177384-A2.  
 XX  
 PD 18-OCT-2001.  
 XX  
 PF 06-APR-2001; 2001WO-IB000713.  
 XX  
 PR 07-APR-2000; 2000DE-01019173.  
 XX  
 PA (EPig-) EPIGENOMICS AG.  
 XX  
 PI Olek A, Piepenbrock C, Berlin K;  
 XX  
 DR WPI; 2001-657177/75.  
 XX  
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is  
 PT designed to detect single-nucleotide polymorphisms and cytosine  
 PT methylation status.  
 XX  
 PS Claim 1; SEQ ID NO 192692; 29pp + Sequence Listing; German.  
 XX  
 CC This invention describes novel oligonucleotide primers or peptide nucleic  
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
 CC and cytosine methylation status in chemically pretreated genomic DNA. The  
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
 CC range of diseases including immune system, gastrointestinal, respiratory,  
 CC central nervous system, cardiovascular and metabolic disorders. The  
 CC oligomers are also used for detecting cell type differentiation. ABC00010  
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073  
 CC represent the oligomers described in the invention. NOTE: The sequence  
 CC data for this patent did not form part of the printed specification, but  
 CC was obtained in electronic format from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences  
 XX  
 SQ Sequence 13 BP; 3 A; 6 C; 1 G; 2 T; 0 U; 1 Other;  
 Query Match 21.7%; Score 10.4; DB 1; Length 13;  
 Best Local Similarity 91.7%; Pred. No. 75;  
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 1720 TGACGTTGAGG 1731  
 Db |||||  
 13 TGACGTTGAGG 2

RESULT 65  
ABF92697/C  
ID ABF92697 standard; DNA; 13 BP.  
XX  
AC ABF92697;  
XX  
DT 22-FEB-2002 (first entry)  
XX  
DE Oligonucleotide SEQ ID NO 192694 for detecting SNP TSC0047415.  
XX  
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
OS Homo sapiens.  
XX  
PN WO200177384-A2.  
XX  
PD 18-OCT-2001.  
XX  
PE 06-APR-2001; 2001WO-IB000713.  
XX  
PR 07-APR-2000; 2000DE-01019173.  
XX  
PA (EPIC-) EPIGENOMICS AG.  
XX  
PI Olek A, Piepenbrock C, Berlin K;  
XX  
DR WPI; 2001-657177/75.  
XX  
PT Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX  
PS Claim 1; SEQ ID NO 192694; 29bp + Sequence Listing; German.  
XX  
CC This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 3 A; 6 C; 1 G; 2 T; 0 U; 1 Other;  
Query Match 21.7%; Score 10.4; DB 1; Length 13;  
Best Local Similarity 91.7%; Pred. No. 75;  
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
OY 1720 TGATGTCGAGG 1731  
Db 13 TGATGTCGAGG 2  
RESULT 66  
ABF56731/C  
ID ABF56731 standard; DNA; 13 BP.  
XX  
AC ABF56731;  
XX  
DT 21-FEB-2002 (first entry)  
XX  
DE Oligonucleotide SEQ ID NO 156728 for detecting SNP TSC0039520.  
XX  
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

KM central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
OS Homo sapiens.  
XX  
PN WO200177384-A2.  
XX  
PD 18-OCT-2001.  
XX  
PE 06-APR-2001; 2001WO-IB000713.  
XX  
PR 07-APR-2000; 2000DE-01019173.  
XX  
PA (EPIC-) EPIGENOMICS AG.  
XX  
PI Olek A, Piepenbrock C, Berlin K;  
XX  
DR WPI; 2001-657177/75.  
XX  
PT Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX  
PS Claim 1; SEQ ID NO 156728; 29bp + Sequence Listing; German.  
XX  
CC This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 1 A; 5 C; 0 G; 6 T; 0 U; 1 Other;  
Query Match 21.7%; Score 10.4; DB 1; Length 13;  
Best Local Similarity 91.7%; Pred. No. 75;  
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
OY 1736 GACGAGGAAAT 1747  
Db 13 GACGAGGAAAT 2  
RESULT 67  
ABC94620  
ID ABC94620 standard; DNA; 13 BP.  
XX  
AC ABC94620;  
XX  
DT 21-FEB-2002 (first entry)  
XX  
DE Oligonucleotide SEQ ID NO 94637 for detecting SNP TSC0023588.  
XX  
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
OS Homo sapiens.  
XX  
PN WO200177384-A2.  
XX  
PD 18-OCT-2001.  
XX  
PE 06-APR-2001; 2001WO-IB000713.  
XX  
PR 07-APR-2000; 2000DE-01019173.  
XX  
PA (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;  
XX WPI; 2001-657177/75.  
XX  
XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX  
XX Claim 1; SEQ ID NO 94637; 29pp + Sequence Listing; German.  
XX  
XX This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 4 A; 0 C; 5 G; 4 T; 0 U; 0 Other;  
XX  
Query Match 21.7%; Score 10.4; DB 1; Length 13;  
Best Local Similarity 91.7%; Pred. No. 75;  
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
OY 1721 GATGTTGAGCGA 1732  
Db 2 GATTTGAGCGA 13  
XX  
RESULT 68  
ABF18906  
ID ABF18906 standard; DNA; 13 BP.  
XX  
XX ABP18906;  
AC  
XX 21-FEB-2002 (first entry)  
XT  
XX Oligonucleotide SEQ ID NO 118903 for detecting SNP TSC0029684.  
DE  
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
XX Homo sapiens.  
OS  
XX WO200177384-A2.  
PN  
XX 18-OCT-2001.  
PD  
XX 06-APR-2001; 2001WO-IB000713.  
PF  
XX 07-APR-2000; 2000DE-01019173.  
PR  
XX (EPIC-) EPIGENOMICS AG.  
PS  
XX Olek A, Piepenbrock C, Berlin K;  
PI  
XX WPI; 2001-657177/75.  
DR  
XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX  
XX Claim 1; SEQ ID NO 118903; 29pp + Sequence Listing; German.  
XX  
XX This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 5 A; 0 C; 6 G; 2 T; 0 U; 0 Other;  
XX  
Query Match 21.7%; Score 10.4; DB 1; Length 13;  
Best Local Similarity 91.7%; Pred. No. 75;  
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
OY 1721 GATGTTGAGCGA 1732  
Db 2 GATGTAGCGGA 13  
XX  
RESULT 69  
ABH43431/C  
ID ABH43431 standard; DNA; 13 BP.  
XX  
XX ABH43431;  
AC  
XX 22-FEB-2002 (first entry)  
DT  
XX Oligonucleotide SEQ ID NO 243408 for detecting SNP TSC0010229.  
DE  
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
XX Homo sapiens.  
OS  
XX WO200177384-A2.  
PN  
XX 18-OCT-2001.  
PD  
XX 06-APR-2001; 2001WO-IB000713.  
PF  
XX 07-APR-2000; 2000DE-01019173.  
PR  
XX (EPIC-) EPIGENOMICS AG.  
PS  
XX Olek A, Piepenbrock C, Berlin K;  
PI  
XX WPI; 2001-657177/75.  
DR  
XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX  
XX Claim 1; SEQ ID NO 243408; 29pp + Sequence Listing; German.  
XX  
XX This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 5 A; 5 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 21.7%; Score 10.4; DB 1; Length 13;  
 Best Local Similarity 91.7%; Pred. No. 75;  
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1718 ACTGATGTTGAG 1729  
 |||||  
 12 AGTGATGTTGAG 1

Db 12 AGTGATGTTGAG 1

RESULT 70  
 ABF11939/c  
 ID ABF11939 standard; DNA; 13 BP.  
 XX  
 AC ABF11939;  
 XX  
 DT 21-FEB-2002 (first entry)  
 XX  
 DE Oligonucleotide SEQ ID NO 111936 for detecting SNP TSC0027936.  
 XX  
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200177384-A2.  
 XX  
 PD 18-OCT-2001.  
 XX  
 PF 06-APR-2001; 2001WO-IB000713.  
 XX  
 PR 07-APR-2000; 2000DE-01019173.  
 XX  
 PA (EPIC-) EPIGENOMICS AG.  
 XX  
 PI Olek A, Piepenbrock C, Berlin K;  
 XX  
 DR WPI; 2001-657177/75.  
 XX  
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is  
 PT designed to detect single-nucleotide polymorphisms and cytosine  
 PT methylation status.  
 XX  
 PS Claim 1; SEQ ID NO 111936; 29bp + Sequence Listing; German.  
 CC This invention describes novel oligonucleotide primers or peptide nucleic  
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
 CC and cytosine methylation status in chemically pretreated genomic DNA. The  
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
 CC range of diseases including immune system, gastrointestinal, respiratory,  
 CC central nervous system, cardiovascular and metabolic disorders. The  
 CC oligomers are also used for detecting cell type differentiation. ABC00010  
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073  
 CC represent the oligomers described in the invention. NOTE: The sequence  
 CC data for this patent did not form part of the printed specification, but  
 CC was obtained in electronic format from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences  
 XX  
 SQ Sequence 13 BP; 4 A; 6 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 21.7%; Score 10.4; DB 1; Length 13;  
 Best Local Similarity 91.7%; Pred. No. 75;  
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1721 GATGTTGAGGA 1732  
 |||||  
 12 GATGTTGAGGA 1

Db 12 GATGTTGAGGA 1

RESULT 71  
 ABF92696  
 ID ABF92696 standard; DNA; 13 BP.  
 XX

AC ABF92696;  
 XX  
 DT 22-FEB-2002 (first entry)  
 XX  
 DE Oligonucleotide SEQ ID NO 192693 for detecting SNP TSC0047415.  
 XX  
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200177384-A2.  
 XX  
 PD 18-OCT-2001.  
 XX  
 PF 06-APR-2001; 2001WO-IB000713.  
 XX  
 PR 07-APR-2000; 2000DE-01019173.  
 XX  
 PA (EPIC-) EPIGENOMICS AG.  
 XX  
 PI Olek A, Piepenbrock C, Berlin K;  
 XX  
 DR WPI; 2001-657177/75.  
 XX  
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is  
 PT designed to detect single-nucleotide polymorphisms and cytosine  
 PT methylation status.  
 XX  
 PS Claim 1; SEQ ID NO 192693; 29bp + Sequence Listing; German.  
 CC This invention describes novel oligonucleotide primers or peptide nucleic  
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
 CC and cytosine methylation status in chemically pretreated genomic DNA. The  
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
 CC range of diseases including immune system, gastrointestinal, respiratory,  
 CC central nervous system, cardiovascular and metabolic disorders. The  
 CC oligomers are also used for detecting cell type differentiation. ABC00010  
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073  
 CC represent the oligomers described in the invention. NOTE: The sequence  
 CC data for this patent did not form part of the printed specification, but  
 CC was obtained in electronic format from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences  
 XX  
 SQ Sequence 13 BP; 2 A; 1 C; 6 G; 3 T; 0 U; 1 Other;

Query Match 21.7%; Score 10.4; DB 1; Length 13;  
 Best Local Similarity 91.7%; Pred. No. 75;  
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1720 TGATGTCGAGG 1731  
 |||||  
 1 TGATGTCGAGG 12

Db 1 TGATGTCGAGG 12

RESULT 72  
 ABH14878  
 ID ABH14878 standard; DNA; 13 BP.  
 XX  
 AC ABH14878;  
 XX  
 DT 22-FEB-2002 (first entry)  
 XX  
 DE Oligonucleotide SEQ ID NO 214855 for detecting SNP TSC0052286.  
 XX  
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200177384-A2.

XX 18-OCT-2001.  
PD 06-APR-2001; 2001WO-IB000713.  
XX  
PF 07-APR-2000; 2000DE-01019173.  
XX  
PR (EPig-) EPIGENOMICS AG.  
XX  
PA Olek A, Piepenbrock C, Berlin K;  
PI WPI; 2001-657177/75.  
XX  
DR  
XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX  
PS Claim 1; SEQ ID NO 214855; 29pp + Sequence Listing; German.  
XX  
CC This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 5 A; 0 C; 5 G; 2 T; 0 U; 1 Other;  
XX  
Query Match 21.7%; Score 10.4; DB 1; Length 13;  
Best Local Similarity 91.7%; Pred. No. 75;  
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
XX  
QY 1725 TTGAGGAGACAG 1736  
DB 1 TTGAGGAGAAAG 12  
XX  
RESULT 73  
ABC78922  
ID ABC78922 standard; DNA; 13 BP.  
XX  
AC ABC78922;  
XX  
DT 21-FEB-2002 (first entry)  
XX  
DE Oligonucleotide SEQ ID NO 78939 for detecting SNP TSC0020091.  
XX  
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
OS Homo sapiens.  
XX  
XX WO200177384-A2.  
XX  
XX 18-OCT-2001.  
PD  
PF 06-APR-2001; 2001WO-IB000713.  
XX  
PR 07-APR-2000; 2000DE-01019173.  
XX  
XX (EPig-) EPIGENOMICS AG.  
XX  
XX Olek A, Piepenbrock C, Berlin K;  
PI WPI; 2001-657177/75.  
XX  
XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX  
PS Claim 1; SEQ ID NO 78939; 29pp + Sequence Listing; German.  
XX  
CC This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 8 A; 0 C; 4 G; 1 T; 0 U; 0 Other;  
XX  
Query Match 21.7%; Score 10.4; DB 1; Length 13;  
Best Local Similarity 91.7%; Pred. No. 75;  
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
XX  
QY 1736 GACAGAGAAAT 1747  
DB 1 GAAAGAGAAAT 12  
XX  
RESULT 74  
ABF56730  
ID ABF56730 standard; DNA; 13 BP.  
XX  
AC ABF56730;  
XX  
DT 21-FEB-2002 (first entry)  
XX  
DE Oligonucleotide SEQ ID NO 156727 for detecting SNP TSC0039520.  
XX  
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
OS Homo sapiens.  
XX  
XX WO200177384-A2.  
XX  
XX 18-OCT-2001.  
PD  
PF 06-APR-2001; 2001WO-IB000713.  
XX  
PR 07-APR-2000; 2000DE-01019173.  
XX  
XX (EPig-) EPIGENOMICS AG.  
XX  
XX Olek A, Piepenbrock C, Berlin K;  
PI WPI; 2001-657177/75.  
XX  
XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX  
PS Claim 1; SEQ ID NO 156727; 29pp + Sequence Listing; German.  
XX  
CC This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
 CC represent the oligomers described in the invention. NOTE: The sequence  
 CC data for this patent did not form part of the printed specification, but  
 CC was obtained in electronic format from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences

XX SQ Sequence 13 BP; 6 A; 0 C; 5 G; 1 T; 0 U; 1 Other;

Query Match 21.7%; Score 10.4; DB 1; Length 13;  
 Best Local Similarity 91.7%; Pred. No. 75;  
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 1736 GACGAGAAAT 1747  
 Db 1 GACGAGAAAT 12

RESULT 75

ABF18907/c  
 ID ABF18907 standard; DNA; 13 BP.

AC ABF18907;

DT 21-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 118904 for detecting SNP TSC0029684.

DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

OS WO200177384-A2.

PN 18-OCT-2001.

PD 06-APR-2001; 2001MO-IB000713.

PF 07-APR-2000; 2000DE-01019173.

PR (EPIC-) EPIGENOMICS AG.

PA Olek A, Piepenbrock C, Berlin K;

PI WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.

XX Claim 1; SEQ ID NO 118904; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic  
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
 CC and cytosine methylation status in chemically pretreated genomic DNA. The  
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
 CC range of diseases including immune system, gastrointestinal, respiratory,  
 CC central nervous system, cardiovascular and metabolic disorders. The  
 CC oligomers are also used for detecting cell type differentiation. ABC00010  
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
 CC represent the oligomers described in the invention. NOTE: The sequence  
 CC data for this patent did not form part of the printed specification, but  
 CC was obtained in electronic format from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences

XX SQ Sequence 13 BP; 2 A; 6 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 21.7%; Score 10.4; DB 1; Length 13;  
 Best Local Similarity 91.7%; Pred. No. 75;  
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 1721 GATGTTGAGGA 1732

Db 12 GATGTTGAGGA 1

RESULT 76

ID ABH58052 standard; DNA; 13 BP.

AC ABH58052;

DT 22-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 258029 for detecting SNP TSC0062747.

DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001MO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PA (EPIC-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

PN WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
 PT designed to detect single-nucleotide polymorphisms and cytosine  
 PT methylation status.

XX Claim 1; SEQ ID NO 258029; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic  
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
 CC and cytosine methylation status in chemically pretreated genomic DNA. The  
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
 CC range of diseases including immune system, gastrointestinal, respiratory,  
 CC central nervous system, cardiovascular and metabolic disorders. The  
 CC oligomers are also used for detecting cell type differentiation. ABC00010  
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
 CC represent the oligomers described in the invention. NOTE: The sequence  
 CC data for this patent did not form part of the printed specification, but  
 CC was obtained in electronic format from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences

XX SQ Sequence 13 BP; 2 A; 0 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 21.7%; Score 10.4; DB 1; Length 13;  
 Best Local Similarity 91.7%; Pred. No. 75;  
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 1720 TGATGTTGAGGG 1731  
 Db 2 TTTATGTTGAGGG 13

RESULT 77

ID AAF42671/c  
 AAF42671 standard; DNA; 10 BP.

AC AAF42671;

DT 23-MAR-2001 (first entry)

XX Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:10810.

XX Yeast; *Saccharomyces cerevisiae*; characterisation; cell cycle; NORF;  
 KW not previously assigned open reading frame; nonannotated ORF; SAGE;  
 KW serial analysis of gene expression; antifungal; tag; identification;  
 KW linker; PCR primer; ds.  
 XX  
 OS *Saccharomyces cerevisiae*.  
 XX  
 PN WO200077214-A2.  
 XX  
 PD 21-DEC-2000.  
 XX  
 PF 14-JUN-2000; 2000WO-US016223.  
 XX  
 PR 16-JUN-1999; 99US-00335032.  
 XX  
 PA (UYJO ) UNIV JOHNS HOPKINS.  
 XX  
 PI Velculescu V, Vogelstein B, Kinzler K;  
 XX  
 DR WPI; 2001-061874/07.  
 XX  
 PT Yeast gene coding sequences comprising NORF genes with serial analysis of  
 PT gene expression (SAGE) tags, useful for studying, monitoring and  
 PT affecting phases of the cell cycle.  
 PS  
 PS Example; Page 336; 419pp; English.  
 XX  
 CC The present invention describes an isolated DNA molecule comprising a  
 CC coding sequence of a yeast gene selected from a group of 745 NORF (not  
 CC previously assigned open reading frame; or nonannotated ORF) genes  
 CC comprising a SAGE (serial analysis of gene expression) tag. Also  
 CC described are: (1) a method (M1) of using NORF genes to affect the cell  
 CC cycle comprising administering a NORF gene whose expression varies by at  
 CC least 10% between any two phases of the cell cycle selected from log  
 CC phase, S phase and G2/M; (2) a method (M2) for screening candidate  
 CC antifungal drugs comprising: (a) contacting a test substance with a yeast  
 CC cell; and (b) monitoring expression of a NORF gene whose expression  
 CC varies as in M1, where a test substance which modifies the expression of  
 CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for  
 CC identifying human genes which are involved in cell cycle progression  
 CC comprising contacting human DNA with a probe which comprises at least 10  
 CC contiguous nucleotides of a NORF gene whose expression varies as in M1;  
 CC and (4) a method (M4) for identifying a candidate drug as a member of a  
 CC class of drugs having a characteristic effect on gene expression in a  
 CC yeast cell comprising contacting a yeast cell with a candidate drug and  
 CC monitoring expression in the yeast cell of at least 1 NORF gene whose  
 CC expression is affected by the class of drugs. The NORF genes may be used  
 CC to study, monitor and affect phases of the cell cycle, the differentially  
 CC expressed genes may be used as markers of phases of the cell cycle. The  
 CC methods may be used to identify candidate drugs which affect the cell  
 CC cycle and for identification of antifungal drugs. AAF33368 to AAF44064  
 CC represent SAGE tags used in the exemplification of the present invention.  
 CC AAF33362 to AAF33267 represent linkers and PCR primers used in the SAGE  
 CC method, in the exemplification of the present invention  
 XX  
 SQ Sequence 10 BP; 4 A; 3 C; 1 G; 2 T; 0 U; 0 Other;  
 XX  
 QY Query Match 20.8%; Score 10; DB 1; Length 10;  
 Db Best Local Similarity 100.0%; Pred. No. 72;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 1719 CTGATGTTGA 1728  
 10 CTGATGTTGA 1  
 RESULT 78  
 AAD25438  
 ID AAD25438 standard; DNA; 10 BP.  
 XX  
 AC AAD25438;  
 XX

DT 12-MAR-2002 (first entry)  
 XX  
 DE Human GNRH2 gene polymorphism detecting primer #9.  
 XX  
 KW Human; gonadotropin-releasing hormone 2; GNRH2 gene; haplotyping;  
 KW genotyping; gene therapy; reproductive disorder; polymorphism; primer;  
 KW ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200187910-A2.  
 XX  
 PD 22-NOV-2001.  
 XX  
 PF 18-MAY-2001; 2001WO-US016353.  
 XX  
 PR 18-MAY-2000; 2000US-0205187P.  
 XX  
 PA (GENA-) GENAISSANCE PHARM INC.  
 XX  
 PI Duda A, Klem SE, Nandabalan K, Sausker BA;  
 XX  
 DR WPI; 2002-055683/07.  
 XX  
 PT New genetic variants of gonadotropin-releasing hormone 2 isogene, useful  
 PT in studying expression and function of protein and for screening drugs to  
 PT treat diseases e.g. reproduction disorders.  
 PS  
 PS Claim 18; Page 13; 64pp; English.  
 XX  
 CC The invention relates to genetic variants of human gonadotropin-  
 CC releasing hormone 2 (GNRH2) gene. The invention also relates to  
 CC compositions and methods for haplotyping and/or genotyping the GNRH2 gene  
 CC in an individual. Polynucleotides of the invention are useful for  
 CC studying the expression and function of GNRH2 and in expressing GNRH2  
 CC proteins for use in screening candidate drugs to treat diseases related  
 CC to GNRH2 activity. They are also used in gene therapy. The methods of the  
 CC invention are useful in determining whether an individual has a haplotype  
 CC or haplotype pairs. The haplotyping method is useful for improving the  
 CC development of drugs for treating diseases associated with GNRH2  
 CC activity, e.g., reproductive disorders. The present sequence is a primer  
 CC used for detecting human GNRH2 gene polymorphisms  
 XX  
 SQ Sequence 10 BP; 1 A; 3 C; 3 G; 3 T; 0 U; 0 Other;  
 XX  
 QY Query Match 20.8%; Score 10; DB 1; Length 10;  
 Db Best Local Similarity 100.0%; Pred. No. 72;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 1712 CTGCTGACTG 1721  
 1 CTGCTGACTG 10  
 RESULT 79  
 AAD53533  
 ID AAD53533 standard; DNA; 10 BP.  
 XX  
 AC AAD53533;  
 XX  
 DT 28-MAY-2003 (first entry)  
 XX  
 DE Human GNRH2 gene polymorphism detecting primer #9.  
 XX  
 KW Human; gonadotropin-releasing hormone 2; GNRH2; reproductive disorder;  
 KW gynaecological; cytostatic; hormonal; target validation; gene therapy;  
 KW drug screening; lead compound; primer; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 AC WO200294850-A2.  
 XX  
 PN

PD 28-NOV-2002.  
 XX 01-NOV-2001; 2001WO-US050630.  
 XX 18-MAY-2001; 2001WO-US016353.  
 XX (GENA-) GENAISSANCE PHARM INC.  
 XX Duda A, Kijem SE, Nandabalan K, Saueker EA;  
 XX WPI; 2003-148454/14.  
 XX New gonadotropin-releasing hormone 2 (GNRH2) polypeptide encoded by  
 PT genetic variants having polymorphisms in the GNRH2 gene, for studying the  
 PT function of, and treating disorders, such as, reproductive disorders.  
 XX Claim 16; Col 14; 33pp; English.  
 XX The invention relates to gonadotropin-releasing hormone 2 (GNRH2) and its  
 CC nucleic acid sequence. Polymorphic variants of the GNRH2 gene are useful  
 CC in studying the expression and function of GNRH2, and in expressing GNRH2  
 CC proteins for use in screening candidate drugs for treating diseases  
 CC associated with GNRH2 activity, such as reproductive disorders.  
 CC Polynucleotides comprising a polymorphic gene variant or fragment may be  
 CC used for therapeutic purposes, where a patient could benefit from  
 CC expression or increased expression of a particular GNRH2 protein isoform,  
 CC or an expression vector encoding the isoform may be administered to the  
 CC patient. Haplotype information is useful in improving the efficiency and  
 CC output of several steps in a drug discovery and development process,  
 CC including target validation, identifying lead compounds, and early phase  
 CC clinical trials. GNRH2 gene is used in gene therapy. The present sequence  
 CC is a primer used for detecting human GNRH2 gene polymorphisms  
 XX Sequence 10 BP; 1 A; 3 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 20.8%; Score 10; DB 1; Length 10;  
 Best Local Similarity 100.0%; Pred. No. 72;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1712 CTGCTGACTG 1721  
 |||||  
 1 CTGCTGACTG 10

RESULT 80  
 ABV63381  
 ID ABV63381 standard; cDNA; 11 BP.  
 XX  
 AC ABV63381;

XX 21-OCT-2002 (first entry)  
 XX  
 DE Human skin EST 1167.

XX Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhoeic;  
 KM immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;  
 KM psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.  
 XX  
 OS Homo sapiens.

XX WO200253774-A2.

XX 11-JUL-2002.

XX 20-DEC-2001; 2001WO-EP015179.

XX 03-JAN-2001; 2001DE-01000127.

XX (HENK ) HENKEL KGAA.

XX Petersohn D, Conradt M, Hofmann K;

XX WPI; 2002-590638/63.

XX In vitro identification of skin-expressed genes, useful for determining  
 PT homeostasis and identifying cosmetic or pharmaceutical agents against  
 PT e.g. skin cancer.

XX Disclosure; Page 57; 1345pp; German.

XX The invention relates to in vitro identification (M1) of genes expressed  
 CC in the skin of humans or animals by subjecting a mixture of genetically  
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)  
 CC so as to identify skin-expressed genes and quantify their expression.  
 CC (M1) is useful for identifying genes involved in skin homeostasis; to  
 CC determine skin homeostasis and to test agent (A) that maintains or  
 CC promotes skin homeostasis or that can be used for treating skin  
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;  
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;  
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the  
 CC skin. The present sequence is that of a human expressed sequence tag  
 CC (EST) of the invention  
 XX

Sequence 11 BP; 2 A; 2 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 20.8%; Score 10; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 76;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1715 CTGACTGATG 1724  
 |||||  
 1 CTGACTGATG 10

RESULT 81  
 ABV70802  
 ID ABV70802 standard; cDNA; 11 BP.  
 XX  
 AC ABV70802;

XX 21-OCT-2002 (first entry)

XX Human skin EST 8588.

XX Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhoeic;  
 KM immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;  
 KM psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.  
 XX  
 OS Homo sapiens.

XX WO200253774-A2.

XX 11-JUL-2002.

XX 20-DEC-2001; 2001WO-EP015179.

XX 03-JAN-2001; 2001DE-01000127.

XX (HENK ) HENKEL KGAA.

XX Petersohn D, Conradt M, Hofmann K;

XX WPI; 2002-590638/63.

XX In vitro identification of skin-expressed genes, useful for determining  
 PT homeostasis and identifying cosmetic or pharmaceutical agents against  
 PT e.g. skin cancer.

XX Claim 24; Page 275; 1345pp; German.

XX The invention relates to in vitro identification (M1) of genes expressed  
 CC in the skin of humans or animals by subjecting a mixture of genetically  
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)  
 CC so as to identify skin-expressed genes and quantify their expression.  
 CC (M1) is useful for identifying genes involved in skin homeostasis; to  
 CC determine skin homeostasis and to test agent (A) that maintains or

```

CC promotes skin homeostasis or that can be used for treating skin
CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC skin. The present sequence is that of a human expressed sequence tag
CC (EST) of the invention
XX
SQ Sequence 11 BP; 2 A; 2 C; 4 G; 3 T; 0 U; 0 Other;
XX
Query Match 20.8%; Score 10; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 76;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1715 CTGACTGATG 1724
Db 1 CTGACTGATG 10
XX
RESULT 82
ABV67895/c
ID ABV67895 standard; cDNA; 11 BP.
XX
AC ABV67895;
XX
DT 21-OCT-2002 (first entry)
XX
DE Human skin EST 5681.
XX
KW Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhoeic;
KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
OS Homo sapiens.
XX
PN WO200253774-A2.
XX
PD 11-JUL-2002.
XX
PF 20-DEC-2001; 2001WO-EP015179.
XX
PR 03-JAN-2001; 2001DE-01000127.
XX
PA (HENKEL ) HENKEL KGAA.
XX
PI Petersohn D, Conradt M, Hofmann K;
XX
DR WPI; 2002-590638/63.
XX
PT In vitro identification of skin-expressed genes, useful for determining
PT homeostasis and identifying cosmetic or pharmaceutical agents against
PT e.g. skin cancer.
XX
PS Disclosure; Page 182; 1345bp; German.
XX
CC The invention relates to in vitro identification (M1) of genes expressed
CC in the skin of humans or animals by subjecting a mixture of genetically
CC encoded factors from skin, to serial analysis of gene expression (SAGE)
CC so as to identify skin-expressed genes and quantify their expression.
CC (M1) is useful for identifying genes involved in skin homeostasis; to
CC determine skin homeostasis and to test agent (A) that maintains or
CC promotes skin homeostasis or that can be used for treating skin
CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC skin. The present sequence is that of a human expressed sequence tag
CC (EST) of the invention
XX
SQ Sequence 11 BP; 0 A; 3 C; 2 G; 6 T; 0 U; 0 Other;
XX
Query Match 20.8%; Score 10; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 76;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1731 GAACAGACAG 1740
Db 10 GAACAGACAG 1
XX
RESULT 83
ABV64816/c
ID ABV64816 standard; cDNA; 11 BP.
XX
AC ABV64816;
XX
DT 21-OCT-2002 (first entry)
XX
DE Human skin EST 2602.
XX
KW Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhoeic;
KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
OS Homo sapiens.
XX
PN WO200253774-A2.
XX
PD 11-JUL-2002.
XX
PF 20-DEC-2001; 2001WO-EP015179.
XX
PR 03-JAN-2001; 2001DE-01000127.
XX
PA (HENKEL ) HENKEL KGAA.
XX
PI Petersohn D, Conradt M, Hofmann K;
XX
DR WPI; 2002-590638/63.
XX
PT In vitro identification of skin-expressed genes, useful for determining
PT homeostasis and identifying cosmetic or pharmaceutical agents against
PT e.g. skin cancer.
XX
PS Disclosure; Page 97; 1345bp; German.
XX
CC The invention relates to in vitro identification (M1) of genes expressed
CC in the skin of humans or animals by subjecting a mixture of genetically
CC encoded factors from skin, to serial analysis of gene expression (SAGE)
CC so as to identify skin-expressed genes and quantify their expression.
CC (M1) is useful for identifying genes involved in skin homeostasis; to
CC determine skin homeostasis and to test agent (A) that maintains or
CC promotes skin homeostasis or that can be used for treating skin
CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC skin. The present sequence is that of a human expressed sequence tag
CC (EST) of the invention
XX
SQ Sequence 11 BP; 5 A; 1 C; 3 G; 2 T; 0 U; 0 Other;
XX
Query Match 20.8%; Score 10; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 76;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1747 TGCAATCATT 1756
Db 11 TGCAATCATT 2
XX
RESULT 84
AB179664
ID AB179664 standard; DNA; 12 BP.
XX
AC AB179664;
XX
DT 22-FEB-2002 (first entry)
XX

```

```

DE Oligonucleotide primer SEQ ID NO 379637 for detecting SNP TSC0063401.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 379637; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 6 A; 0 C; 4 G; 2 T; 0 U; 0 Other;
SQ
Query Match 20.8%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 80;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1739 AGGAGAAATG 1748
Db 3 AGGAGAAATG 12
RESULT 85
ABH71192
ID ABH71192 standard; DNA; 12 BP.
XX
XX ABH71192;
AC
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 271169 for detecting SNP TSC0002415.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX

```

```

XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 271169; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 2 A; 0 C; 5 G; 5 T; 0 U; 0 Other;
SQ
Query Match 20.8%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 80;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1722 ATGTTGAGCG 1731
Db 1 ATGTTGAGCG 10
RESULT 86
ABH80366/c
ID ABH80366 standard; DNA; 12 BP.
XX
XX ABH80366;
AC
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 280359 for detecting SNP TSC0008516.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX

```

PS Claim 1, SEQ ID NO 280359; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC9989, ABE00010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published\_pct\_sequences

XX

SQ Sequence 12 BP; 2 A; 5 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 20.8%; Score 10; DB 1; Length 12;  
Best Local Similarity 100.0%; Pred. No. 80;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0.

Gy 1739 AGGAGGAATG 1748  
Db 10 AGGAGGAATG 1

RESULT 87

ID ABH87503 standard; DNA; 12 BP.  
XX  
AC ABH87503;  
XX  
DT 22-FEB-2002 (first entry)  
XX  
DE Oligonucleotide primer SEQ ID NO 287496 for detecting SNP TSC0013116.  
XX  
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; sg;  
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
OS Homo sapiens.  
XX  
PN WO200177384-A2.  
XX  
PD 18-OCT-2001.  
XX  
PF 06-APR-2001; 2001WO-IB000713.  
PP  
PR 07-APR-2000; 2000DE-01019173.  
XX  
PA (EPIC-) EPIGENOMICS AG.  
XX  
PI Olek A, Piepenbrock C, Berlin K;  
XX WPI; 2001-657177/75.  
RR  
XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX

Claim 1; SEQ ID NO 287496; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC9989, ABE00010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at

CC

```

CC      ftp.wipo.int/pub/published_pct_sequences
XX
SQ      Sequence 12 BP; 3 A; 0 C; 5 G; 4 T; 0 U; 0 Other;
XX
XX      Query Match          20.8%; Score 10; DB 1; Length 12;
XX      Best Local Similarity 100.0%; Pred. No. 80;
XX      Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY      1720 TGATGTTGAG 1729
XX      |||||
XX      3 TGATGTTGAG 12
XX
Db
XX
XX      RESULT 88
XX      ID AB101362
XX      AB101362 standard; DNA; 12 BP.
XX
XX      AC AB101362;
XX
XX      DT 22-FEB-2002 (first entry)
XX
XX      DE Oligonucleotide primer SEQ ID NO 301335 for detecting SNP TSC0019456.
XX
XX      KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX      KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX      OS Homo sapiens.
XX
XX      PN WO200177384-A2.
XX
XX      PD 18-OCT-2001.
XX
XX      PF 06-APR-2001; 2001WO-IB000713.
XX
XX      PR 07-APR-2000; 2000DE-01019173.
XX
XX      PA (EPIG-) EPIGENOMICS AG.
XX
XX      PI Olek A, Pienbrock C, Berlin K;
XX
XX      DR WPI; 2001-657177/75.
XX
XX      FT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX      PT designed to detect single-nucleotide polymorphisms and cytosine
XX      PT methylation status.
XX
XX      PS Claim 1; SEQ ID NO 301335; 29ppd + Sequence Listing; German.
XX
XX      CC This invention describes novel oligonucleotide primers or peptide nucleic
XX      CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX      CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX      CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX      CC range of diseases including immune system, gastrointestinal, respiratory,
XX      CC central nervous system, cardiovascular and metabolic disorders. The
XX      CC oligomers are also used for detecting cell type differentiation. ABC00010
XX      CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX      CC represent the oligomers described in the invention. NOTE: The sequence
XX      CC data for this patent did not form part of the printed specification, but
XX      CC was obtained in electronic format from WIPO at
XX      CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ      Sequence 12 BP; 5 A; 0 C; 4 G; 3 T; 0 U; 0 Other;
XX
XX      Query Match          20.8%; Score 10; DB 1; Length 12;
XX      Best Local Similarity 100.0%; Pred. No. 80;
XX      Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY      1739 AGGAGAAATG 1748
XX      |||||
XX      2 AGGAGAAATG 11
XX
Db

```

```

RESULT 89
AA14857/c
ID AAX14857 standard; DNA; 13 BP.
XX
AC AAX14857;
XX
DT 27-AUG-2003 (revised)
DT 24-MAR-1999 (first entry)
XX
DE Triple helix third strand of 23S rRNA gene nucleotides 1758-1770.
XX
XX Tripleplex formation; DNA detection; triple helix; identification; bacteria;
KM oncogene; virus; ss.
XX
OS Synthetic.
OS Leptospira interrogans.
XX
XX US5861244-A.
XX
PD 19-JAN-1999.
XX
PF 22-DEC-1993; 93US-00173489.
XX
PR 29-OCT-1992; 92US-00968436.
XX
PA (PROF-) PROFILE DIAGNOSTIC SCI INC.
XX
PI Hepburn AG, Wang C;
XX
DR WPI; 1999-130384/11.
XX
PT Assay of genetic sequences based on triplex formation from double
PT stranded analytic - and hybrid of anchor and reporter sequences, with
PT reporter released if triplex formation occurs, used e.g. to identify
PT bacteria.
XX
XX Disclosure; Col 21-22; 168pp; English.
XX
XX The present sequence represents a polynucleotide that is able to form a
CC triple helix with a double stranded sequence. Cytosine bases in the
CC present can be replaced with 5-methylcytosine for increased triplex
CC stability. The present sequence is used in the assay of the invention,
CC where it can be part of the anchor DNA or reporter DNA sequence. The
CC assay comprises adding a sample containing double-stranded DNA test
CC sequences to an aqueous medium containing at least one complex of anchor
CC DNA, attached to a solid support, and reporter DNA, where either a part
CC of the anchor DNA or reporter DNA is designed to form a triple-strand
CC structure with part of the test sequence. Triplex formation results in
CC displacement of the reporter DNA which is detected as an indication of
CC the presence of the DNA test sequence. The method is used to detect DNA
CC sequences, particularly for identification of bacteria (by detecting
CC genes for ribosomal RNA) in clinical samples, but also detection of
CC oncogenes and Hepatitis B virus. (Updated on 27-AUG-2003 to correct OS
CC field.)
XX
SQ Sequence 13 BP; 0 A; 7 C; 1 G; 5 T; 0 U; 0 Other;
Query Match 20.8%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 84;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1727 GAGGAAACAG 1736
DB 12 GAGGAAACAG 3
RESULT 90
ABF28166
ID ABF28166 standard; DNA; 13 BP.
XX
AC ABF28166;
XX
DT 21-FEB-2002 (first entry)
XX

```

```

XX
DE Oligonucleotide SEQ ID NO 128163 for detecting SNP TSC0032096.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
PA Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
XX
DR WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 128163; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 1 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 20.8%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 84;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1721 GATGTGAGG 1730
DB 2 GATGTGAGG 11
RESULT 91
ABH24633/c
ID ABH24633 standard; DNA; 13 BP.
XX
AC ABH24633;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 224610 for detecting SNP TSC0054745.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX

```

PF 06-APR-2001; 2001WO-IB000713.  
XX  
PR 07-APR-2000; 2000DE-01019173.  
XX  
PA (EPIC-) EPIGENOMICS AG.  
XX  
PI Olek A, Piepenbrock C, Berlin K;  
XX  
XX WPI; 2001-657177/75.  
DR  
XX  
PT Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
PS  
XX Claim 1; SEQ ID NO 224610; 29pp + Sequence Listing; German.  
XX  
CC This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 1 A; 7 C; 0 G; 5 T; 0 U; 0 Other;  
Query Match 20.8%; Score 10; DB 1; Length 13;  
Best Local Similarity 100.0%; Pred. No. 84;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1739 AGGAGAAATG 1748  
Db 11 AGGAGAAATG 2  
RESULT 92  
ABF87825/c  
ID ABF87825 standard; DNA; 13 BP.  
XX  
AC ABF87825;  
XX  
XX 22-FEB-2002 (first entry)  
DT  
XX  
DE Oligonucleotide SEQ ID NO 187822 for detecting SNP TSC0001439.  
XX  
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
XX Homo sapiens.  
OS  
XX  
XX WO200177384-A2.  
PN  
XX  
PD 18-OCT-2001.  
XX  
PF 06-APR-2001; 2001WO-IB000713.  
XX  
XX 07-APR-2000; 2000DE-01019173.  
PR  
XX  
XX (EPIC-) EPIGENOMICS AG.  
XX  
XX Olek A, Piepenbrock C, Berlin K;  
XX  
XX WPI; 2001-657177/75.  
DR  
XX  
PT Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.

XX  
XX Claim 1; SEQ ID NO 187822; 29pp + Sequence Listing; German.  
PS  
XX  
CC This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 4 A; 7 C; 0 G; 2 T; 0 U; 0 Other;  
Query Match 20.8%; Score 10; DB 1; Length 13;  
Best Local Similarity 100.0%; Pred. No. 84;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1723 TGTGAGGGA 1732  
Db 11 TGTGAGGGA 2  
RESULT 93  
ABC95357  
ID ABC95357 standard; DNA; 13 BP.  
XX  
AC ABC95357;  
XX  
XX 21-FEB-2002 (first entry)  
DT  
XX  
DE Oligonucleotide SEQ ID NO 95374 for detecting SNP TSC0023742.  
XX  
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
XX Homo sapiens.  
OS  
XX  
XX WO200177384-A2.  
PN  
XX  
PD 18-OCT-2001.  
XX  
PF 06-APR-2001; 2001WO-IB000713.  
XX  
XX 07-APR-2000; 2000DE-01019173.  
PR  
XX  
XX (EPIC-) EPIGENOMICS AG.  
XX  
XX Olek A, Piepenbrock C, Berlin K;  
XX  
XX WPI; 2001-657177/75.  
DR  
XX  
PT Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
PS  
XX  
XX Claim 1; SEQ ID NO 95374; 29pp + Sequence Listing; German.  
XX  
CC This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP, 6 A, 4 C, 0 G, 2 T, 0 U, 1 Other;

Query Match 20.8%; Score 10; DB 1; Length 13;  
Best Local Similarity 83.3%; Pred. No. 84;  
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1743 GAAATGATCCA 1754  
:|||||  
DB 1 RAAATCATCCA 12

RESULT 94  
ABF87824  
ID ABF87824 standard; DNA; 13 BP.

XX  
AC ABF87824;  
XX  
DT 22-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 187821 for detecting SNP TSC0001439.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
XX designed to detect single-nucleotide polymorphisms and cytosine  
XX methylation status.

XX Claim 1; SEQ ID NO 187821; 29bp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic  
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
XX and cytosine methylation status in chemically pretreated genomic DNA. The  
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
XX range of diseases including immune system, gastrointestinal, respiratory,  
XX central nervous system, cardiovascular and metabolic disorders. The  
XX oligomers are also used for detecting cell type differentiation. ABC00010  
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
XX represent the oligomers described in the invention. NOTE: The sequence  
XX data for this patent did not form part of the printed specification, but  
XX was obtained in electronic format from WIPO at  
XX ftp.wipo.int/pub/published\_pct\_sequences

XX Sequence 13 BP, 2 A, 0 C, 7 G, 4 T, 0 U, 0 Other;

Query Match 20.8%; Score 10; DB 1; Length 13;  
Best Local Similarity 100.0%; Pred. No. 84;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1723 GTTTGAGGGA 1732  
|||||  
DB 3 GTTTGAGGGA 12

RESULT 95  
ABH06507/C  
ID ABH06507 standard; DNA; 13 BP.

XX  
AC ABH06507;  
XX  
DT 22-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 206484 for detecting SNP TSC0050541.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
XX designed to detect single-nucleotide polymorphisms and cytosine  
XX methylation status.

XX Claim 1; SEQ ID NO 206484; 29bp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic  
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
XX and cytosine methylation status in chemically pretreated genomic DNA. The  
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
XX range of diseases including immune system, gastrointestinal, respiratory,  
XX central nervous system, cardiovascular and metabolic disorders. The  
XX oligomers are also used for detecting cell type differentiation. ABC00010  
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
XX represent the oligomers described in the invention. NOTE: The sequence  
XX data for this patent did not form part of the printed specification, but  
XX was obtained in electronic format from WIPO at  
XX ftp.wipo.int/pub/published\_pct\_sequences

XX Sequence 13 BP, 2 A, 5 C, 0 G, 5 T, 0 U, 1 Other;

Query Match 20.8%; Score 10; DB 1; Length 13;  
Best Local Similarity 100.0%; Pred. No. 84;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1724 GTTTGAGGGA 1733  
|||||  
DB 12 GTTTGAGGGA 3

RESULT 96  
ABH06506  
ID ABH06506 standard; DNA; 13 BP.

XX  
AC ABH06506;  
XX  
DT 22-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 206483 for detecting SNP TSC0050541.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX Homo sapiens.  
OS  
XX WO200177384-A2.  
XX  
XX 18-OCT-2001.  
XX  
XX  
XX 06-APR-2001; 2001WO-IB000713.  
XX  
XX 07-APR-2000; 2000DE-01019173.  
XX  
XX (EPIC-) EPIGENOMICS AG.  
XX  
XX  
XX Olek A, Piegenbrock C, Berlin K;  
XX  
XX WPI; 2001-657177/75.  
XX  
XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX  
XX  
XX Claim 1; SEQ ID NO 206483; 29pp + Sequence Listing; German.  
XX  
XX This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
XX  
XX Sequence 13 BP; 5 A; 0 C; 5 G; 2 T; 0 U; 1 Other;  
SQ  
XX  
XX Query Match 20.8%; Score 10; DB 1; Length 13;  
Best Local Similarity 100.0%; Pred. No. 84;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1724 GTTGAGCGAA 1733  
Db 2 GTTGAGCGAA 11  
XX  
XX RESULT 97  
ABF97342  
ID ABF97342 standard; DNA; 13 BP.  
XX  
XX ABE97342;  
XX  
XX 22-FEB-2002 (first entry)  
XX  
XX Oligonucleotide SEQ ID NO 197339 for detecting SNP TSC0048566.  
DE  
XX  
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
XX Homo sapiens.  
XX  
XX WO200177384-A2.  
XX  
XX 18-OCT-2001.  
XX  
XX 06-APR-2001; 2001WO-IB000713.  
XX  
XX 07-APR-2000; 2000DE-01019173.  
XX  
XX (EPIC-) EPIGENOMICS AG.  
XX  
XX

XX  
XX Olek A, Piegenbrock C, Berlin K;  
XX  
XX WPI; 2001-657177/75.  
XX  
XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX  
XX  
XX Claim 1; SEQ ID NO 197339; 29pp + Sequence Listing; German.  
XX  
XX This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
XX  
XX Sequence 13 BP; 3 A; 0 C; 7 G; 3 T; 0 U; 0 Other;  
SQ  
XX  
XX Query Match 20.8%; Score 10; DB 1; Length 13;  
Best Local Similarity 100.0%; Pred. No. 84;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1721 GATGTTGAG 1730  
Db 3 GATGTTGAG 12  
XX  
XX RESULT 98  
ABH54593/c  
ID ABH54593 standard; DNA; 13 BP.  
XX  
XX ABH54593;  
XX  
XX 22-FEB-2002 (first entry)  
XX  
XX Oligonucleotide SEQ ID NO 254570 for detecting SNP TSC0062063.  
DE  
XX  
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
XX Homo sapiens.  
XX  
XX WO200177384-A2.  
XX  
XX 18-OCT-2001.  
XX  
XX 06-APR-2001; 2001WO-IB000713.  
XX  
XX 07-APR-2000; 2000DE-01019173.  
XX  
XX (EPIC-) EPIGENOMICS AG.  
XX  
XX Olek A, Piegenbrock C, Berlin K;  
XX  
XX WPI; 2001-657177/75.  
XX  
XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX  
XX  
XX Claim 1; SEQ ID NO 254570; 29pp + Sequence Listing; German.  
XX  
XX This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC

CC and cytosine methylation status in chemically pretreated genomic DNA. The  
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
 CC range of diseases including immune system, gastrointestinal, respiratory,  
 CC central nervous system, cardiovascular and metabolic disorders. The  
 CC oligomers are also used for detecting cell type differentiation. ABC00010  
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
 CC represent the oligomers described in the invention. NOTE: The sequence  
 CC data for this patent did not form part of the printed specification, but  
 CC was obtained in electronic format from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences

SQ Sequence 13 BP; 3 A; 5 C; 0 G; 4 T; 0 U; 1 Other;

Query Match 20.8%; Score 10; DB 1; Length 13;  
 Best Local Similarity 83.3%; Pred. No. 84;  
 Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1723 TGTTGAGGGAAC 1734  
 |||||  
 Db 12 TGTAGAGGAAY 1

RESULT 99  
 ABF97343/C  
 ID ABF97343 standard; DNA; 13 BP.

XX ABF97343;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 197340 for detecting SNP TSC0048566.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
 PT designed to detect single-nucleotide polymorphisms and cytosine  
 PT methylation status.

XX Claim 1; SEQ ID NO 197340; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic  
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
 CC and cytosine methylation status in chemically pretreated genomic DNA. The  
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
 CC range of diseases including immune system, gastrointestinal, respiratory,  
 CC central nervous system, cardiovascular and metabolic disorders. The  
 CC oligomers are also used for detecting cell type differentiation. ABC00010  
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
 CC represent the oligomers described in the invention. NOTE: The sequence  
 CC data for this patent did not form part of the printed specification, but  
 CC was obtained in electronic format from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences

XX Sequence 13 BP; 3 A; 7 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 20.8%; Score 10; DB 1; Length 13;  
 Best Local Similarity 100.0%; Pred. No. 84;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1721 GATGTTGAGG 1730  
 |||||  
 Db 11 GATGTTGAGG 2

RESULT 100  
 ABH54592  
 ID ABH54592 standard; DNA; 13 BP.

XX ABH54592;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 254569 for detecting SNP TSC0062063.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
 PT designed to detect single-nucleotide polymorphisms and cytosine  
 PT methylation status.

XX Claim 1; SEQ ID NO 254569; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic  
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
 CC and cytosine methylation status in chemically pretreated genomic DNA. The  
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
 CC range of diseases including immune system, gastrointestinal, respiratory,  
 CC central nervous system, cardiovascular and metabolic disorders. The  
 CC oligomers are also used for detecting cell type differentiation. ABC00010  
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
 CC represent the oligomers described in the invention. NOTE: The sequence  
 CC data for this patent did not form part of the printed specification, but  
 CC was obtained in electronic format from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences

XX Sequence 13 BP; 4 A; 0 C; 5 G; 3 T; 0 U; 1 Other;

Query Match 20.8%; Score 10; DB 1; Length 13;  
 Best Local Similarity 83.3%; Pred. No. 84;  
 Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1723 TGTTGAGGGAAC 1734  
 |||||  
 Db 2 TGTAGAGGAAY 13

RESULT 101

ABF28167/C  
 ID ABF28167 standard; DNA; 13 BP.

XX

AC ABF28167;  
XX  
DT 21-FEB-2002 (first entry)  
XX  
DE Oligonucleotide SEQ ID NO 128164 for detecting SNP TSC0032096.  
XX  
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
OS Homo sapiens.  
XX  
PN WO200177384-A2.  
XX  
PD 18-OCT-2001.  
XX  
PF 06-APR-2001; 2001WO-IB000713.  
XX  
PR 07-APR-2000; 2000DE-01019173.  
XX  
PA (EPIC-) EPIGENOMICS AG.  
XX  
PI Olek A, Piepenbrock C, Berlin K;  
XX  
DR WPI; 2001-657177/75.  
XX  
PT Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX  
PS Claim 1; SEQ ID NO 128164; 29pp + Sequence Listing; German.  
XX  
CC This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 5 A; 5 C; 1 G; 2 T; 0 U; 0 Other;  
XX  
Query Match 20.8%; Score 10; DB 1; Length 13;  
Best Local Similarity 100.0%; Pred. No. 84;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1721 GAGTTGAGG 1730  
DB 12 GAGTTGAGG 3  
XX  
RESULT 102  
ABH24632  
ID ABH24632 standard; DNA; 13 BP.  
XX  
AC ABH24632;  
XX  
DT 22-FEB-2002 (first entry)  
XX  
DE Oligonucleotide SEQ ID NO 224609 for detecting SNP TSC0054745.  
XX  
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
OS Homo sapiens.  
XX  
PN WO200177384-A2.

XX  
PD 18-OCT-2001.  
XX  
PF 06-APR-2001; 2001WO-IB000713.  
XX  
PR 07-APR-2000; 2000DE-01019173.  
XX  
PA (EPIC-) EPIGENOMICS AG.  
XX  
PI Olek A, Piepenbrock C, Berlin K;  
XX  
DR WPI; 2001-657177/75.  
XX  
PT Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX  
PS Claim 1; SEQ ID NO 224609; 29pp + Sequence Listing; German.  
XX  
CC This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 5 A; 0 C; 7 G; 1 T; 0 U; 0 Other;  
XX  
Query Match 20.8%; Score 10; DB 1; Length 13;  
Best Local Similarity 100.0%; Pred. No. 84;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1739 AGGAGGAATG 1748  
DB 3 AGGAGGAATG 12  
XX  
RESULT 103  
ABC95356/c  
ID ABC95356 standard; DNA; 13 BP.  
XX  
AC ABC95356;  
XX  
DT 21-FEB-2002 (first entry)  
XX  
DE Oligonucleotide SEQ ID NO 95373 for detecting SNP TSC0023742.  
XX  
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
OS Homo sapiens.  
XX  
PN WO200177384-A2.  
XX  
PD 18-OCT-2001.  
XX  
PF 06-APR-2001; 2001WO-IB000713.  
XX  
PR 07-APR-2000; 2000DE-01019173.  
XX  
PA (EPIC-) EPIGENOMICS AG.  
XX  
PI Olek A, Piepenbrock C, Berlin K;  
XX  
DR WPI; 2001-657177/75.  
XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is  
 PT designed to detect single-nucleotide polymorphisms and cytosine  
 PT methylation status.  
 PS Claim 1; SEQ ID NO 95373; 29pp + Sequence Listing; German.  
 XX  
 CC This invention describes novel oligonucleotide primers or peptide nucleic  
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
 CC and cytosine methylation status in chemically pretreated genomic DNA. The  
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
 CC range of diseases including immune system, gastrointestinal, respiratory,  
 CC central nervous system, cardiovascular and metabolic disorders. The  
 CC oligomers are also used for detecting cell type differentiation. ABC00010  
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073  
 CC represent the oligomers described in the invention. NOTE: The sequence  
 CC data for this patent did not form part of the printed specification, but  
 CC was obtained in electronic format from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences  
 CC  
 SQ Sequence 13 BP; 2 A; 0 C; 4 G; 6 T; 0 U; 1 Other;  
 Query Match 20.4%; Score 10; DB 1; Length 13;  
 Best Local Similarity 83.3%; Pred. No. 84;  
 Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;  
 Oy 1743 GAATGATCCCA 1754  
 :|||||  
 Db 13 RAAATCATCCCA 2  
 RESULT 104  
 AAA92487  
 ID AAA92487 standard; DNA; 13 BP.  
 XX  
 AC AAA92487;  
 XX  
 DT 16-JAN-2001 (first entry)  
 XX  
 DE DNA replication method related primer #3.  
 XX  
 KW DNA replication; PCR; primer; cancerisation; ss.  
 XX  
 OS Unidentified.  
 XX  
 PN JP2000217599-A.  
 XX  
 PD 08-AUG-2000.  
 XX  
 PF 29-JAN-1999; 99JP-00021135.  
 XX  
 PR 29-JAN-1999; 99JP-00021135.  
 XX  
 PA (FUJITSU) FUJITSU LTD.  
 PA (AGEN) AGENCY OF IND SCI & TECHNOLOGY.  
 XX  
 DR WPI; 2000-605052/58.  
 XX  
 PT Replication method of DNA and apparatus for designing polymerase chain  
 PT reactions for giving important information in the mechanism of  
 PT cancerization of cells.  
 XX  
 PS Disclosure; Page 5; 13pp; Japanese.  
 XX  
 CC The present invention describes a method for the replication of a DNA in  
 CC which only a specific DNA contained in a mixture of DNAs is replicated by  
 CC using a polymerase chain reaction (PCR), comprising a primer acting as a  
 CC replication point to the DNAs present in mixture and a sequence-specific  
 CC substance which adheres only to the DNA. The method can be used for  
 CC giving important information in the mechanism of cancerisation of cells  
 CC in which many similar genes interact complicatedly. The present sequence  
 CC represents a primer which is used in the exemplification of the method of  
 CC the present invention

SQ Sequence 13 BP; 4 A; 2 C; 5 G; 2 T; 0 U; 0 Other;  
 Query Match 20.4%; Score 9.8; DB 1; Length 13;  
 Best Local Similarity 84.6%; Pred. No. 89;  
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 Oy 1722 ATGTGAGGAGAC 1734  
 :|||||  
 Db 1 ATGTGAGGAGAC 13  
 RESULT 105  
 ABC22259/c  
 ID ABC22259 standard; DNA; 13 BP.  
 XX  
 AC ABC22259;  
 XX  
 DT 20-FEB-2002 (first entry)  
 XX  
 DE Oligonucleotide SEQ ID NO 22276 for detecting SNP TSC0004415.  
 XX  
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200177384-A2.  
 XX  
 PD 18-OCT-2001.  
 XX  
 PF 06-APR-2001; 2001WO-1B000713.  
 XX  
 PR 07-APR-2000; 2000DE-01019173.  
 XX  
 PA (EPiG-) EPIGENOMICS AG.  
 XX  
 PI Olek A, Piepenbrock C, Berlin K;  
 XX  
 DR WPI; 2001-657177/75.  
 XX  
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is  
 PT designed to detect single-nucleotide polymorphisms and cytosine  
 PT methylation status.  
 PS Claim 1; SEQ ID NO 22276; 29pp + Sequence Listing; German.  
 XX  
 CC This invention describes novel oligonucleotide primers or peptide nucleic  
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
 CC and cytosine methylation status in chemically pretreated genomic DNA. The  
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
 CC range of diseases including immune system, gastrointestinal, respiratory,  
 CC central nervous system, cardiovascular and metabolic disorders. The  
 CC oligomers are also used for detecting cell type differentiation. ABC00010  
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073  
 CC represent the oligomers described in the invention. NOTE: The sequence  
 CC data for this patent did not form part of the printed specification, but  
 CC was obtained in electronic format from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences  
 CC  
 SQ Sequence 13 BP; 2 A; 7 C; 0 G; 4 T; 0 U; 0 Other;  
 Query Match 20.4%; Score 9.8; DB 1; Length 13;  
 Best Local Similarity 84.6%; Pred. No. 89;  
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 Oy 1725 TTGAGGAGAGAGA 1737  
 :|||||  
 Db 13 TTGAGGAGAGAGA 1  
 RESULT 106  
 ABH34097/c

```

ID  ABH34097 standard; DNA; 13 BP.
XX
XX  ABH34097;
AC
XX
XX  22-FEB-2002 (first entry)
DT
XX
XX  Oligonucleotide SEQ ID NO 234074 for detecting SNP TSC0057120.
DE
XX  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX  Homo sapiens.
OS
XX  WO200177384-A2.
XX
XX  18-OCT-2001.
XX
XX  06-APR-2001; 2001WO-IB000713.
XX
XX  07-APR-2000; 2000DE-01019173.
XX
XX  (EPIC-) EPIGENOMICS AG.
XX
XX  Olek A, Piepenbrock C, Berlin K;
XX
XX  WPI; 2001-657177/75.
XX
XX  Set of oligonucleotides, useful for diagnosis and cell typing, is
PT  designed to detect single-nucleotide polymorphisms and cytosine
PT  methylation status.
XX
XX  Claim 1; SEQ ID NO 234074; 29bp + Sequence Listing; German.
XX
XX  This invention describes novel oligonucleotide primers or peptide nucleic
CC  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC  and cytosine methylation status in chemically pretreated genomic DNA. The
CC  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC  range of diseases including immune system, gastrointestinal, respiratory,
CC  central nervous system, cardiovascular and metabolic disorders. The
CC  oligomers are also used for detecting cell type differentiation. ABC00010
CC  -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC  represent the oligomers described in the invention. NOTE: The sequence
CC  data for this patent did not form part of the printed specification, but
CC  was obtained in electronic format from WIPO at
CC  ftp.wipo.int/pub/published_pct_sequences
XX
XX  Sequence 13 BP; 2 A; 8 C; 0 G; 3 T; 0 U; 0 Other;
SQ
XX
XX  Query Match 20.4%; Score 9.8; DB 1; Length 13;
XX  Best Local Similarity 84.6%; Pred. No. 89;
XX  Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX  1724 GTTGAGGGAACAG 1736
QY
XX
XX  13 GTTGAGGGAAGAG 1
Db
XX
XX  RESULT 107
XX  ABC20825/c
XX  ABC20825 standard; DNA; 13 BP.
XX
XX  ABC20825;
XX
XX  20-FEB-2002 (first entry)
DT
XX
XX  Oligonucleotide SEQ ID NO 20842 for detecting SNP TSC0004233.
DE
XX
XX  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX  Homo sapiens.
OS

```

```

XX  WO200177384-A2.
XX
XX  18-OCT-2001.
XX
XX  06-APR-2001; 2001WO-IB000713.
XX
XX  07-APR-2000; 2000DE-01019173.
XX
XX  (EPIC-) EPIGENOMICS AG.
XX
XX  Olek A, Piepenbrock C, Berlin K;
XX
XX  WPI; 2001-657177/75.
XX
XX  Set of oligonucleotides, useful for diagnosis and cell typing, is
PT  designed to detect single-nucleotide polymorphisms and cytosine
PT  methylation status.
XX
XX  Claim 1; SEQ ID NO 20842; 29bp + Sequence Listing; German.
XX
XX  This invention describes novel oligonucleotide primers or peptide nucleic
CC  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC  and cytosine methylation status in chemically pretreated genomic DNA. The
CC  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC  range of diseases including immune system, gastrointestinal, respiratory,
CC  central nervous system, cardiovascular and metabolic disorders. The
CC  oligomers are also used for detecting cell type differentiation. ABC00010
CC  -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC  represent the oligomers described in the invention. NOTE: The sequence
CC  data for this patent did not form part of the printed specification, but
CC  was obtained in electronic format from WIPO at
CC  ftp.wipo.int/pub/published_pct_sequences
XX
XX  Sequence 13 BP; 3 A; 4 C; 0 G; 6 T; 0 U; 0 Other;
SQ
XX
XX  Query Match 20.4%; Score 9.8; DB 1; Length 13;
XX  Best Local Similarity 84.6%; Pred. No. 89;
XX  Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX  1739 AGGAGAAATGCAT 1751
QY
XX
XX  13 AGGTGAATGAAT 1
Db
XX
XX  RESULT 108
XX  ABC07406
XX  ABC07406 standard; DNA; 13 BP.
XX
XX  ABC07406;
XX
XX  20-FEB-2002 (first entry)
DT
XX
XX  Oligonucleotide SEQ ID NO 7397 for detecting SNP TSC0002151.
DE
XX
XX  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX  Homo sapiens.
OS
XX
XX  WO200177384-A2.
XX
XX  18-OCT-2001.
XX
XX  06-APR-2001; 2001WO-IB000713.
XX
XX  07-APR-2000; 2000DE-01019173.
XX
XX  (EPIC-) EPIGENOMICS AG.
XX
XX  Olek A, Piepenbrock C, Berlin K;
XX

```

DR WPI; 2001-657177/75.  
XX  
PT Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
PS  
XX Claim 1; SEQ ID NO 7397; 29pp + Sequence Listing; German.  
CC This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 4 A; 0 C; 7 G; 2 T; 0 U; 0 Other;  
Query Match 20.4%; Score 9.8; DB 1; Length 13;  
Best Local Similarity 84.6%; Pred. No. 89;  
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
DY 1720 TGATGTTGAGGGA 1732  
DB 1 TGAGATGAGGGA 13  
RESULT 109  
ABF07048  
ID ABF07048 standard; DNA; 13 BP.  
XX  
AC ABF07048;  
XX  
DT 21-FEB-2002 (first entry)  
XX  
DE Oligonucleotide SEQ ID NO 107045 for detecting SNP TSC0026803.  
XX  
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
OS Homo sapiens.  
XX  
PN WO200177384-A2.  
XX  
PD 18-OCT-2001.  
XX  
PF 06-APR-2001; 2001WO-IB000713.  
XX  
PR 07-APR-2000; 2000DE-01019173.  
XX  
PA (EPIC-) EPIGENOMICS AG.  
XX  
PI Olek A, Piepenbrock C, Berlin K;  
XX  
DR WPI; 2001-657177/75.  
XX  
PT Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX  
PS Claim 1; SEQ ID NO 107045; 29pp + Sequence Listing; German.  
CC  
CC This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 4 A; 0 C; 6 G; 3 T; 0 U; 0 Other;  
Query Match 20.4%; Score 9.8; DB 1; Length 13;  
Best Local Similarity 84.6%; Pred. No. 89;  
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 4 A; 0 C; 6 G; 3 T; 0 U; 0 Other;  
Query Match 20.4%; Score 9.8; DB 1; Length 13;  
Best Local Similarity 84.6%; Pred. No. 89;  
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
DY 1721 GATGTTGAGGGA 1733  
DB 1 GAGGTTGAGGTA 13  
RESULT 110  
ABC87934  
ID ABC87934 standard; DNA; 13 BP.  
XX  
AC ABC87934;  
XX  
DT 21-FEB-2002 (first entry)  
XX  
DE Oligonucleotide SEQ ID NO 87951 for detecting SNP TSC0022105.  
XX  
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
OS Homo sapiens.  
XX  
PN WO200177384-A2.  
XX  
PD 18-OCT-2001.  
XX  
PF 06-APR-2001; 2001WO-IB000713.  
XX  
PR 07-APR-2000; 2000DE-01019173.  
XX  
PA (EPIC-) EPIGENOMICS AG.  
XX  
PI Olek A, Piepenbrock C, Berlin K;  
XX  
DR WPI; 2001-657177/75.  
XX  
PT Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX  
PS Claim 1; SEQ ID NO 87951; 29pp + Sequence Listing; German.  
CC  
CC This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 U; 0 Other;  
Query Match 20.4%; Score 9.8; DB 1; Length 13;  
Best Local Similarity 84.6%; Pred. No. 89;  
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1720 TGATGTTGAGGA 1732  
||| ||| ||| |||  
Db 1 TGATGTTGAGTGA 13

RESULT 111  
ABF21698  
ID ABF21698 standard; DNA; 13 BP.  
XX  
AC ABF21698;  
XX  
DT 21-FEB-2002 (first entry)  
XX  
DE Oligonucleotide SEQ ID NO 121695 for detecting SNP TSC0030400.  
XX  
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
OS Homo sapiens.  
XX  
PN WO200177384-A2.  
XX  
PD 18-OCT-2001.  
XX  
PF 06-APR-2001; 2001WO-IB000713.  
XX  
PR 07-APR-2000; 2000DE-01019173.  
XX  
PS (EPIC-) EPIGENOMICS AG.  
XX  
PA (EPIC-) EPIGENOMICS AG.  
XX  
PI Olek A, Piepenbrock C, Berlin K;  
XX  
DR WPI; 2001-657177/75.  
XX  
PT Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX  
PS Claim 1; SEQ ID NO 121695; 29pp + Sequence Listing; German.  
XX  
CC This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 20.4%; Score 9.8; DB 1; Length 13;  
Best Local Similarity 84.6%; Pred. No. 89;  
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1721 GATGTTGAGGAA 1733  
||| ||| ||| |||  
Db 1 GCTTTTGAGGGA 13

RESULT 112  
ABH20206  
ID ABH20206 standard; DNA; 13 BP.  
XX  
AC ABH20206;  
XX  
DT 22-FEB-2002 (first entry)

XX  
DE Oligonucleotide SEQ ID NO 220183 for detecting SNP TSC0053581.  
XX  
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
OS Homo sapiens.  
XX  
PN WO200177384-A2.  
XX  
PD 18-OCT-2001.  
XX  
PF 06-APR-2001; 2001WO-IB000713.  
XX  
PR 07-APR-2000; 2000DE-01019173.  
XX  
PS (EPIC-) EPIGENOMICS AG.  
XX  
PA (EPIC-) EPIGENOMICS AG.  
XX  
PI Olek A, Piepenbrock C, Berlin K;  
XX  
DR WPI; 2001-657177/75.  
XX  
PT Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX  
PS Claim 1; SEQ ID NO 220183; 29pp + Sequence Listing; German.  
XX  
CC This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 3 A; 0 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 20.4%; Score 9.8; DB 1; Length 13;  
Best Local Similarity 84.6%; Pred. No. 89;  
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1718 ACTGATGTTGAGG 1730  
||| ||| ||| |||  
Db 1 ATTGATGTTTAGG 13

RESULT 113  
ABH34096  
ID ABH34096 standard; DNA; 13 BP.  
XX  
AC ABH34096;  
XX  
DT 22-FEB-2002 (first entry)  
XX  
DE Oligonucleotide SEQ ID NO 234073 for detecting SNP TSC0057120.  
XX  
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
OS Homo sapiens.  
XX  
PN WO200177384-A2.  
XX  
PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.  
XX  
PR 07-APR-2000; 2000DE-01019173.  
XX  
XX (EPIC-) EPIGENOMICS AG.  
XX  
PI Olek A, Piepenbrock C, Berlin K;  
XX  
XX WPI; 2001-657177/75.  
DR  
XX  
XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX  
XX Claim 1; SEQ ID NO 234073; 29pp + Sequence listing; German.  
PS  
XX This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 3 A; 0 C; 8 G; 2 T; 0 U; 0 Other;  
XX  
Query Match 20.4%; Score 9.8; DB 1; Length 13;  
Best Local Similarity 84.6%; Pred. No. 89;  
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
XX  
QY 1724 GTTGAGCGAACAAG 1736  
Db 1 GTTGAGCGGAGAG 13  
XX  
RESULT 114  
ABH42048  
ID ABH42048 standard; DNA; 13 BP.  
XX  
AC ABH42048;  
XX  
DT 22-FEB-2002 (first entry)  
XX  
DE Oligonucleotide SEQ ID NO 242025 for detecting SNP TSC0059034.  
XX  
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
XX Homo sapiens.  
OS  
XX  
XX WO200177384-A2.  
PN  
XX  
PD 18-OCT-2001.  
XX  
XX 06-APR-2001; 2001WO-IB000713.  
PF  
XX  
XX 07-APR-2000; 2000DE-01019173.  
PR  
XX  
XX (EPIC-) EPIGENOMICS AG.  
XX  
XX Olek A, Piepenbrock C, Berlin K;  
PI  
XX  
XX WPI; 2001-657177/75.  
DR  
XX  
XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.

XX  
PS Claim 1; SEQ ID NO 242025; 29pp + Sequence listing; German.  
XX  
XX This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 6 A; 0 C; 4 G; 3 T; 0 U; 0 Other;  
XX  
Query Match 20.4%; Score 9.8; DB 1; Length 13;  
Best Local Similarity 84.6%; Pred. No. 89;  
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
XX  
QY 1725 TTGAGCGAACAAG 1737  
Db 1 TTGAGCGAAGAAG 13  
XX  
RESULT 115  
ABC48762  
ID ABC48762 standard; DNA; 13 BP.  
XX  
AC ABC48762;  
XX  
DT 21-FEB-2002 (first entry)  
XX  
DE Oligonucleotide SEQ ID NO 48779 for detecting SNP TSC0013859.  
XX  
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
XX Homo sapiens.  
OS  
XX  
XX WO200177384-A2.  
PN  
XX  
PD 18-OCT-2001.  
XX  
XX 06-APR-2001; 2001WO-IB000713.  
PF  
XX  
XX 07-APR-2000; 2000DE-01019173.  
PR  
XX  
XX (EPIC-) EPIGENOMICS AG.  
XX  
XX Olek A, Piepenbrock C, Berlin K;  
PI  
XX  
XX WPI; 2001-657177/75.  
DR  
XX  
XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX  
XX Claim 1; SEQ ID NO 48779; 29pp + Sequence listing; German.  
PS  
XX  
XX This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at  
ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 6 A; 0 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 20.4%; Score 9.8; DB 1; Length 13;  
Best Local Similarity 84.6%; Pred. No. 89;  
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1739 AGGAGAAATGCAT 1751  
Db 1 ATGAGAAATGTAT 13

RESULT 116  
ABCI2427/C  
ID ABCI2427 standard; DNA; 13 BP.

AC ABCI2427;

DT 20-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 12434 for detecting SNP TSC0002943.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.

PS Claim 1; SEQ ID NO 12434; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX

SQ Sequence 13 BP; 5 A; 4 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 20.4%; Score 9.8; DB 1; Length 13;  
Best Local Similarity 84.6%; Pred. No. 89;  
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1721 GATGTGAGGAA 1733  
Db 13 GATGTTATGGA 1

RESULT 117  
ABC87935/C  
ID ABC87935 standard; DNA; 13 BP.

AC ABC87935;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 87952 for detecting SNP TSC0022105.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.

PS Claim 1; SEQ ID NO 87952; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX

SQ Sequence 13 BP; 4 A; 6 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 20.4%; Score 9.8; DB 1; Length 13;  
Best Local Similarity 84.6%; Pred. No. 89;  
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1720 TGATGTTGAGGA 1732  
Db 13 TGATGCTAGTGA 1

RESULT 118  
ABC41627/C  
ID ABC41627 standard; DNA; 13 BP.

AC ABC41627;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 41644 for detecting SNP TSC0012495.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX Homo sapiens.  
XX WO200177384-A2.  
XX 18-OCT-2001.  
XX 06-APR-2001; 2001WO-IB000713.  
XX 07-APR-2000; 2000DE-01019173.  
XX (EPIG-) EPIGENOMICS AG.  
XX Olek A, Piepenbrock C, Berlin K;  
XX WPI; 2001-657177/75.  
XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
XX designed to detect single-nucleotide polymorphisms and cytosine  
XX methylation status.  
XX Claim 1; SEQ ID NO 41644; 29pp + Sequence Listing; German.  
XX This invention describes novel oligonucleotide primers or peptide nucleic  
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
XX and cytosine methylation status in chemically pretreated genomic DNA. The  
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
XX range of diseases including immune system, gastrointestinal, respiratory,  
XX central nervous system, cardiovascular and metabolic disorders. The  
XX oligomers are also used for detecting cell type differentiation. ABC00010  
XX -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073  
XX represent the oligomers described in the invention. NOTE: The sequence  
XX data for this patent did not form part of the printed specification, but  
XX was obtained in electronic format from WIPO at  
XX ftp.wipo.int/pub/published\_pct\_sequences

XX Sequence 13 BP; 0 A; 7 C; 0 G; 6 T; 0 U; 0 Other;

XX Query Match 20.4%; Score 9.8; DB 1; Length 13;  
XX Best Local Similarity 84.6%; Pred. No. 89;  
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1730 GGAACGACGACGA 1742  
DB 13 GGAAGAGAGAGGA 1  
|||||  
|

RESULT 119  
ABH24244/C  
ID ABH24244 standard; DNA; 13 BP.  
AC ABH24244;  
XX  
XX 22-FEB-2002 (first entry)  
XX  
XX Oligonucleotide SEQ ID NO 224221 for detecting SNP TSC0054636.  
XX  
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX Homo sapiens.  
XX WO200177384-A2.  
XX 18-OCT-2001.  
XX 06-APR-2001; 2001WO-IB000713.  
XX 07-APR-2000; 2000DE-01019173.  
XX (EPIG-) EPIGENOMICS AG.  
XX

XX Olek A, Piepenbrock C, Berlin K;  
XX WPI; 2001-657177/75.  
XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
XX designed to detect single-nucleotide polymorphisms and cytosine  
XX methylation status.  
XX Claim 1; SEQ ID NO 224221; 29pp + Sequence Listing; German.  
XX This invention describes novel oligonucleotide primers or peptide nucleic  
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
XX and cytosine methylation status in chemically pretreated genomic DNA. The  
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
XX range of diseases including immune system, gastrointestinal, respiratory,  
XX central nervous system, cardiovascular and metabolic disorders. The  
XX oligomers are also used for detecting cell type differentiation. ABC00010  
XX -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073  
XX represent the oligomers described in the invention. NOTE: The sequence  
XX data for this patent did not form part of the printed specification, but  
XX was obtained in electronic format from WIPO at  
XX ftp.wipo.int/pub/published\_pct\_sequences

XX Sequence 13 BP; 4 A; 0 C; 2 G; 7 T; 0 U; 0 Other;

XX Query Match 20.4%; Score 9.8; DB 1; Length 13;  
XX Best Local Similarity 84.6%; Pred. No. 89;  
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1744 AATGATGCATCATT 1756  
DB 13 AATATCATTCATT 1  
|||||  
|

RESULT 120  
ABF86806  
ID ABF86806 standard; DNA; 13 BP.  
AC ABF86806;  
XX  
XX 22-FEB-2002 (first entry)  
XX  
XX Oligonucleotide SEQ ID NO 186803 for detecting SNP TSC0046049.  
XX  
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX Homo sapiens.  
XX WO200177384-A2.  
XX 18-OCT-2001.  
XX 06-APR-2001; 2001WO-IB000713.  
XX 07-APR-2000; 2000DE-01019173.  
XX (EPIG-) EPIGENOMICS AG.  
XX Olek A, Piepenbrock C, Berlin K;  
XX WPI; 2001-657177/75.  
XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
XX designed to detect single-nucleotide polymorphisms and cytosine  
XX methylation status.  
XX Claim 1; SEQ ID NO 186803; 29pp + Sequence Listing; German.  
XX This invention describes novel oligonucleotide primers or peptide nucleic  
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 4 A; 0 C; 4 G; 5 T; 0 U; 0 Other;  
  
Query Match 20.4%; Score 9.8; DB 1; Length 13;  
Best Local Similarity 84.6%; Pred. No. 89;  
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1721 GATGTTGAGGAA 1733  
Db 1 GATGTTGAGTTAA 13  
|||||  
|  
  
RESULT 121  
ABC83525/c  
ID ABC83525 standard; DNA; 13 BP.  
XX  
AC ABC83525;  
XX  
XX 21-FEB-2002 (first entry)  
DT  
XX  
DE Oligonucleotide SEQ ID NO 83542 for detecting SNP TSC0021041.  
XX  
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
OS Homo sapiens.  
XX  
PN WO200177384-A2.  
XX  
PD 18-OCT-2001.  
XX  
XX 06-APR-2001; 2001WO-IB000713.  
PF  
XX 07-APR-2000; 2000DE-01019173.  
PR  
XX (EPIC-) EPIGENOMICS AG.  
PA  
XX Olek A, Piepenbrock C, Berlin K;  
PI  
XX WPI; 2001-657177/75.  
DR  
XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX  
XX Claim 1; SEQ ID NO 83542; 29pp + Sequence Listing; German.  
PS  
XX  
XX This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 2 A; 5 C; 0 G; 6 T; 0 U; 0 Other;

Query Match 20.4%; Score 9.8; DB 1; Length 13;  
Best Local Similarity 84.6%; Pred. No. 89;  
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1735 AGACAGAGAAAT 1747  
Db 13 AGACAGAGAAAT 1  
|||||  
|  
  
RESULT 122  
ABH24245  
ID ABH24245 standard; DNA; 13 BP.  
XX  
AC ABH24245;  
XX  
XX 22-FEB-2002 (first entry)  
DT  
XX  
DE Oligonucleotide SEQ ID NO 224222 for detecting SNP TSC0054636.  
XX  
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
OS Homo sapiens.  
XX  
PN WO200177384-A2.  
XX  
PD 18-OCT-2001.  
XX  
XX 06-APR-2001; 2001WO-IB000713.  
PF  
XX 07-APR-2000; 2000DE-01019173.  
PR  
XX (EPIC-) EPIGENOMICS AG.  
PA  
XX Olek A, Piepenbrock C, Berlin K;  
PI  
XX WPI; 2001-657177/75.  
DR  
XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX  
XX Claim 1; SEQ ID NO 224222; 29pp + Sequence Listing; German.  
PS  
XX  
XX This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 7 A; 2 C; 0 G; 4 T; 0 U; 0 Other;  
  
Query Match 20.4%; Score 9.8; DB 1; Length 13;  
Best Local Similarity 84.6%; Pred. No. 89;  
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1744 AATGATGCATT 1756  
Db 1 AATGATGCATT 13  
|||||  
|  
  
RESULT 123  
ABH42049/c  
ID ABH42049 standard; DNA; 13 BP.  
XX

```

AC ABH42049;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 242026 for detecting SNP TSC0059034.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
PS Claim 1; SEQ ID NO 242026; 29bp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 4 C; 0 G; 6 T; 0 U; 0 Other;
XX
Query Match 20.4%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 89;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 1725 TTGAGGACACAGA 1737
XX |||||
XX 13 TTGAGGACACAGA 1
XX
RESULT 124
ABH50272
XX ID ABH50272 standard; DNA; 13 BP.
XX
AC ABH50272;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 250249 for detecting SNP TSC0061098.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX

```

```

XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
PS Claim 1; SEQ ID NO 250249; 29bp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 U; 0 Other;
XX
Query Match 20.4%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 89;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 1721 GATGTTGAGGAAA 1733
XX |||||
XX 1 GATGTTGAGGAAA 13
XX
RESULT 125
ABCT4874
XX ID ABC74874 standard; DNA; 13 BP.
XX
AC ABC74874;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 74891 for detecting SNP TSC0019229.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX

```

PT	Set of oligonucleotides; useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
PS	Claim 1; SEQ ID NO 74891; 29pp + Sequence listing; German.
XX	This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC000010-ABG99989, ABE00010-ABF99989, ABH0010-ABH99989 and ABI0010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences
SQ	Sequence 13 BP; 2 A; 0 C; 5 G; 6 T; 0 U; 0 Other;
Query Match	20.4%; Score 9.8; DB 1; Length 13;
Best Local Similarity	84.6%; Pred. No. 89;
Matches	11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY	1718 ACTGATGTTGAGG 1730 1 ATTGTTGTTGAGG 13
Db	ABC10734 standard; DNA; 13 BP.
ID	ABC10734;
AC	ABC10734;
XX	20-FEB-2002 (first entry)
DT	Oligonucleotide SEQ ID NO 10725 for detecting SNP TSCC002683.
DE	SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS; peptide nucleic acid; cytosine methylation; cardiovascular; primer. 89;
KM	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	Homo sapiens.
OS	WO200177384-A2.
PN	18-OCT-2001.
XX	06-APR-2001; 2001WO-IB000713.
PD	07-APR-2000; 2000DE-01019173.
PF	(EPIC-) EPIGENOMICS AG.
XX	Olek A, Piepenbrock C, Berlin K;
PA	WPI; 2001-657177/75.
XX	Set of oligonucleotides; useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
PT	Claim 1; SEQ ID NO 10725; 29pp + Sequence listing; German.
PS	This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC000010-

CC	-ABC99989; ABF00010-ABH99989; ABH00010-ABH99989 and ABI00010-ABI82073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
XX	
XX	Sequence 13 BP; 8 A; 0 C; 3 G; 2 T; 0 U; 0 Other;
SO	
XX	
PS	Claim 1; SEQ ID NO 220184; 29pp + Sequence Listing; German.
XX	
CC	This invention describes novel oligonucleotide primers or peptide nucleic
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	range of diseases including immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligonucleotides are also used for detecting cell type differentiation. ABC00010
CC	-ABC99989; ABF00010-ABF99989; ABH00010-ABH9989 and ABI00010-ABI82073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
XX	
XX	Sequence 13 BP; 6 A; 4 C; 0 G; 3 T; 0 U; 0 Other;
SO	
XX	
PS	Query Match 20.4%; Score 9.8; DB 1; Length 13;
XX	Best Local Similarity 84.6%; Pred. No. 89;
XX	Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX	
XX	1735 AGACAGGAGAAAT 1747
XX	
XX	1 ATAAAGAGAAAT 13
DB	
XX	
XX	RESULT 127
XX	ABH20207/c
XX	ID ABH20207 standard; DNA; 13 BP.
XX	
XX	ABH20207;
XX	
XX	22-FEB-2002 (first entry)
XX	
XX	Oligonucleotide SEQ ID NO 220184 for detecting SNP TSC0053581.
DE	
XX	
XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	
XX	Homo sapiens.
OS	
XX	
XX	WO200177384-A2.
XX	
XX	18-OCT-2001.
XX	
XX	06-APR-2001; 2001WO-IB000713.
XX	
XX	07-APR-2000; 2000DE-01019173.
XX	
XX	(EPIC-) EPICENOMICS AG.
PA	
XX	Olek A, Piepenbrock C, Berlin K;
PI	
XX	WPI; 2001-657177/75.
DR	
XX	
XX	Set of oligonucleotides, useful for diagnosis and cell typing, is
PT	designed to detect single-nucleotide polymorphisms and cytosine
PT	methylation status.
XX	
XX	

Db 13 ATGATGTTAGG 1  
| | | | | | | | | |  
RESULT 128  
ABH10408  
ID ABH10408 standard; DNA; 13 BP.  
XX  
AC ABH10408;  
XX  
DT 22-FEB-2002 (first entry)  
XX  
DE Oligonucleotide SEQ ID NO 210385 for detecting SNP TSC0005915.  
XX  
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
OS Homo sapiens.  
XX  
PN WO200177384-A2.  
XX  
PD 18-OCT-2001.  
XX  
PF 06-APR-2001; 2001WO-IB000713.  
XX  
PR 07-APR-2000; 2000DE-01019173.  
XX  
PS (EPIC-) EPIGENOMICS AG.  
XX  
PI Olek A, Piepenbrock C, Berlin K;  
XX  
DR WPI; 2001-657177/75.  
XX  
PT Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX  
PS Claim 1; SEQ ID NO 210385; 29pp + Sequence listing; German.  
XX  
CC This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 6 A; 0 C; 4 G; 3 T; 0 U; 0 Other;  
XX  
Query Match 20.4%; Score 9.8; DB 1; Length 13;  
Best Local Similarity 84.6%; Pred. No. 89;  
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
XX  
QY 1721 GATGTTAGGAGAA 1733  
| | | | | | | | | |  
Db 1 GATATTGAGGAAA 13  
| | | | | | | | | |  
RESULT 129  
ABF86807/c  
ID ABF86807 standard; DNA; 13 BP.  
XX  
AC ABF86807;  
XX  
DT 22-FEB-2002 (first entry)  
XX  
DE Oligonucleotide SEQ ID NO 186804 for detecting SNP TSC0046049.  
XX  
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
OS Homo sapiens.  
XX  
PN WO200177384-A2.  
XX  
PD 18-OCT-2001.  
XX  
PF 06-APR-2001; 2001WO-IB000713.  
XX  
PR 07-APR-2000; 2000DE-01019173.  
XX  
PS (EPIC-) EPIGENOMICS AG.  
XX  
PI Olek A, Piepenbrock C, Berlin K;  
XX  
DR WPI; 2001-657177/75.  
XX  
PT Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX  
PS Claim 1; SEQ ID NO 186804; 29pp + Sequence listing; German.  
XX  
CC This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 5 A; 4 C; 0 G; 4 T; 0 U; 0 Other;  
XX  
Query Match 20.4%; Score 9.8; DB 1; Length 13;  
Best Local Similarity 84.6%; Pred. No. 89;  
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
XX  
QY 1721 GATGTTAGGAGAA 1733  
| | | | | | | | | |  
Db 13 GATGTTGAGTTAA 1  
| | | | | | | | | |  
RESULT 130  
ABF88831/c  
ID ABF88831 standard; DNA; 13 BP.  
XX  
AC ABF88831;  
XX  
DT 22-FEB-2002 (first entry)  
XX  
DE Oligonucleotide SEQ ID NO 188828 for detecting SNP TSC0046484.  
XX  
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
OS Homo sapiens.  
XX  
PN WO200177384-A2.  
XX  
PD 18-OCT-2001.  
XX  
PF 06-APR-2001; 2001WO-IB000713.

```

XX 07-APR-2000; 2000DE-01019173.
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 188828; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 3 A; 5 C; 0 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 20.4%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 89;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0.
XX
XX 1720 TGATGTTGAGGGA 1732
XX ||||| |||||
XX 13 TGATCTAAGGGA 1
XX
XX RESULT 131
XX ABF88833/C
XX ID ABF88833 standard; DNA; 13 BP.
XX
XX ABF88833;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 188830 for detecting SNP TSC0046484.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001MO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 188830; 29pp + Sequence Listing; German.

```

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at [ftp.wipo.int/pub/published\\_pct\\_sequences](http://wipo.int/pub/published_pct_sequences)

XX Sequence 13 BP, 3 A, 6 C, 0 G, 4 T, 0 U, 0 Other;

XX Query Match 20.4%, Score 9.8; DB 1; Length 13;  
XX Best Local Similarity 84.6%; Pred.No. 89;  
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1720 TGATGTTGAGGGA 1732  
          |||||     |||||  
Db 13 TGATGTGAAGGGA 1

RESULT 132  
ABH64891/C  
ID ABH64891 standard; DNA, 13 BP.  
XX ABH64891;  
XX  
XX ABH64891;  
XX  
XX 22-FEB-2002 (first entry)  
XX  
XX Oligonucleotide SEQ ID NO 264868 for detecting SNP TSC0064202.  
XX  
XX  
XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
XX Homo sapiens.  
XX  
XX  
XX WO200177384-A2.  
XX  
XX 18-OCT-2001.  
XX  
XX 06-APR-2001; 2001WO-IB000713.  
XX  
XX 07-APR-2000; 2000DE-01019173.  
XX  
XX (EPIG-) EPIGENOMICS AG.  
XX  
XX  
XX Olek A, Piepenbrock C, Berlin K;  
XX  
XX WPI; 2001-657177/75.  
XX  
XX  
XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
XX designed to detect single-nucleotide polymorphisms and cytosine  
XX methylation status.  
XX  
XX  
XX Claim 1; SEQ ID NO 264868; 29pp + Sequence Listing; German.  
XX  
XX This invention describes novel oligonucleotide primers or peptide nucleic  
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
XX and cytosine methylation status in chemically pretreated genomic DNA. The  
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
XX range of diseases including immune system, gastrointestinal, respiratory,  
XX central nervous system, cardiovascular and metabolic disorders. The  
XX oligomers are also used for detecting cell type differentiation. ABC00010  
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
XX represent the oligomers described in the invention. NOTE: The sequence  
XX data for this patent did not form part of the printed specification, but  
XX was obtained in electronic format from WIPO at  
XX [ftp.wipo.int/pub/published\\_pct\\_sequences](http://wipo.int/pub/published_pct_sequences)

XX Sequence 13 BP; 2 A; 5 C; 0 G; 6 T; 0 U; 0 Other;  
SQ Query Match 20.4%; Score 9.8; DB 1; Length 13;  
Best Local Similarity 84.6%; Pred. No. 89;  
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1721 GATGTGAGGAA 1733  
DB 13 GATGATGAGGAA 1  
RESULT 133  
ABC0824  
ID ABC0824 standard; DNA; 13 BP.  
AC ABC0824;  
XX  
XX 20-FEB-2002 (first entry)  
DT  
XX  
DE Oligonucleotide SEQ ID NO 20841 for detecting SNP TSC0004233.  
XX  
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
XX Homo sapiens.  
OS  
XX  
XX WO200177384-A2.  
PN  
XX  
XX 18-OCT-2001.  
PD  
XX  
XX 06-APR-2001; 2001WO-IB000713.  
PF  
XX  
XX 07-APR-2000; 2000DE-01019173.  
PR  
XX  
XX (EPiG-) EPIGENOMICS AG.  
PA  
XX  
XX Olek A, Piepenbrock C, Berlin K;  
PI  
XX  
XX WPI; 2001-657177/75.  
DR  
XX  
XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
PT  
XX  
XX Claim 1; SEQ ID NO 20841; 29pp + Sequence Listing; German.  
XX  
XX This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
CC  
XX  
SQ Sequence 13 BP; 6 A; 0 C; 4 G; 3 T; 0 U; 0 Other;  
Query Match 20.4%; Score 9.8; DB 1; Length 13;  
Best Local Similarity 84.6%; Pred. No. 89;  
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1739 AGGAGAAATGAT 1751  
DB 1 AGGTGAAATGAAAT 13  
RESULT 134

ABC97855/C  
ID ABC97855 standard; DNA; 13 BP.  
XX  
XX ABC97855;  
AC  
XX  
XX 21-FEB-2002 (first entry)  
DT  
XX  
DE Oligonucleotide SEQ ID NO 97872 for detecting SNP TSC0024301.  
XX  
XX  
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
XX Homo sapiens.  
OS  
XX  
XX WO200177384-A2.  
PN  
XX  
XX 18-OCT-2001.  
PD  
XX  
XX 06-APR-2001; 2001WO-IB000713.  
PF  
XX  
XX 07-APR-2000; 2000DE-01019173.  
PR  
XX  
XX (EPiG-) EPIGENOMICS AG.  
PA  
XX  
XX Olek A, Piepenbrock C, Berlin K;  
PI  
XX  
XX WPI; 2001-657177/75.  
DR  
XX  
XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
PT  
XX  
XX Claim 1; SEQ ID NO 97872; 29pp + Sequence Listing; German.  
XX  
XX This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
CC  
XX  
SQ Sequence 13 BP; 2 A; 8 C; 0 G; 3 T; 0 U; 0 Other;  
Query Match 20.4%; Score 9.8; DB 1; Length 13;  
Best Local Similarity 84.6%; Pred. No. 89;  
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1724 GTTGAGGAAACAG 1736  
DB 13 GTTGAGGAGAAAG 1  
RESULT 135  
ABC8763/C  
ID ABC8763 standard; DNA; 13 BP.  
AC ABC8763;  
XX  
XX 21-FEB-2002 (first entry)  
DT  
XX  
DE Oligonucleotide SEQ ID NO 48780 for detecting SNP TSC0013859.  
XX  
XX  
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX

OS	Homo sapiens.
PN	WO200177384-A2.
XX	
XX	
PD	18-OCT-2001.
XX	
XX	
PE	06-APR-2001; 2001WO-IB000713.
XX	
XX	
PR	07-APR-2000; 2000DE-01019173.
XX	
PA	(EPIG-) EPIGENOMICS AG.
XX	
PI	Olek A, Piepenbrock C, Berlin K;
DR	WPI; 2001-657177/75.
XX	
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is
PT	designed to detect single-nucleotide polymorphisms and cytosine
PT	methylation status.
XX	
PS	Claim 1; SEQ ID NO 48780; 29pp + Sequence Listing; German.
XX	
CC	This invention describes novel oligonucleotide primers or peptide nucleic
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	range of diseases including immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligomers are also used for detecting cell type differentiation. ABC00010
CC	-ABC99989, ABR00010-ABF99989, ABH00010-ABH99989 and ABR00010-ABR82073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
XX	
SO	Sequence 13 BP; 4 A; 3 C; 0 G; 6 T; 0 U; 0 Other;
	Query Match 20.4%; Score 9.8; DB 1; Length 13;
	Best Local Similarity 84.6%; Pred. No. 89;
	Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY	1739 AGGAGAAATGCAT 1751
DB	13 ATGAGAAATGTAT 1
RESULT 136	
ABC07407/C	
ID	ABC07407 standard; DNA; 13 BP.
XX	
AC	ABC07407;
XX	
DT	20-FEB-2002 (first entry)
XX	
DE	Oligonucleotide SEQ ID NO 7398 for detecting SNP TSC0002151.
XX	
XX	
KW	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	
OS	Homo sapiens.
XX	
PN	WO200177384-A2.
XX	
PD	18-OCT-2001.
XX	
PE	06-APR-2001; 2001WO-IB000713.
XX	
PR	07-APR-2000; 2000DE-01019173.
XX	
PA	(EPIG-) EPIGENOMICS AG.
XX	
PI	Olek A, Piepenbrock C, Berlin K;

XX		WPI; 2001-657177/75.
DR		
XX		
PT		Set of oligonucleotides, useful for diagnosis and cell typing, is
PR		designed to detect single-nucleotide polymorphisms and cytosine
PT		methylation status.
XX		
PB		Claim 1; SEQ ID NO 7398; 29pp + Sequence Listing; German.
XX		
CC		This invention describes novel oligonucleotide primers or peptide nucleic
CC		acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC		and cytosine methylation status in chemically pretreated genomic DNA. The
CC		oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC		range of diseases including immune system, gastrointestinal, respiratory,
CC		central nervous system, cardiovascular and metabolic disorders. The
CC		oligomers are also used for detecting cell type differentiation. ABC00010
CC		-ABC99989, ABF00010-ABF99989, ABI00010-ABI99989 and ABI00010-ABI82073
CC		represent the oligomers described in the invention. NOTE: The sequence
CC		data for this patent did not form part of the printed specification, but
CC		was obtained in electronic format from WIPO at
CC		ftp.wipo.int/pub/published_pct_sequences
XX		
SQ		Sequence 13 BP; 2 A; 7 C; 0 G; 4 T; 0 U; 0 Other;
Query Match	20.4%; Score 9.8; DB 1; Length 13;	
Best Local Similarity	84.6%; Pred. No. 89;	
Matches 11; Conservative	0; Mismatches 2; Indels 0; Gaps 0;	
OY	1720 TGATGTTGAGGGA 1732	
Dd	 13 TGACGATTAGGGA 1	
RESULT 137		
ID	ABF18398	
XX	ABF18398 standard; DNA; 13 BP.	
XX		
AC	ABF18398;	
XX		
DT	21-FEB-2002 (first entry)	
XX		
DE	Oligonucleotide SEQ ID NO 118395 for detecting SNP TSC0029588.	
XX		
KM	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;	
KV	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;	
WM	central nervous system; gastrointestinal; respiratory; immune; metabolic.	
XX		
OS	Homo sapiens.	
XX		
PN	WO200177384-A2.	
PD		
FD	18-OCT-2001.	
XX		
PF	06-APR-2001; 2001MO-IB000713.	
PR		
PA	07-APR-2000; 2000DB-01019173.	
XX		
PA	(EPIG-) EPIGENOMICS AG.	
XX		
PL	Olek A, Piepenbrock C, Berlin K;	
DR		
XX	WPI; 2001-657177/75.	
PT		
FT	Set of oligonucleotides, useful for diagnosis and cell typing, is	
PT	designed to detect single-nucleotide polymorphisms and cytosine	
XX	methylation status.	
PS		
PS	Claim 1; SEQ ID NO 118395; 29pp + Sequence Listing; German.	
CC		
CC	This invention describes novel oligonucleotide primers or peptide nucleic	
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)	
CC	and cytosine methylation status in chemically pretreated genomic DNA. The	
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a	
CC	range of diseases including immune system, gastrointestinal, respiratory,	
CC	central nervous system, cardiovascular and metabolic disorders. The	
CC	oligomers are also used for detecting cell type differentiation. ABC00010	
CC	-ABC99989, ABF00010-ABF99989, ABI00010-ABI99989 and ABI00010-ABI82073	
CC	represent the oligomers described in the invention. NOTE: The sequence	
CC	data for this patent did not form part of the printed specification, but	
CC	was obtained in electronic format from WIPO at	
CC	ftp.wipo.int/pub/published_pct_sequences	
XX		

CC range of diseases including immune system, gastrointestinal, respiratory,  
 CC central nervous system, cardiovascular and metabolic disorders. The  
 CC oligomers are also used for detecting cell type differentiation. ABC00010  
 CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI02073  
 CC represent the oligomers described in the invention. NOTE: The sequence  
 CC data for this patent did not form part of the printed specification, but  
 CC was obtained in electronic format from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences

SQ Sequence 13 BP; 3 A; 0 C; 3 G; 7 T; 0 U; 0 Other;  
 Query Match 20.4%; Score 9.8; DB 1; Length 13;  
 Best Local Similarity 84.6%; Pred. No. 89;  
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1716 TGACTGATGTTGA 1728  
 DB 1 TGATTGATGTTTA 13

RESULT 138  
 ABF21699/c  
 ID ABF21699 standard; DNA; 13 BP.  
 AC ABF21699;  
 XX  
 XX 21-FEB-2002 (first entry)  
 DT  
 XX  
 DE Oligonucleotide SEQ ID NO 121696 for detecting SNP TSC0030400.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.  
 XX Homo sapiens.

XX MO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
 PT designed to detect single-nucleotide polymorphisms and cytosine  
 PT methylation status.

PS Claim 1; SEQ ID NO 121696; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic  
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
 CC and cytosine methylation status in chemically pretreated genomic DNA. The  
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
 CC range of diseases including immune system, gastrointestinal, respiratory,  
 CC central nervous system, cardiovascular and metabolic disorders. The  
 CC oligomers are also used for detecting cell type differentiation. ABC00010  
 CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI02073  
 CC represent the oligomers described in the invention. NOTE: The sequence  
 CC data for this patent did not form part of the printed specification, but  
 CC was obtained in electronic format from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences

XX Sequence 13 BP; 4 A; 6 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 20.4%; Score 9.8; DB 1; Length 13;  
 Best Local Similarity 84.6%; Pred. No. 89;

Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1721 GATGTTGAGGGA 1733

DB 13 GGTTTGAGGGA 1

RESULT 139  
 ABF46516  
 ID ABF46516 standard; DNA; 13 BP.

AC ABF46516;  
 XX  
 XX 21-FEB-2002 (first entry)  
 DT  
 XX  
 DE Oligonucleotide SEQ ID NO 146513 for detecting SNP TSC0036945.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX MO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
 PT designed to detect single-nucleotide polymorphisms and cytosine  
 PT methylation status.

PS Claim 1; SEQ ID NO 146513; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic  
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
 CC and cytosine methylation status in chemically pretreated genomic DNA. The  
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
 CC range of diseases including immune system, gastrointestinal, respiratory,  
 CC central nervous system, cardiovascular and metabolic disorders. The  
 CC oligomers are also used for detecting cell type differentiation. ABC00010  
 CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI02073  
 CC represent the oligomers described in the invention. NOTE: The sequence  
 CC data for this patent did not form part of the printed specification, but  
 CC was obtained in electronic format from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences

XX Sequence 13 BP; 6 A; 0 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 20.4%; Score 9.8; DB 1; Length 13;  
 Best Local Similarity 84.6%; Pred. No. 89;  
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1721 GATGTTGAGGGA 1733

DB 1 GATGTTGAAAGA 13

RESULT 140  
 ABF51962  
 ID ABF51962 standard; DNA; 13 BP.

AC ABF51962;  
 XX

DT 21-FEB-2002 (first entry)  
XX Oligonucleotide SEQ ID NO 151959 for detecting SNP TSC0038398.  
DE  
XX  
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
XX Homo sapiens.  
OS  
XX  
XX WO200177384-A2.  
PN  
XX  
XX 18-OCT-2001.  
PD  
XX  
XX 06-APR-2001; 2001WO-IB000713.  
PF  
XX  
XX 07-APR-2000; 2000DE-01019173.  
PR  
XX  
XX (EPIC-) EPIDENOMICS AG.  
PA  
XX  
XX Olek A, Piepenbrock C, Berlin K;  
PI  
XX  
XX WPI; 2001-657177/75.  
DR  
XX  
XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX  
XX  
XX Claim 1; SEQ ID NO 151959; 29pp + Sequence listing; German.  
PS  
XX  
XX This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 4 A; 0 C; 4 G; 5 T; 0 U; 0 Other;  
XX  
Query Match 20.4%; Score 9.8; DB 1; Length 13;  
Best Local Similarity 84.6%; Pred. No. 89;  
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
XX  
QY 1720 TGATGTTGAGGGA 1732  
DB 1 TAAATTTGAGGGA 13  
XX  
RESULT 141  
ABF51963/c  
ID ABF51963 standard; DNA; 13 BP.  
XX  
XX ABF51963;  
AC  
XX  
XX 21-FEB-2002 (first entry)  
DT  
XX  
XX Oligonucleotide SEQ ID NO 151960 for detecting SNP TSC0038398.  
DE  
XX  
XX  
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
XX Homo sapiens.  
OS  
XX  
XX WO200177384-A2.  
PN  
XX  
XX 18-OCT-2001.  
PD

XX  
XX 06-APR-2001; 2001WO-IB000713.  
PF  
XX  
XX 07-APR-2000; 2000DE-01019173.  
PR  
XX  
XX (EPIC-) EPIDENOMICS AG.  
PA  
XX  
XX Olek A, Piepenbrock C, Berlin K;  
PI  
XX  
XX WPI; 2001-657177/75.  
DR  
XX  
XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX  
XX  
XX Claim 1; SEQ ID NO 151960; 29pp + Sequence listing; German.  
PS  
XX  
XX This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 5 A; 4 C; 0 G; 4 T; 0 U; 0 Other;  
XX  
Query Match 20.4%; Score 9.8; DB 1; Length 13;  
Best Local Similarity 84.6%; Pred. No. 89;  
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
XX  
QY 1720 TGATGTTGAGGGA 1732  
DB 13 TAAATTTGAGGGA 1  
XX  
RESULT 142  
ABF02354  
ID ABF02354 standard; DNA; 13 BP.  
XX  
XX ABF02354;  
AC  
XX  
XX 21-FEB-2002 (first entry)  
DT  
XX  
XX Oligonucleotide SEQ ID NO 102351 for detecting SNP TSC0025526.  
DE  
XX  
XX  
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
XX Homo sapiens.  
OS  
XX  
XX WO200177384-A2.  
PN  
XX  
XX 18-OCT-2001.  
PD  
XX  
XX 06-APR-2001; 2001WO-IB000713.  
PF  
XX  
XX 07-APR-2000; 2000DE-01019173.  
PR  
XX  
XX (EPIC-) EPIDENOMICS AG.  
PA  
XX  
XX Olek A, Piepenbrock C, Berlin K;  
PI  
XX  
XX WPI; 2001-657177/75.  
DR  
XX  
XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.  
 XX  
 PS Claim 1; SEQ ID NO 102351; 29pp + Sequence Listing; German.  
 CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, CC central nervous system, cardiovascular and metabolic disorders. The CC oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 CC represent the oligomers described in the invention. NOTE: The sequence CC data for this patent did not form part of the printed specification, but CC was obtained in electronic format from WIPO at CC ftp.wipo.int/pub/published\_pct\_sequences CC  
 XX  
 SQ Sequence 13 BP; 5 A; 0 C; 4 G; 4 T; 0 U; 0 Other;  
 Query Match 20.4%; Score 9.8; DB 1; Length 13;  
 Best Local Similarity 84.6%; Pred. No. 89;  
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1723 TGTTCAGGAGACA 1735  
 Db 1 TGTTCAGGAGAAA 13  
 RESULT 143  
 ABC41626  
 ID ABC41626 standard; DNA; 13 BP.  
 AC ABC41626;  
 XX  
 DT 21-FEB-2002 (first entry)  
 DE Oligonucleotide SEQ ID NO 41643 for detecting SNP TSC0012495.  
 XX  
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS; KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss; KW central nervous system; gastrointestinal; respiratory; immune; metabolic.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200177384-A2.  
 XX  
 PD 18-OCT-2001.  
 XX  
 PF 06-APR-2001; 2001WO-IB000713.  
 XX  
 PR 07-APR-2000; 2000DE-01019173.  
 XX  
 PA (EPIC-) EPIGENOMICS AG.  
 XX  
 PI Olek A, Piepenbrock C, Berlin K;  
 XX  
 DR WPI; 2001-657177/75.  
 XX  
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is PT designed to detect single-nucleotide polymorphisms and cytosine PT methylation status.  
 XX  
 PS Claim 1; SEQ ID NO 41643; 29pp + Sequence Listing; German.  
 CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, CC central nervous system, cardiovascular and metabolic disorders. The CC oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 CC represent the oligomers described in the invention. NOTE: The sequence CC

CC data for this patent did not form part of the printed specification, but CC was obtained in electronic format from WIPO at CC ftp.wipo.int/pub/published\_pct\_sequences CC  
 XX  
 SQ Sequence 13 BP; 6 A; 0 C; 7 G; 0 T; 0 U; 0 Other;  
 Query Match 20.4%; Score 9.8; DB 1; Length 13;  
 Best Local Similarity 84.6%; Pred. No. 89;  
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1730 GGAACAGACAGCA 1742  
 Db 1 GGAACAGACAGCA 13  
 RESULT 144  
 ABC97854  
 ID ABC97854 standard; DNA; 13 BP.  
 AC ABC97854;  
 XX  
 DT 21-FEB-2002 (first entry)  
 DE Oligonucleotide SEQ ID NO 97871 for detecting SNP TSC0024301.  
 XX  
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS; KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss; KW central nervous system; gastrointestinal; respiratory; immune; metabolic.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200177384-A2.  
 XX  
 PD 18-OCT-2001.  
 XX  
 PF 06-APR-2001; 2001WO-IB000713.  
 XX  
 PR 07-APR-2000; 2000DE-01019173.  
 XX  
 PA (EPIC-) EPIGENOMICS AG.  
 XX  
 PI Olek A, Piepenbrock C, Berlin K;  
 XX  
 DR WPI; 2001-657177/75.  
 XX  
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is PT designed to detect single-nucleotide polymorphisms and cytosine PT methylation status.  
 XX  
 PS Claim 1; SEQ ID NO 97871; 29pp + Sequence Listing; German.  
 CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, CC central nervous system, cardiovascular and metabolic disorders. The CC oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 CC represent the oligomers described in the invention. NOTE: The sequence CC data for this patent did not form part of the printed specification, but CC was obtained in electronic format from WIPO at CC ftp.wipo.int/pub/published\_pct\_sequences CC  
 XX  
 SQ Sequence 13 BP; 3 A; 0 C; 8 G; 2 T; 0 U; 0 Other;  
 Query Match 20.4%; Score 9.8; DB 1; Length 13;  
 Best Local Similarity 84.6%; Pred. No. 89;  
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1724 GTTGAGGAGACAG 1736  
 Db 1 GTTGAGGAGAGAG 13

XX	ABF14030/C
ID	ABF14030 standard; DNA, 13 BP.
XX	
AC	ABF14030;
XX	
DT	21-FEB-2002 (first entry)
XX	
DE	Oligonucleotide SEQ ID NO 114027 for detecting SNP TSC0028539.
XX	
XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss/
XX	central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS	Homo sapiens.
XX	
PN	WO200177384-A2.
PD	18-OCT-2001.
PF	06-APR-2001; 2001MO-IB000713.
PR	07-APR-2000; 2000DE-01019173.
PA	(EPIG-) EPIGENOMICS AG.
PI	Olek A, Piepenbrock C, Berlin K;
DR	WPI; 2001-657177/75.
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
PS	Claim 1; SEQ ID NO 114027; 29pp + Sequence Listing; German.
CC	This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences
SQ	Sequence 13 BP; 3 A; 0 C; 4 G; 6 T; 0 U; 0 Other;
Query Match	20.4%; Score 9.8; DB 1; Length 13;
Best Local Similarity	84.6%; Pred. No. 89;
Matches	11; Conservative 0; Mismatches 2; Indels 0; Gaps 0
OY	1744 AAATGATTCATT 1756               DB 13 AAATCATTCACCT 1
RESULT 146	
ABF88830	
ID	ABF88830 standard; DNA, 13 BP.
AC	ABF88830;
DT	22-FEB-2002 (first entry)
DE	Oligonucleotide SEQ ID NO 188827 for detecting SNP TSC0046484.
XX	
XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	
OS	Homo sapiens.
XX	
PM	WO200177384-A2.
XX	
XX	18-OCT-2001.
PD	
PF	06-APR-2001; 2001WO-IB000713.
XX	
PR	07-APR-2000; 2000DE-01019173.
XX	
PA	(EPIC-) EPIGENOMICS AG.
XX	
PI	Olek A, Piepenbrock C, Berlin K,
XX	
DR	WPI; 2001-657177/75.
XX	
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is
PT	designed to detect single-nucleotide polymorphisms and cytosine
PT	methylation status.
XX	
PS	Claim 1; SEQ ID NO 188827; 29pp + Sequence Listing; German.
XX	
CC	This invention describes novel oligonucleotide primers or peptide nucleic
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	range of diseases including immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligonucleotides are also used for detecting cell type differentiation. ABC00010
CC	-ABC09989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
XX	
SQ	Sequence 13 BP; 5 A; 0 C; 5 G; 3 T; 0 U; 0 Other;
XX	
Query Match	20.4%; Score 9.8; DB 1; Length 13;
Best Local Similarity	84.6%; Pred. No. 89;
Matches 11; Conservative	0; Mismatches 2; Indels 0; Gaps 0;
QY	1720 TGATGTTGAGGCA 1732
DB	1 TGATGTAAGGCA 13
RESULT 147	
ABH44534	
ID	ABH44534 standard; DNA; 13 BP.
AC	ABH44534;
XX	
DT	22-FEB-2002 (first entry)
DE	
XX	
XX	Oligonucleotide SEQ ID NO 244511 for detecting SNP TSC0059697.
KM	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KX	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	
OS	Homo sapiens.
XX	
PM	WO200177384-A2.
XX	
PD	18-OCT-2001.
XX	
PF	06-APR-2001; 2001WO-IB000713.
XX	
PR	07-APR-2000; 2000DE-01019173.
XX	

PA (EPIG-) EPIGENOMICS AG.  
 XX  
 PI Olek A, Piepenbrock C, Berlin K;  
 XX WPI; 2001-657177/75.  
 DR  
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
 PT designed to detect single-nucleotide polymorphisms and cytosine  
 PT methylation status.  
 XX  
 PS Claim 1; SEQ ID NO 244511; 29pp + Sequence Listing; German.  
 XX  
 CC This invention describes novel oligonucleotide primers or peptide nucleic  
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
 CC and cytosine methylation status in chemically pretreated genomic DNA. The  
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
 CC range of diseases including immune system, gastrointestinal, respiratory,  
 CC central nervous system, cardiovascular and metabolic disorders. The  
 CC oligomers are also used for detecting cell type differentiation. ABC00010  
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
 CC represent the oligomers described in the invention. NOTE: The sequence  
 CC data for this patent did not form part of the printed specification, but  
 CC was obtained in electronic format from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences  
 CC  
 SO Sequence 13 BP; 4 A; 0 C; 5 G; 4 T; 0 U; 0 Other;  
 XX  
 QY Query Match 20.4%; Score 9.8; DB 1; Length 13;  
 Best Local Similarity 84.6%; Pred. No. 89;  
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 XX  
 Db 1723 TGTGAGGAGACA 1735  
 1 TGTGAGGAGACA 13  
 XX  
 RESULT 148  
 ABC53910  
 ID ABC53910 standard; DNA; 13 BP.  
 XX  
 AC ABC53910;  
 XX  
 DT 21-FEB-2002 (first entry)  
 XX  
 DE Oligonucleotide SEQ ID NO 53927 for detecting SNP TSC0014835.  
 XX  
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200177384-A2.  
 XX  
 PD 18-OCT-2001.  
 XX  
 PF 06-APR-2001; 2001WO-IB000713.  
 XX  
 PR 07-APR-2000; 2000DE-01019173.  
 XX  
 PA (EPIG-) EPIGENOMICS AG.  
 XX  
 PI Olek A, Piepenbrock C, Berlin K;  
 XX WPI; 2001-657177/75.  
 DR  
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
 PT designed to detect single-nucleotide polymorphisms and cytosine  
 PT methylation status.  
 XX  
 PS Claim 1; SEQ ID NO 53927; 29pp + Sequence Listing; German.  
 XX  
 CC This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
 CC and cytosine methylation status in chemically pretreated genomic DNA. The  
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
 CC range of diseases including immune system, gastrointestinal, respiratory,  
 CC central nervous system, cardiovascular and metabolic disorders. The  
 CC oligomers are also used for detecting cell type differentiation. ABC00010  
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
 CC represent the oligomers described in the invention. NOTE: The sequence  
 CC data for this patent did not form part of the printed specification, but  
 CC was obtained in electronic format from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences  
 CC  
 SO Sequence 13 BP; 4 A; 0 C; 4 G; 5 T; 0 U; 0 Other;  
 XX  
 QY Query Match 20.4%; Score 9.8; DB 1; Length 13;  
 Best Local Similarity 84.6%; Pred. No. 89;  
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 XX  
 Db 1718 ACTGATGTTGAGG 1730  
 1 ATTGATGTTAAGG 13  
 XX  
 RESULT 149  
 ABF07049/C  
 ID ABF07049 standard; DNA; 13 BP.  
 XX  
 AC ABF07049;  
 XX  
 DT 21-FEB-2002 (first entry)  
 XX  
 DE Oligonucleotide SEQ ID NO 107046 for detecting SNP TSC0026803.  
 XX  
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200177384-A2.  
 XX  
 PD 18-OCT-2001.  
 XX  
 PF 06-APR-2001; 2001WO-IB000713.  
 XX  
 PR 07-APR-2000; 2000DE-01019173.  
 XX  
 PA (EPIG-) EPIGENOMICS AG.  
 XX  
 PI Olek A, Piepenbrock C, Berlin K;  
 XX WPI; 2001-657177/75.  
 DR  
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
 PT designed to detect single-nucleotide polymorphisms and cytosine  
 PT methylation status.  
 XX  
 PS Claim 1; SEQ ID NO 107046; 29pp + Sequence Listing; German.  
 XX  
 CC This invention describes novel oligonucleotide primers or peptide nucleic  
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
 CC and cytosine methylation status in chemically pretreated genomic DNA. The  
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
 CC range of diseases including immune system, gastrointestinal, respiratory,  
 CC central nervous system, cardiovascular and metabolic disorders. The  
 CC oligomers are also used for detecting cell type differentiation. ABC00010  
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
 CC represent the oligomers described in the invention. NOTE: The sequence  
 CC data for this patent did not form part of the printed specification, but  
 CC was obtained in electronic format from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences  
 CC  
 SO Sequence 13 BP; 3 A; 6 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 20.4%; Score 9.8; DB 1; Length 13;  
 Best Local Similarity 84.6%; Pred. No. 89;  
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1721 GATGTTGAGGGA 1733  
 |||||  
 DB 13 GAGGTGAGGTAA 1

RESULT 150  
 ABE18399/c  
 ID ABE18399 standard; DNA; 13 BP.

XX ABE18399;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 118396 for detecting SNP TSC0029588.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is  
 PT designed to detect single-nucleotide polymorphisms and cytosine  
 PT methylation status.

XX Claim 1; SEQ ID NO 118396; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic  
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
 CC and cytosine methylation status in chemically pretreated genomic DNA. The  
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
 CC range of diseases including immune system, gastrointestinal, respiratory,  
 CC central nervous system, cardiovascular and metabolic disorders. The  
 CC oligomers are also used for detecting cell type differentiation. ABC00010  
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
 CC represent the oligomers described in the invention. NOTE: The sequence  
 CC data for this patent did not form part of the printed specification, but  
 CC was obtained in electronic format from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences

XX Sequence 13 BP; 7 A; 3 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 20.4%; Score 9.8; DB 1; Length 13;  
 Best Local Similarity 84.6%; Pred. No. 89;  
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1716 TGACTGATGTTGA 1728  
 |||||  
 DB 13 TGATTGATGTTTA 1

RESULT 151

ABF88832  
 ID ABF88832 standard; DNA; 13 BP.

XX ABE88832;  
 AC  
 XX 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 188829 for detecting SNP TSC0046484.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is  
 PT designed to detect single-nucleotide polymorphisms and cytosine  
 PT methylation status.

XX Claim 1; SEQ ID NO 188829; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic  
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
 CC and cytosine methylation status in chemically pretreated genomic DNA. The  
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
 CC range of diseases including immune system, gastrointestinal, respiratory,  
 CC central nervous system, cardiovascular and metabolic disorders. The  
 CC oligomers are also used for detecting cell type differentiation. ABC00010  
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
 CC represent the oligomers described in the invention. NOTE: The sequence  
 CC data for this patent did not form part of the printed specification, but  
 CC was obtained in electronic format from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences

XX Sequence 13 BP; 4 A; 0 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 20.4%; Score 9.8; DB 1; Length 13;  
 Best Local Similarity 84.6%; Pred. No. 89;  
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1720 TGATGTTGAGGGA 1732  
 |||||  
 DB 1 TGATGTAAGGGA 13

RESULT 152

ABH64890  
 ID ABH64890 standard; DNA; 13 BP.

XX ABE64890;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 264867 for detecting SNP TSC0064202.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.



CC oligomers are also used for detecting cell type differentiation. ABC00010  
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
 CC represent the oligomers described in the invention. NOTE: The sequence  
 CC data for this patent did not form part of the printed specification, but  
 CC was obtained in electronic format from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences  
 CC XX

Sequence 13 BP; 5 A; 4 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 20.4%; Score 9.8; DB 1; Length 13;  
 Best Local Similarity 84.6%; Pred. No. 89;  
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1718 ACTGATGTTGAG 1730  
 Db 13 ATTGATGTTAAG 1

RESULT 155  
 ABC83524  
 ID ABC83524 standard; DNA; 13 BP.  
 XX  
 AC ABC83524;  
 XX  
 DT 21-FEB-2002 (first entry)  
 XX  
 DE Oligonucleotide SEQ ID NO 83541 for detecting SNP TSC0021041.  
 XX  
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200177384-A2.  
 XX  
 PD 18-OCT-2001.  
 XX  
 PF 06-APR-2001; 2001WO-IB000713.  
 XX  
 PR 07-APR-2000; 2000DE-01019173.  
 XX  
 PA (EPIC-) EPIGENOMICS AG.  
 XX  
 PI Olek A, Piepenbrock C, Berlin K;  
 XX  
 DR WPI; 2001-657177/75.  
 XX  
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is  
 PT designed to detect single-nucleotide polymorphisms and cytosine  
 PT methylation status.  
 XX  
 PS Claim 1; SEQ ID NO 83541; 29pp + Sequence Listing; German.  
 XX  
 CC This invention describes novel oligonucleotide primers or peptide nucleic  
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
 CC and cytosine methylation status in chemically pretreated genomic DNA. The  
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
 CC range of diseases including immune system, gastrointestinal, respiratory,  
 CC central nervous system, cardiovascular and metabolic disorders. The  
 CC oligomers are also used for detecting cell type differentiation. ABC00010  
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
 CC represent the oligomers described in the invention. NOTE: The sequence  
 CC data for this patent did not form part of the printed specification, but  
 CC was obtained in electronic format from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences  
 CC XX

Sequence 13 BP; 6 A; 0 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 20.4%; Score 9.8; DB 1; Length 13;  
 Best Local Similarity 84.6%; Pred. No. 89;  
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1735 AGACAGGAGAAAT 1747  
 Db 1 AGACAGGAGAAAT 13

RESULT 156  
 ABF11986/c  
 ID ABF11986 standard; DNA; 13 BP.  
 XX  
 AC ABF11986;  
 XX  
 DT 21-FEB-2002 (first entry)  
 XX  
 DE Oligonucleotide SEQ ID NO 111983 for detecting SNP TSC0027952.  
 XX  
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200177384-A2.  
 XX  
 PD 18-OCT-2001.  
 XX  
 PF 06-APR-2001; 2001WO-IB000713.  
 XX  
 PR 07-APR-2000; 2000DE-01019173.  
 XX  
 PA (EPIC-) EPIGENOMICS AG.  
 XX  
 PI Olek A, Piepenbrock C, Berlin K;  
 XX  
 DR WPI; 2001-657177/75.  
 XX  
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is  
 PT designed to detect single-nucleotide polymorphisms and cytosine  
 PT methylation status.  
 XX  
 PS Claim 1; SEQ ID NO 111983; 29pp + Sequence Listing; German.  
 XX  
 CC This invention describes novel oligonucleotide primers or peptide nucleic  
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
 CC and cytosine methylation status in chemically pretreated genomic DNA. The  
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
 CC range of diseases including immune system, gastrointestinal, respiratory,  
 CC central nervous system, cardiovascular and metabolic disorders. The  
 CC oligomers are also used for detecting cell type differentiation. ABC00010  
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
 CC represent the oligomers described in the invention. NOTE: The sequence  
 CC data for this patent did not form part of the printed specification, but  
 CC was obtained in electronic format from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences  
 CC XX

Sequence 13 BP; 6 A; 0 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 20.4%; Score 9.8; DB 1; Length 13;  
 Best Local Similarity 84.6%; Pred. No. 89;  
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1744 AAATGATTCATT 1756  
 Db 13 AAATGATTCATT 1

RESULT 157  
 ABF11987  
 ID ABF11987 standard; DNA; 13 BP.  
 XX  
 AC ABF11987;  
 XX  
 DT 21-FEB-2002 (first entry)  
 XX

DE Oligonucleotide SEQ ID NO 111984 for detecting SNP TSC0027952.  
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200177384-A2.  
 XX  
 PD 18-OCT-2001.  
 XX  
 PF 06-APR-2001; 2001WO-IB000713.  
 XX  
 PR 07-APR-2000; 2000DE-01019173.  
 XX  
 PA (EPIG-) EPIGENOMICS AG.  
 XX  
 PI Olek A, Piepenbrock C, Berlin K;  
 XX WPI; 2001-657177/75.  
 DR  
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
 PT designed to detect single-nucleotide polymorphisms and cytosine  
 PT methylation status.  
 XX  
 PS Claim 1; SEQ ID NO 111984; 29pb + Sequence Listing; German.  
 XX  
 CC This invention describes novel oligonucleotide primers or peptide nucleic  
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
 CC and cytosine methylation status in chemically pretreated genomic DNA. The  
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
 CC range of diseases including immune system, gastrointestinal, respiratory,  
 CC central nervous system, cardiovascular and metabolic disorders. The  
 CC oligomers are also used for detecting cell type differentiation. ABC00010  
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
 CC represent the oligomers described in the invention. NOTE: The sequence  
 CC data for this patent did not form part of the printed specification, but  
 CC was obtained in electronic format from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences  
 CC  
 CC Sequence 13 BP; 5 A; 2 C; 0 G; 6 T; 0 U; 0 Other;  
 SQ  
 XX  
 Query Match 20.4%; Score 9.8; DB 1; Length 13;  
 Best Local Similarity 84.6%; Pred. No. 89;  
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 OY 1744 AATGATCCATCATT 1756  
 DB 1 AATTTCATTCATT 13  
 XX  
 RESULT 158  
 ABH10409/C  
 ID ABH10409 standard; DNA; 13 BP.  
 XX  
 AC ABH10409;  
 XX  
 DT 22-FEB-2002 (first entry)  
 XX  
 DE Oligonucleotide SEQ ID NO 210386 for detecting SNP TSC0005915.  
 XX  
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200177384-A2.  
 XX  
 PD 18-OCT-2001.  
 XX  
 PF 06-APR-2001; 2001WO-IB000713.  
 XX  
 PR 07-APR-2000; 2000DE-01019173.  
 XX  
 PA (EPIG-) EPIGENOMICS AG.  
 XX  
 PI Olek A, Piepenbrock C, Berlin K;  
 XX WPI; 2001-657177/75.  
 DR  
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
 PT designed to detect single-nucleotide polymorphisms and cytosine  
 PT methylation status.  
 XX  
 PS Claim 1; SEQ ID NO 210386; 29pb + Sequence Listing; German.  
 XX  
 CC This invention describes novel oligonucleotide primers or peptide nucleic  
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
 CC and cytosine methylation status in chemically pretreated genomic DNA. The  
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
 CC range of diseases including immune system, gastrointestinal, respiratory,  
 CC central nervous system, cardiovascular and metabolic disorders. The  
 CC oligomers are also used for detecting cell type differentiation. ABC00010  
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
 CC represent the oligomers described in the invention. NOTE: The sequence  
 CC data for this patent did not form part of the printed specification, but  
 CC was obtained in electronic format from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences  
 CC  
 CC Sequence 13 BP; 5 A; 2 C; 0 G; 6 T; 0 U; 0 Other;  
 SQ  
 XX  
 Query Match 20.4%; Score 9.8; DB 1; Length 13;  
 Best Local Similarity 84.6%; Pred. No. 89;  
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 OY 1721 GATGTTGAGCGGAA 1733  
 DB 13 GATTATGAGGAAA 1  
 XX  
 RESULT 159  
 ABH44535/C  
 ID ABH44535 standard; DNA; 13 BP.  
 XX  
 AC ABH44535;  
 XX  
 DT 22-FEB-2002 (first entry)  
 XX  
 DE Oligonucleotide SEQ ID NO 244512 for detecting SNP TSC0059697.  
 XX  
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200177384-A2.  
 XX  
 PD 18-OCT-2001.  
 XX  
 PF 06-APR-2001; 2001WO-IB000713.  
 XX  
 PR 07-APR-2000; 2000DE-01019173.  
 XX  
 PA (EPIG-) EPIGENOMICS AG.  
 XX  
 PI Olek A, Piepenbrock C, Berlin K;  
 XX WPI; 2001-657177/75.  
 DR  
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
 PT designed to detect single-nucleotide polymorphisms and cytosine  
 PT methylation status.  
 XX

XX  
 PR 07-APR-2000; 2000DE-01019173.  
 XX  
 PA (EPIG-) EPIGENOMICS AG.  
 XX  
 PI Olek A, Piepenbrock C, Berlin K;  
 XX WPI; 2001-657177/75.  
 DR  
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
 PT designed to detect single-nucleotide polymorphisms and cytosine  
 PT methylation status.  
 XX  
 PS Claim 1; SEQ ID NO 210386; 29pb + Sequence Listing; German.  
 XX  
 CC This invention describes novel oligonucleotide primers or peptide nucleic  
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
 CC and cytosine methylation status in chemically pretreated genomic DNA. The  
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
 CC range of diseases including immune system, gastrointestinal, respiratory,  
 CC central nervous system, cardiovascular and metabolic disorders. The  
 CC oligomers are also used for detecting cell type differentiation. ABC00010  
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
 CC represent the oligomers described in the invention. NOTE: The sequence  
 CC data for this patent did not form part of the printed specification, but  
 CC was obtained in electronic format from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences  
 CC  
 CC Sequence 13 BP; 3 A; 4 C; 0 G; 6 T; 0 U; 0 Other;  
 SQ  
 XX  
 Query Match 20.4%; Score 9.8; DB 1; Length 13;  
 Best Local Similarity 84.6%; Pred. No. 89;  
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 OY 1721 GATGTTGAGCGGAA 1733  
 DB 13 GATTATGAGGAAA 1  
 XX  
 RESULT 159  
 ABH44535/C  
 ID ABH44535 standard; DNA; 13 BP.  
 XX  
 AC ABH44535;  
 XX  
 DT 22-FEB-2002 (first entry)  
 XX  
 DE Oligonucleotide SEQ ID NO 244512 for detecting SNP TSC0059697.  
 XX  
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200177384-A2.  
 XX  
 PD 18-OCT-2001.  
 XX  
 PF 06-APR-2001; 2001WO-IB000713.  
 XX  
 PR 07-APR-2000; 2000DE-01019173.  
 XX  
 PA (EPIG-) EPIGENOMICS AG.  
 XX  
 PI Olek A, Piepenbrock C, Berlin K;  
 XX WPI; 2001-657177/75.  
 DR  
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
 PT designed to detect single-nucleotide polymorphisms and cytosine  
 PT methylation status.  
 XX

PS Claim 1, SEQ ID NO 244512, 29bp + Sequence Listing; German.  
XX  
CC This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 4 A; 5 C; 0 G; 4 T; 0 U; 0 Other;  
  
Query Match 20.4%; Score 9.8; DB 1; Length 13;  
Best Local Similarity 84.6%; Pred. No. 89;  
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
OY 1723 TGTTAGGGAACA 1735  
Db 13 TGTTAGGGAACA 1  
|||||  
|  
  
RESULT 160  
ABH50273/c  
ID ABH50273 standard; DNA; 13 BP.  
XX  
AC ABH50273;  
XX  
DT 22-FEB-2002 (first entry)  
XX  
DE Oligonucleotide SEQ ID NO 250250 for detecting SNP TSC0061098.  
XX  
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
OS Homo sapiens.  
XX  
PN WO200177384-A2.  
XX  
PD 18-OCT-2001.  
XX  
PF 06-APR-2001; 2001WO-IB000713.  
XX  
PR 07-APR-2000; 2000DE-01019173.  
XX  
PA (EPIG-) EPIGENOMICS AG.  
XX  
PI Olek A, Piepenbrock C, Berlin K;  
XX  
DR WPI; 2001-657177/75.  
XX  
XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
XX designed to detect single-nucleotide polymorphisms and cytosine  
XX methylation status.  
PT  
XX  
PS Claim 1, SEQ ID NO 250250, 29bp + Sequence Listing; German.  
XX  
XX This invention describes novel oligonucleotide primers or peptide nucleic  
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
XX and cytosine methylation status in chemically pretreated genomic DNA. The  
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
XX range of diseases including immune system, gastrointestinal, respiratory,  
XX central nervous system, cardiovascular and metabolic disorders. The  
XX oligomers are also used for detecting cell type differentiation. ABC00010  
XX -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073  
XX represent the oligomers described in the invention. NOTE: The sequence  
XX data for this patent did not form part of the printed specification, but  
XX was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 5 A; 5 C; 0 G; 3 T; 0 U; 0 Other;  
  
Query Match 20.4%; Score 9.8; DB 1; Length 13;  
Best Local Similarity 84.6%; Pred. No. 89;  
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
OY 1721 GATGTTGAGGAA 1733  
Db 13 GATGTTGAGGAA 1  
|||||  
|  
  
RESULT 161  
ABC72954  
ID ABC72954 standard; DNA; 13 BP.  
XX  
AC ABC72954;  
XX  
DT 21-FEB-2002 (first entry)  
XX  
DE Oligonucleotide SEQ ID NO 72971 for detecting SNP TSC0018828.  
XX  
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
OS Homo sapiens.  
XX  
PN WO200177384-A2.  
XX  
PD 18-OCT-2001.  
XX  
PF 06-APR-2001; 2001WO-IB000713.  
XX  
PR 07-APR-2000; 2000DE-01019173.  
XX  
PA (EPIG-) EPIGENOMICS AG.  
XX  
PI Olek A, Piepenbrock C, Berlin K;  
XX  
DR WPI; 2001-657177/75.  
XX  
XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
XX designed to detect single-nucleotide polymorphisms and cytosine  
XX methylation status.  
PT  
XX  
PS Claim 1, SEQ ID NO 72971, 29bp + Sequence Listing; German.  
XX  
XX This invention describes novel oligonucleotide primers or peptide nucleic  
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
XX and cytosine methylation status in chemically pretreated genomic DNA. The  
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
XX range of diseases including immune system, gastrointestinal, respiratory,  
XX central nervous system, cardiovascular and metabolic disorders. The  
XX oligomers are also used for detecting cell type differentiation. ABC00010  
XX -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073  
XX represent the oligomers described in the invention. NOTE: The sequence  
XX data for this patent did not form part of the printed specification, but  
XX was obtained in electronic format from WIPO at  
XX ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 6 A; 0 C; 7 G; 0 T; 0 U; 0 Other;  
  
Query Match 20.4%; Score 9.8; DB 1; Length 13;  
Best Local Similarity 84.6%; Pred. No. 89;  
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
OY 1736 GACGACGAAATG 1748  
Db 1 GACGACGAAATG 13  
|||||  
|

```

RESULT 162
ABC72955/c
ID ABC72955 standard; DNA; 13 BP.
XX
XX ABC72955;
XX
XX 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 72972 for detecting SNP TSC0018828.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 72972; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 0 A; 7 C; 0 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 20.4%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 89;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 1736 GACAGGAGGAATG 1748
XX 13 GACAGGAGGAAGG 1
XX
XX RESULT 163
ABC74875/c
ID ABC74875 standard; DNA; 13 BP.
XX
XX ABC74875;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 74892 for detecting SNP TSC0019229.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX

```

```

XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 74892; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 6 A; 5 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 20.4%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 89;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 1718 ACTGATGTGAGG 1730
XX 13 ATGTGTTGAGG 1
XX
XX RESULT 164
ABC10735/c
ID ABC10735 standard; DNA; 13 BP.
XX
XX ABC10735;
XX
XX 20-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 10726 for detecting SNP TSC0002683.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX

```

PI Olek A, Piepenbrock C, Berlin K;  
XX WPI; 2001-657177/75.  
XX  
PT Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX  
XX Claim 1; SEQ ID NO 10726; 29pp + Sequence Listing; German.  
PS  
CC This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 2 A; 3 C; 0 G; 8 T; 0 U; 0 Other;  
Query Match 20.4%; Score 9.8; DB 1; Length 13;  
Best Local Similarity 84.6%; Pred. No. 89;  
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Oy 1735 AGACAGGAGGAAT 1747  
Db 13 ATTAAGGAGGAAT 1  
RESULT 165  
ABC12426  
ID ABC12426 standard; DNA; 13 BP.  
XX  
AC ABC12426;  
XX  
DT 20-FEB-2002 (first entry)  
XX  
DE Oligonucleotide SEQ ID NO 12433 for detecting SNP TSC0002943.  
XX  
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
OS Homo sapiens.  
XX  
PN WO200177384-A2.  
XX  
PD 18-OCT-2001.  
XX  
PF 06-APR-2001; 2001WO-IB000713.  
XX  
PR 07-APR-2000; 2000DE-01019173.  
XX  
PA (EPig-) EPIGENOMICS AG.  
XX  
PI Olek A, Piepenbrock C, Berlin K;  
XX  
DR WPI; 2001-657177/75.  
XX  
PT Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX  
XX Claim 1; SEQ ID NO 12433; 29pp + Sequence Listing; German.  
PS  
CC This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 2 A; 3 C; 0 G; 8 T; 0 U; 0 Other;  
Query Match 20.4%; Score 9.8; DB 1; Length 13;  
Best Local Similarity 84.6%; Pred. No. 89;  
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 4 A; 0 C; 4 G; 5 T; 0 U; 0 Other;  
Query Match 20.4%; Score 9.8; DB 1; Length 13;  
Best Local Similarity 84.6%; Pred. No. 89;  
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Oy 1721 GATGTTGAGGGA 1733  
Db 1 GATGTTTATGGA 13  
RESULT 166  
ABF02355/C  
ID ABF02355 standard; DNA; 13 BP.  
XX  
AC ABF02355;  
XX  
DT 21-FEB-2002 (first entry)  
XX  
DE Oligonucleotide SEQ ID NO 102352 for detecting SNP TSC0025526.  
XX  
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
OS Homo sapiens.  
XX  
PN WO200177384-A2.  
XX  
PD 18-OCT-2001.  
XX  
PF 06-APR-2001; 2001WO-IB000713.  
XX  
PR 07-APR-2000; 2000DE-01019173.  
XX  
PA (EPig-) EPIGENOMICS AG.  
XX  
PI Olek A, Piepenbrock C, Berlin K;  
XX  
DR WPI; 2001-657177/75.  
XX  
PT Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX  
XX Claim 1; SEQ ID NO 102352; 29pp + Sequence Listing; German.  
PS  
CC This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 4 A; 4 C; 0 G; 5 T; 0 U; 0 Other;  
Query Match 20.4%; Score 9.8; DB 1; Length 13;

Best Local Similarity 84.6%; Pred. No. 89;  
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1723 TGTTGAGGAAACA 1735

Db 13 TGTTAGGAAAA 1

RESULT 167

ABF14031

ID ABF14031 standard; DNA; 13 BP.

AC ABF14031;

DT 21-FEB-2002 (first entry)

XX oligonucleotide SEQ ID NO 114028 for detecting SNP TSC0028539.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-1B000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is  
designed to detect single-nucleotide polymorphisms and cytosine  
methylation status.

PS Claim 1; SEQ ID NO 114028; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic  
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
and cytosine methylation status in chemically pretreated genomic DNA. The  
oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
range of diseases including immune system, gastrointestinal, respiratory,  
central nervous system, cardiovascular and metabolic disorders. The  
oligonucleotides are also used for detecting cell type differentiation. ABC00010  
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
represent the oligomers described in the invention. NOTE: The sequence  
data for this patent did not form part of the printed specification, but  
was obtained in electronic format from WIPO at  
ftp.wipo.int/pub/published\_pct\_sequences

XX Sequence 13 BP; 6 A; 4 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 20.4%; Score 9.8; DB 1; Length 13;  
Best Local Similarity 84.6%; Pred. No. 89;  
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1744 AAATGATCCATT 1756

Db 1 AAATACATCCACT 13

RESULT 168

ABF46517/C

ID ABF46517 standard; DNA; 13 BP.

XX ABF46517;

XX 21-FEB-2002 (first entry)

DT oligonucleotide SEQ ID NO 146514 for detecting SNP TSC0036945.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-1B000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is  
designed to detect single-nucleotide polymorphisms and cytosine  
methylation status.

PS Claim 1; SEQ ID NO 146514; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic  
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
and cytosine methylation status in chemically pretreated genomic DNA. The  
oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
range of diseases including immune system, gastrointestinal, respiratory,  
central nervous system, cardiovascular and metabolic disorders. The  
oligonucleotides are also used for detecting cell type differentiation. ABC00010  
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
represent the oligomers described in the invention. NOTE: The sequence  
data for this patent did not form part of the printed specification, but  
was obtained in electronic format from WIPO at  
ftp.wipo.int/pub/published\_pct\_sequences

XX Sequence 13 BP; 3 A; 4 C; 0 G; 6 T; 0 U; 0 Other;

Query Match 20.4%; Score 9.8; DB 1; Length 13;  
Best Local Similarity 84.6%; Pred. No. 89;  
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1721 GATTTGAGGAA 1733

Db 13 GATTTGAAAAA 1

RESULT 169

ADD15389/C

ID ADD15389 standard; DNA; 13 BP.

AC ADD15389;

DT 15-JUN-2004 (first entry)

XX Plasmid pHTV-LTR EcoRI/HindIII restriction fragment 2 with target DNA.

XX ss; polyamide alkylator; conjugate; hairpin; regulator; gene therapy;

XX knockout; pHTV-LTR EcoRI/HindIII.

XX Synthetic.

XX Unidentified.

XX Human immunodeficiency virus 1.

XX US6559125-B1.

```

XX 06-MAY-2003.
XX
XX 26-JAN-2001; 2001US-00772315.
XX
XX 28-JAN-2000; 2000US-0178821P.
XX
XX (CALY ) CALIFORNIA INST OF TECHNOLOGY.
XX
XX Dervan PB, Wurtz N, Chang A;
XX
XX WPI; 2003-775986/73.
XX
XX Polyimide-alkylator conjugate for therapeutic purposes, comprises
XX alkylator linked to polyimide having pyrrolic and/or imidazole amino acid.
XX
XX Disclosure; SEQ ID NO 3; 52pp; English.
XX
XX This invention relates to a novel polyamide alkylator conjugate.
XX Specifically, it refers to a hairpin polyamide comprising a pyrrolic and/
XX or imidazole amino acid linked to a gamma aminobutyric acid, which in
XX turn is linked to the alkylator that selectively alkylates only one
XX strand of a double-stranded DNA molecule. The present invention describes
XX a conjugate that can be used to target a predetermined DNA sequence and
XX thereby inhibit DNA-protein interactions, and hence provides a novel
XX regulator of gene expression. As such, in addition to competing with
XX transcription factors, the conjugates can be used in gene therapy to
XX target a gene's coding region for use as a knockout reagent. This
XX oligonucleotide sequence is restriction fragment 2 derived from the
XX plasmid pHRV-LTR EcoRI/HindIII that contains the target DNA sequence of
XX the polyamide alkylator conjugate of the invention.
XX
SQ Sequence 13 BP; 2 A; 4 C; 4 G; 3 T; 0 U; 0 Other;

Query Match          20.4%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 89;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1741 GAGAAATGCATCC 1753
DB 13 GAGAGCTGCATCC 1

RESULT 170
ABT39656/c
ID ABT39656 standard; DNA; 17 BP.
XX
XX ABT39656;
XX
XX 12-JUN-2003 (first entry)
XX
XX Tumour suppression related human fukutin oligo SEQ ID No 5293.
XX
XX Cytoostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
XX anti-sense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
XX schizophrenia; protein chip; gene therapy; tumour suppression;
XX human fukutin; ds.
XX
XX Homo sapiens.
XX
XX WO2003025175-A2.
XX
XX 27-MAR-2003.
XX
XX 17-SEP-2002; 2002WO-IB004208.
XX
XX 17-SEP-2001; 2001FR-00011978.
XX
XX (MOLE-) MOLECULAR ENGINES LAB.
XX
XX Telerman A, Amson R, Tuijnder M;
XX
XX WPI; 2003-313353/30.

```

```

XX New isolated nucleic acid, useful for treating viral diseases associated
XX with tumors and cell degeneration, also related polypeptides, antibodies
XX and transfected cells.
XX
XX Disclosure; Page 652; 720pp; French.
XX
XX The invention relates to a novel isolated 17 mer nucleic acid sequence,
XX given in the specification, a sequence containing at least 15 consecutive
XX nucleotides from the 17 mer sequence, a sequence with, after optimal
XX alignment, at least 80 % identity to the 17 mer sequence, a sequence that
XX hybridizes to them under highly stringent conditions, or the complement
XX of any of them, or the corresponding RNA. The novel isolated nucleic
XX acids of the invention are useful as probes and primers for detecting,
XX identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
XX component of a gene chip, in vitro as (anti)sense reagents, and for
XX production of recombinant polypeptides. Any of the nucleic acids,
XX polypeptides, vectors containing the nucleic acids, cells containing the
XX vector or antibodies directed against the polypeptides are useful for
XX preparation of pharmaceuticals for prevention and/or treatment of viral
XX diseases that are characterised by development of tumours or cell
XX degeneration, specifically cancer but also Alzheimer's disease and
XX schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
XX patient samples is useful for diagnosis and/or prognosis of these
XX diseases. The polypeptides can also be used to generate antibodies, and
XX both the polypeptide and antibodies are useful as components of protein
XX chips. The nucleic acid sequences of the invention can be used in gene
XX therapy. This polynucleotide sequence represents a tumour suppression
XX related human fukutin oligonucleotide of the invention
XX
SQ Sequence 17 BP; 8 A; 2 C; 6 G; 1 T; 0 U; 0 Other;

Query Match          18.3%; Score 8.8; DB 1; Length 17;
Best Local Similarity 83.3%; Pred. No. 1,3e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1712 CTCCTGACTGAT 1723
DB 13 CTCCTGCTGAT 2

```

Search completed: July 13, 2004, 11:03:43  
Job time : 1 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: July 13, 2004, 11:05:04 ; Search time 0.001 Seconds

(without alignments)  
52.032 Million cell updates/sec

Title: us-10-000-213-3

Perfect score: 48  
Sequence: 1 gctgctgactgactgactgag.....caggagaatgcattc 48

Scoring table: IDENTITY NUC  
Gapop 10.0 , Gapext 0.5

Searched: 41 seqs, 542 residues

Total number of hits satisfying chosen parameters: 82

Minimum DB seq length: 8  
Maximum DB seq length: 80

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 50 summaries

Database : rml.db:\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	14.8	30.8	18	US-08-897-340-27	Sequence 27, Appl
2	14.8	30.8	18	US-09-252-329-27	Sequence 27, Appl
3	14.4	30.0	18	US-09-679-298A-23	Sequence 23, Appl
4	13.4	27.9	16	US-09-371-772B-5840	Sequence 5840, Ap
5	13	27.1	17	US-09-866-108A-8341	Sequence 8341, Ap
6	13	27.1	17	US-09-866-108A-8342	Sequence 8342, Ap
7	13	27.1	17	US-09-866-108A-8344	Sequence 8344, Ap
8	13	27.1	17	US-09-866-108A-8345	Sequence 8345, Ap
9	13	27.1	17	US-09-866-108A-8345	Sequence 8345, Ap
10	12.8	26.7	16	US-09-371-772B-5841	Sequence 67, Appl
11	12.8	26.7	16	US-08-533-472-5	Sequence 5, Appl1
12	11.8	24.6	15	US-08-292-620A-78	Sequence 78, Appl
13	11.8	24.6	15	US-09-071-945-78	Sequence 78, Appl
14	11.8	24.6	15	US-09-081-646-601	Sequence 601, App
15	11.4	23.7	15	US-09-081-646-601	Sequence 601, App
16	10.4	21.7	12	US-08-458-181-8	Sequence 8, Appl1
17	10.4	21.7	12	US-08-458-181-8	Sequence 8, Appl1
18	10.4	21.7	12	PCT-US93-02172-8	Sequence 8, Appl1
19	10	20.8	13	US-08-173-489C-244	Sequence 244, App
20	9.8	20.4	13	US-08-284-746-10	Sequence 10, Appl
21	9.8	20.4	13	US-08-284-746-17	Sequence 17, Appl
22	9.8	20.4	13	US-08-772-315-3	Sequence 3, Appl1
23	9.8	20.4	13	US-08-025-038-11	Sequence 11, Appl
24	9.4	19.6	12	US-08-545-785-2	Sequence 2, Appl1
25	9	18.8	10	US-08-388-353-515	Sequence 515, App
26	9	18.8	10	US-08-388-353-515	Sequence 515, App
27	9	18.8	10	US-08-488-551B-515	Sequence 515, App
28	9	18.8	10	US-08-488-551B-515	Sequence 516, App
29	9	18.8	10	US-08-488-551B-833	Sequence 833, App
30	9	18.8	10	US-08-488-551B-834	Sequence 834, App
31	9	18.8	10	US-08-618-834C-17	Sequence 17, Appl
32	9	18.8	10	US-08-618-834C-54	Sequence 54, Appl
33	9	18.8	10	US-09-508-753B-21	Sequence 21, Appl

34	9	18.8	11	US-08-192-942-8	Sequence 8, Appl1
35	9	18.8	11	US-08-646-695-15	Sequence 15, Appl
36	9	18.8	11	PCT-US96-06053-15	Sequence 15, Appl
37	9	18.8	12	US-08-173-489C-256	Sequence 256, Appl
38	9	18.8	12	US-08-507-032-14	Sequence 14, Appl
39	9	18.8	12	US-08-862-431-22	Sequence 22, Appl
40	9	18.8	12	US-08-244-087-12	Sequence 12, Appl
41	9	18.8	12	PCT-US92-09955-12	Sequence 12, Appl
42	7.4	15.4	15	US-09-081-646-601	Sequence 601, App
43	7	14.6	17	US-09-866-108A-8341	Sequence 8341, Ap
44	7	14.6	17	US-09-866-108A-8342	Sequence 8342, Ap
45	7	14.6	17	US-09-866-108A-8343	Sequence 8343, Ap
46	6.2	12.9	17	US-09-866-108A-8344	Sequence 8344, Ap
47	6.2	12.9	17	US-09-866-108A-8345	Sequence 8345, Ap
48	5.8	12.1	10	US-08-388-353-515	Sequence 515, App
49	5.8	12.1	10	US-08-488-551B-515	Sequence 515, App
50	5.8	12.1	10	US-08-488-551B-833	Sequence 833, App

## ALIGNMENTS

RESULT 1  
US-08-897-340-27/c  
Sequence 27, Application US/08897340  
Patent No. 5955306  
GENERAL INFORMATION:  
APPLICANT: Gimeno, Carlos J. and Errada, Patrick, R.  
TITLE OF INVENTION: Weight Control Pathway Genes and Uses  
TITLE OF INVENTION: Therefor  
NUMBER OF SEQUENCES: 36  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: LAHIVE & COCKFIELD, LLP  
STREET: 28 State Street  
CITY: Boston  
STATE: Massachusetts  
COUNTRY: USA  
ZIP: 02109  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/897,340  
FILING DATE:  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/715, 032  
FILING DATE: 17-SEP-1996  
ATTORNEY/AGENT INFORMATION:  
NAME: Silveri, Jean M.  
REGISTRATION NUMBER: 39,030  
REFERENCE/DOCKET NUMBER: MNI-005CP  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (617)227-7400  
TELEFAX: (617)227-5941  
INFORMATION FOR SEQ ID NO: 27:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 18 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: cDNA  
US-08-897-340-27  
Query Match 30.8%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 2.9;  
Matches 16; Conservatve 0; Mismatches 2; Indels 0; Gaps 0;

```
RESULT 2
US-09-252-329-27/c
; Sequence 27, Application US/09252329
; Patent No. 6147192
; GENERAL INFORMATION:
; APPLICANT: Gimeno, Carlos J. and Errada, Patrick, R.
; TITLE OF INVENTION: Weight Control Pathway Genes and Uses
; TITLE OF INVENTION: Therefor
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD, LLP
; STREET: 28 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/252,329
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/897,340
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Silverl, Jean M.
; REGISTRATION NUMBER: 39,030
; REFERENCE/DOCKET NUMBER: NMI-005CP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)227-5941
; INFORMATION FOR SEQ ID NO: 27:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-09-252-329-27

Query Match 30.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2.9;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1714 GCTGACTGATGTTGAGG 1731
DB 18 GCTGACTGAGCTGAGG 1

RESULT 3
US-09-679-298A-23/c
; Sequence 23, Application US/09679298A
; Patent No. 6566131
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SMAD6 EXPRESSION
; FILE REFERENCE: RTS-0045
; CURRENT APPLICATION NUMBER: US/09/679,298A
; CURRENT FILING DATE: 2001-03-05
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 23
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
```

```
US-09-679-298A-23

Query Match 30.0%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 3.4;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1723 TGTGAGGGAACGAC 1738
DB 18 TGTGAGGGAACGAC 3

RESULT 4
US-09-371-772B-5840
; Sequence 5840, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: MCSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Bacobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MEH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: Patent version 3.0
; SEQ ID NO 5840
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5840

Query Match 27.9%; Score 13.4; DB 1; Length 16;
Best Local Similarity 60.0%; Pred. No. 4.7;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 1715 CTGACTGATGTTGAG 1729
DB 2 CUGAGUGAGUGUGAG 16

RESULT 5
US-09-866-108A-8341/c
; Sequence 8341, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU Yizhong
; APPLICANT: Ji, Yonggang
; APPLICANT: PENN, Shatton G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEONICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
```

PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: Aecomica Sequence Listing Engine  
Patent No. 6686188  
SEQ ID NO 8341  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108A-8341

Query Match 27.1%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 5.8;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1713 TGCTGACTGATGT 1725  
Db 17 TGCTGACTGATGT 5

RESULT 6  
US-09-866-108A-8342/c  
Sequence 8342, Application US/09866108A  
Patent No. 6686188  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharon G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: AECOMICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108A  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: Aecomica Sequence Listing Engine  
Patent No. 6686188  
SEQ ID NO 8342  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens

US-09-866-108A-8342

Query Match 27.1%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 5.8;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1713 TGCTGACTGATGT 1725  
Db 16 TGCTGACTGATGT 4

RESULT 7  
US-09-866-108A-8343/c  
Sequence 8343, Application US/09866108A  
Patent No. 6686188  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharon G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: AECOMICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108A  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: Aecomica Sequence Listing Engine  
Patent No. 6686188  
SEQ ID NO 8343  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108A-8343

Query Match 27.1%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 5.8;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1713 TGCTGACTGATGT 1725  
Db 15 TGCTGACTGATGT 3

RESULT 8  
US-09-866-108A-8344/c  
Sequence 8344, Application US/09866108A  
Patent No. 6686188  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang

APPLICANT: PENN, Sharon G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: AEOMICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108A  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263, 6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: Aecomica Sequence Listing Engine  
SEQ ID NO 8344  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108A-8344

Query Match 27.1%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 5.8;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1713 TGCTGACTGATGT 1725  
Db 14 TGCTGACTGATGT 2

RESULT 9  
US-09-866-108A-8345/C  
Sequence 8345, Application US/09866108A  
Patent No. 6686188  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharon G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: AEOMICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108A  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263, 6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667

PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: Aecomica Sequence Listing Engine  
SEQ ID NO 8345  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108A-8345

Query Match 27.1%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 5.8;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1713 TGCTGACTGATGT 1725  
Db 13 TGCTGACTGATGT 1

RESULT 10  
US-08-666-341A-67/C  
Sequence 67, Application US/0866341A  
Patent No. 6365345  
GENERAL INFORMATION:  
APPLICANT:  
TITLE OF INVENTION: Antisense nucleic Acids for the  
TITLE OF INVENTION: prevention and treatment of disorders in which expression  
NUMBER OF SEQUENCES: 106  
CORRESPONDENCE ADDRESS: 106  
ADDRESSER: Jacobson, Price, Holman and Stern, PLLC  
STREET: 400 Seventh street, N.W.  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20004  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disc  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/666,341A  
FILING DATE: 15-AUG-1996  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: EP 93120710.4  
INFORMATION FOR SEQ ID NO: 67:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 16 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: unknown  
TOPOLOGY: unknown  
MOLECULE TYPE: DNA (genomic)  
ANTI-SENSE: YES  
US-08-666-341A-67

Query Match 26.7%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 6;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1723 TGTGAGGAGACAGAC 1738

Db 16 TGTGAGGAAAAAC 1

## RESULT 11

US-09-371-772B-5841  
Sequence 5841, Application US/09371772B  
Patent No. 6566127  
GENERAL INFORMATION:  
APPLICANT: Ribozyne Pharmaceuticals, Inc.  
APPLICANT: Pavco, Pam  
APPLICANT: McSwiggen, Jim  
APPLICANT: Stinchcomb, Dan  
APPLICANT: Escobedo, Jaime  
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor  
FILE REFERENCE: M8B00, 876-J (237/198)  
CURRENT APPLICATION NUMBER: US/09/371, 772B  
CURRENT FILING DATE: 1999-08-10  
PRIOR APPLICATION NUMBER: US 60/005,974  
PRIOR FILING DATE: 1995-10-26  
PRIOR APPLICATION NUMBER: US 08/584,040  
PRIOR FILING DATE: 1996-01-08  
NUMBER OF SEQ ID NOS: 14225  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 5841  
LENGTH: 16  
TYPE: RNA  
ORGANISM: Homo sapiens  
US-09-371-772B-5841

Query Match 26.7%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 62.5%; Pred. No. 6;  
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1717 GACTGATGTGAGGGA 1732  
Db 1 GAGUGAGUGAGGAA 16

RESULT 12  
US-08-533-472-5  
Sequence 5, Application US/08533472  
Patent No. 5756294  
GENERAL INFORMATION:  
APPLICANT: White, Marga B.  
APPLICANT: Sadzewicz, Lisa K.  
TITLE OF INVENTION: Susceptibility Mutation for Breast and  
TITLE OF INVENTION: Ovarian Cancer  
NUMBER OF SEQUENCES: 6  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS  
STREET: 699 Prince Street  
CITY: Alexandria  
STATE: VA  
COUNTRY: USA  
ZIP: 22314-3187  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/533,472  
FILING DATE: 25-SEP-1995  
CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: Swecker, Robert S.  
REGISTRATION NUMBER: 19,885  
REFERENCE/DOCKET NUMBER: 020160-000  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 703-836-6620  
TELEFAX: 703-836-2021

INFORMATION FOR SEQ ID NO: 5:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: not relevant  
TOPOLOGY: not relevant  
MOLECULE TYPE: DNA (genomic)  
US-08-533-472-5

Query Match 24.6%; Score 11.8; DB 1; Length 15;  
Best Local Similarity 86.7%; Pred. No. 8.5;  
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1731 GAGACAGCAGAGAA 1745  
Db 1 GAGACAGCAGAGAA 15

## RESULT 13

US-08-292-620A-78/C  
Sequence 78, Application US/08292620A  
Patent No. 5837542  
GENERAL INFORMATION:  
APPLICANT: Susan Grimm  
APPLICANT: Dan T. Stinchcomb  
APPLICANT: James McSwiggen  
APPLICANT: Sean Sullivan  
APPLICANT: Kenneth G. Draper  
TITLE OF INVENTION: RIBOZYME TREATMENT OF  
TITLE OF INVENTION: DISEASES OR CONDITIONS  
TITLE OF INVENTION: RELATED TO LEVELS OF  
TITLE OF INVENTION: INTRACELLULAR ADHESION  
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)  
NUMBER OF SEQUENCES: 2390  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071-2066  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/292,620A  
FILING DATE: August 17, 1994  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
PRIOR APPLICATION DATA: including application  
PRIOR APPLICATION DATA: described below:  
APPLICATION NUMBER: 08/008,895  
FILING DATE: January 19, 1993  
APPLICATION NUMBER: 07/989,849  
FILING DATE: December 7, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Marburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 208/149  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 78:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear

two

US-08-292-620A-78

Query Match 24.6%; Score 11.8; DB 1; Length 15;

Best Local Similarity 86.7%; Pred. No. 8.5;  
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1724 GTTGAGGAACAGAC 1738

Db 15 GTCCAGGAACAGAC 1

RESULT 14

US-09-071-845-78/c

; Sequence 78, Application US/09071845

; Patent No. 6132967

; GENERAL INFORMATION:

; APPLICANT: Susan Grimm

; APPLICANT: Dan T. Stinchcomb

; APPLICANT: James McSwigen

; APPLICANT: Sean Sullivan

; APPLICANT: Kenneth G. Draper

; TITLE OF INVENTION: RIBOZYME TREATMENT OF

; TITLE OF INVENTION: DISEASES OR CONDITIONS

; TITLE OF INVENTION: RELATED TO LEVELS OF

; TITLE OF INVENTION: INTRACELLULAR ADHESION

; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)

; NUMBER OF SEQUENCES: 2390

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon &amp; Lyon

; STREET: 633 West Fifth Street

; CITY: Suite 4700

; STATE: Los Angeles

; COUNTRY: U.S.A.

; ZIP: 90071-2066

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

; MEDIUM TYPE: storage

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: IBM P.C. DOS 5.0

; SOFTWARE: Word Perfect 5.1

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/071.845

; FILING DATE:

; CLASSIFICATION:

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US/08/292.620

; FILING DATE: August 17, 1994

; APPLICATION NUMBER: 08/008,895

; FILING DATE: January 19, 1993

; APPLICATION NUMBER: 07/989,849

; FILING DATE: December 7, 1992

; ATTORNEY/AGENT INFORMATION:

; NAME: Warburg, Richard J.

; REGISTRATION NUMBER: 32,327

; REFERENCE/DOCKET NUMBER: 208/149

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (213) 489-1600

; TELEFAX: (213) 955-0440

; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 78:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 15 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; US-09-071-845-78

Query Match 24.6%; Score 11.8; DB 1; Length 15;

Best Local Similarity 86.7%; Pred. No. 8.5;  
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1724 GTTGAGGAACAGAC 1738

Db 15 GTCCAGGAACAGAC 1

RESULT 15

US-09-081-646-601/c

; Sequence 601, Application US/09081646

; Patent No. 6331152

; GENERAL INFORMATION:

; APPLICANT: Kinzler, Kenneth

; APPLICANT: Vogelstein, Bert

; APPLICANT: Zhang, Lin

; APPLICANT: Zhou, Wei

; TITLE OF INVENTION: Gene Expression Profiles in No. 6331152ma1 and

; TITLE OF INVENTION: Cancer Cells

; FILE REFERENCE: 01107.74664

; CURRENT APPLICATION NUMBER: US/09/081.646

; CURRENT FILING DATE: 1998-05-20

; EARLIER APPLICATION NUMBER: 60/047,352

; EARLIER FILING DATE: 1997-05-21

; NUMBER OF SEQ ID NOS: 871

; SOFTWARE: FastSeq for Windows Version 3.0

; SEQ ID NO 601

; LENGTH: 15

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-081-646-601

Query Match 23.7%; Score 11.4; DB 1; Length 15;

Best Local Similarity 92.3%; Pred. No. 10;  
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1739 AGGAGAAATGCAT 1751

Db 14 AGGAGAAATGCAT 2

RESULT 16

US-08-368-071-8

; Sequence 8, Application US/08368071

; Patent No. 5707853

; GENERAL INFORMATION:

; APPLICANT: MILLAN, JOSE L.

; TITLE OF INVENTION: RECOMBINANT CALF INTESTINAL ALKALINE

; TITLE OF INVENTION: PHOSPHATASE

; NUMBER OF SEQUENCES: 13

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: CAMPBELL AND FLORES

; STREET: 4370 LA JOLLA VILLAGE DRIVE, SUITE 700

; CITY: SAN DIEGO

; STATE: CALIFORNIA

; COUNTRY: UNITED STATES

; ZIP: 92122

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: Patentin Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/368.071

; FILING DATE: 03-JAN-1995

; CLASSIFICATION: 435

; ATTORNEY/AGENT INFORMATION:

; NAME: CAMPBELL, CATHERYN

; REGISTRATION NUMBER: 31,815

; REFERENCE/DOCKET NUMBER: P-LJ 1275

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 619-535-9001

; TELEFAX: 619-535-8949

; INFORMATION FOR SEQ ID NO: 8:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 12 base pairs

; TYPE: nucleic acid

STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-368-071-8

Query Match 21.7%; Score 10.4; DB 1; Length 12;  
Best Local Similarity 91.7%; Pred. No. 12;  
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1733 ACAGACAGGAGA 1744  
Db 1 ACAGACAGGAGA 12

RESULT 17

US-08-458-181-8  
Sequence 8, Application US/08458181  
Patent No. 5773226  
GENERAL INFORMATION:  
APPLICANT: MILLAN, JOSE L.  
TITLE OF INVENTION: RECOMBINANT CALF INTESTINAL ALKALINE  
NUMBER OF SEQUENCES: 13  
CORRESPONDENCE ADDRESSES:  
ADDRESSEE: CAMPBELL AND FLORES  
STREET: 4370 LA JOLLA VILLAGE DRIVE, SUITE 700  
CITY: SAN DIEGO  
STATE: CALIFORNIA  
COUNTRY: UNITED STATES  
ZIP: 92122  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/458.181  
FILING DATE: 30-DEC-1994  
CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: CAMPBELL, CATHERYN  
REGISTRATION NUMBER: 31,815  
REFERENCE/DOCKET NUMBER: P-LJ 1275  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 619-535-9001  
TELEFAX: 619-535-8949  
INFORMATION FOR SEQ ID NO: 8:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 12 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-458-181-8

Query Match 21.7%; Score 10.4; DB 1; Length 12;  
Best Local Similarity 91.7%; Pred. No. 12;  
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1733 ACAGACAGGAGA 1744  
Db 1 ACAGACAGGAGA 12

RESULT 18

PCT-US93-02172-8  
Sequence 8, Application PC/TUS9302172  
GENERAL INFORMATION:  
APPLICANT: La Jolla Cancer Research Foundation  
TITLE OF INVENTION: RECOMBINANT CALF INTESTINAL ALKALINE  
NUMBER OF SEQUENCES: 13  
CORRESPONDENCE ADDRESSES:  
ADDRESSEE: La Jolla Cancer Research Foundation  
STREET: 10901 North Torrey Pines Road

CITY: La Jolla  
STATE: California  
COUNTRY: USA  
ZIP: 92037

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version 1.25 (ERO)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: PCT/US93/02172  
FILING DATE: 19930310  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/07/849,219  
FILING DATE: 10-MAR-1992  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (619) 455-6480  
TELEFAX: (619) 455-0181  
TELEX:

INFORMATION FOR SEQ ID NO: 8:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 12 base pairs  
TYPE: NUCLEIC ACID  
STRANDEDNESS: single  
TOPOLOGY: linear  
PCT-US93-02172-8

Query Match 21.7%; Score 10.4; DB 1; Length 12;  
Best Local Similarity 91.7%; Pred. No. 12;  
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1733 ACAGACAGGAGA 1744  
Db 1 ACAGACAGGAGA 12

RESULT 19

US-08-173-489C-244/C  
Sequence 244, Application US/08173489C  
Patent No. 5861244  
GENERAL INFORMATION:  
APPLICANT: WANG, C. -G.  
TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA  
NUMBER OF SEQUENCES: 365  
CORRESPONDENCE ADDRESSES:  
ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,  
STREET: 510 EAST 73RD STREET,  
CITY: NEW YORK  
STATE: NEW YORK  
COUNTRY: USA  
ZIP: 10021  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5 inch, 1.44mb storage  
COMPUTER: IBM PC/XT/AT  
OPERATING SYSTEM: MS-DOS version 6.2  
SOFTWARE: wordperfect version 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/173,489C  
FILING DATE: 22 DEC 1993  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/968,436  
FILING DATE: 29 OCT 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Handelman, Joseph H.  
REGISTRATION NUMBER: 26,179  
REFERENCE/DOCKET NUMBER: U9518-6  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (attorney) (212) 708-1880  
TELEFAX: (attorney) (212) 246-8959

INFORMATION FOR SEQ ID NO: 244:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 13 bases  
TYPE: nucleic acid  
STRANDEDNESS: single stranded  
TOPOLOGY: linear  
MOLECULE TYPE: other nucleic acid  
DESCRIPTION: third strand derived from L.  
HYPOHETICAL: yes  
ANTI-SENSE: no  
PUBLICATION INFORMATION:  
RELEVANT RESIDUES IN SEQ ID NO: 244 :FROM 1 TO 13  
US-08-173-489C-244

Query Match 20.8%; Score 10; DB 1; Length 13;  
Best Local Similarity 100.0%; Pred. No. 15;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1727 GAGGGAACAG 1736  
Db 12 GAGGGAACAG 3

RESULT 20  
Sequence 10, Application US/08284746  
Patent No. 5525468  
GENERAL INFORMATION:  
APPLICANT: James A. McSwigen  
TITLE OF INVENTION: ASSAY FOR RIBOZYME TARGET SITE  
NUMBER OF SEQUENCES: 22  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 611 West Sixth Street  
CITY: Los Angeles  
STATE: California  
COUNTRY: USA  
ZIP: 90017  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb storage  
COMPUTER: IBM compatible  
OPERATING SYSTEM: IBM P.C. DOS (Version 5.0)  
SOFTWARE: Wordperfect (Version 5.1)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/284,746  
FILING DATE:  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 07/883,849  
FILING DATE: May 14, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 197/070  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 10:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 13  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-284-746-10

Query Match 20.4%; Score 9.8; DB 1; Length 13;  
Best Local Similarity 84.6%; Pred. No. 17;  
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1737 ACAGGAGAAATGC 1749  
Db 11 ACAGGAGAAATGC 11

Db 1 ACTGGAGAAAAGC 13

RESULT 21  
US-08-284-746-17/C  
Sequence 17, Application US/08284746  
Patent No. 5525468  
GENERAL INFORMATION:  
APPLICANT: James A. McSwigen  
TITLE OF INVENTION: ASSAY FOR RIBOZYME TARGET SITE  
NUMBER OF SEQUENCES: 22  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 611 West Sixth Street  
CITY: Los Angeles  
STATE: California  
COUNTRY: USA  
ZIP: 90017  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb storage  
COMPUTER: IBM compatible  
OPERATING SYSTEM: IBM P.C. DOS (Version 5.0)  
SOFTWARE: Wordperfect (Version 5.1)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/284,746  
FILING DATE:  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 07/883,849  
FILING DATE: May 14, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 197/070  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 17:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 13  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-284-746-17

Query Match 20.4%; Score 9.8; DB 1; Length 13;  
Best Local Similarity 84.6%; Pred. No. 17;  
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1737 ACAGGAGAAATGC 1749  
Db 13 ACTGGAGAAAAGC 1

RESULT 22  
US-09-772-315-3/C  
Sequence 3, Application US/09772315  
Patent No. 6559125  
GENERAL INFORMATION:  
APPLICANT: DERVAN, Peter  
APPLICANT: WURTZ, Nicholas  
APPLICANT: CHANG, Aileen  
TITLE OF INVENTION: POLYAMIDE-ALKYLATOR CONJUGATES & RELATED PRODUCTS & METHODS  
FILE REFERENCE: GENSOFT09/772315  
CURRENT APPLICATION NUMBER: US/09/772,315  
CURRENT FILING DATE: 2001-01-26  
NUMBER OF SEQ ID NOS: 25  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 3  
LENGTH: 13  
TYPE: DNA  
ORGANISM: Artificial Sequence

FEATURE:  
NAME/KEY: misc feature  
OTHER INFORMATION: Description of Artificial Sequence: HIV-LTR ECOR1/HindIII  
US-09-772-315-3

Query Match  
Best Local Similarity 84.6%; Pred. No. 17;  
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1741 GAGAAATGCATCC 1753  
DB 13 GAGAGCTGCATCC 1

RESULT 23  
US-08-025-038-11/c  
Sequence 11, Application US/08025038  
Patent No. 5545526  
GENERAL INFORMATION:  
APPLICANT: BAXTER-LOWE, Lee-Ann  
TITLE OF INVENTION: Method for HLA Typing  
NUMBER OF SEQUENCES: 46  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Foley & Lardner  
STREET: 777 E. Wisconsin Avenue  
CITY: Milwaukee  
STATE: Wisconsin  
COUNTRY: USA  
ZIP: 53202-5367  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/025,038  
FILING DATE: 19930301  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 07/544,218  
FILING DATE: 27-JUN-1990  
ATTORNEY/AGENT INFORMATION:  
NAME: Meyers, Philip G.  
REGISTRATION NUMBER: 30,478  
REFERENCE/DOCKET NUMBER: 204 854  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (414)289-3761  
TELEFAX: (414)289-3791  
INFORMATION FOR SEQ ID NO: 11:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 12 base pairs  
TYPE: NUCLEIC ACID  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-025-038-11

Query Match  
Best Local Similarity 19.6%; Score 9.4; DB 1; Length 12;  
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1730 GGAACAGCAGC 1740  
DB 12 GGAACAGCAGC 2

RESULT 24  
US-08-545-785-2/c  
Sequence 2, Application US/08545785  
Patent No. 5770713  
GENERAL INFORMATION:  
APPLICANT: Imbach and Rayner  
TITLE OF INVENTION: Phosphorothioate Triester Oligonucleotides

TITLE OF INVENTION: And Method Of Preparation  
NUMBER OF SEQUENCES: 2  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5770713/ris LLP  
STREET: One Liberty Place - 46th Floor  
CITY: Philadelphia  
STATE: PA  
COUNTRY: U.S.A.  
ZIP: 19103  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5 inch disk, 1.44 MB  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: WordPerfect 6.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/545,785  
FILING DATE: 17-JAN-1996  
CLASSIFICATION: 536  
ATTORNEY/AGENT INFORMATION:  
NAME: Joseph Luccl  
REGISTRATION NUMBER: 33,307  
REFERENCE/DOCKET NUMBER: ISIS-2114  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 215-568-3100  
TELEFAX: 215-568-3439  
INFORMATION FOR SEQ ID NO: 2:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 12 bases  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-545-785-2

Query Match  
Best Local Similarity 19.6%; Score 9.4; DB 1; Length 12;  
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1727 GAGGGAAGA 1737  
DB 11 GAGGGAAGA 1

RESULT 25  
US-08-388-353-515/c  
Sequence 515, Application US/08388353  
Patent No. 6010895  
GENERAL INFORMATION:  
APPLICANT: Deacon, Nicholas J.  
APPLICANT: McPhee, Dale A.  
APPLICANT: Cooper, David  
TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1  
NUMBER OF SEQUENCES: 800  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Scully, Scott, Murphy & Presser  
STREET: 400 Garden City Plaza  
CITY: Garden City  
STATE: New York  
COUNTRY: United States  
ZIP: 11530  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/388,353  
FILING DATE: 14-FEB-1995  
CLASSIFICATION: 424  
ATTORNEY/AGENT INFORMATION:  
NAME: Digiglio, Frank S.  
REGISTRATION NUMBER: 31,346

REFERENCE/DOCKET NUMBER: 9606  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (516) 742-4343  
TELEFAX: (516) 742-4366  
INFORMATION FOR SEQ ID NO: 515:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 10 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
US-08-388-353-515

Query Match 18.8%; Score 9; DB 1; Length 10;  
Best Local Similarity 100.0%; Pred. No. 18;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 CATCATTC 1757  
|||||  
Db 10 CATCATTC 2

RESULT 26  
US-08-388-353-516/c  
Sequence 516, Application US/08388353  
Patent No. 6010895  
GENERAL INFORMATION:  
APPLICANT: Deacon, Nicholas J.  
APPLICANT: Learmont, Jennifer C.  
APPLICANT: McPhee, Dale A.  
APPLICANT: Crowe, Suzanne  
APPLICANT: Cooper, David  
TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1  
NUMBER OF SEQUENCES: 800  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Scully, Scott, Murphy & Presser  
STREET: 400 Garden City Plaza  
CITY: Garden City  
STATE: New York  
COUNTRY: United States  
ZIP: 11530  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent in Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/388,353  
FILING DATE: 14-FEB-1995  
CLASSIFICATION: 424  
ATTORNEY/AGENT INFORMATION:  
NAME: DiGioglio, Frank S.  
REGISTRATION NUMBER: 31,346  
REFERENCE/DOCKET NUMBER: 9606  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (516) 742-4343  
TELEFAX: (516) 742-4366  
INFORMATION FOR SEQ ID NO: 516:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 10 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
US-08-388-353-516

Query Match 18.8%; Score 9; DB 1; Length 10;  
Best Local Similarity 100.0%; Pred. No. 18;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1749 CATCATTC 1757

Db 9 CATCATTC 1  
|||||

RESULT 27  
US-08-488-551B-515/c  
Sequence 515, Application US/08488551B  
Patent No. 6015661  
GENERAL INFORMATION:  
APPLICANT: Nicholas J. Deacon  
APPLICANT: David A. McPhee  
APPLICANT: David Cooper  
TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1  
NUMBER OF SEQUENCES: 841  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER  
STREET: 400 GARDEN CITY PLAZA  
CITY: GARDEN CITY  
STATE: NEW YORK  
COUNTRY: U.S.A.  
ZIP: 11530-0299  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent in Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/488,551B  
FILING DATE: 07-JUN-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: PM3864 (AU)  
FILING DATE: 14-FEB-1994  
APPLICATION NUMBER: PM4002 (AU)  
FILING DATE: 21-FEB-1994  
APPLICATION NUMBER: PM0284 (AU)  
FILING DATE: 23-DEC-1994  
APPLICATION NUMBER: US 08/388,353  
FILING DATE: 14-FEB-1995  
APPLICATION NUMBER: PM3021/95  
FILING DATE: 17-MAY-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: FRANK S. DIGIOGLIO  
REFERENCE/DOCKET NUMBER: 9606Z  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (516) 742-4343  
TELEFAX: (516) 742-4366  
INFORMATION FOR SEQ ID NO: 515:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 10 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA  
US-08-488-551B-515

Query Match 18.8%; Score 9; DB 1; Length 10;  
Best Local Similarity 100.0%; Pred. No. 18;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 CATCATTC 1757  
|||||  
Db 10 CATCATTC 2

RESULT 28  
US-08-488-551B-516/c  
Sequence 516, Application US/08488551B  
Patent No. 6015661  
GENERAL INFORMATION:  
APPLICANT: Nicholas J. Deacon  
APPLICANT: David A. McPhee  
APPLICANT: David Cooper  
TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1

```

; NUMBER OF SEQUENCES: 841
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
; STREET: 400 GARDEN CITY PLAZA
; CITY: GARDEN CITY
; STATE: NEW YORK
; COUNTRY: U.S.A.
; ZIP: 11530-0299
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/488,551B
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PM3864 (AU)
; FILING DATE: 14-FEB-1994
; APPLICATION NUMBER: PM4002 (AU)
; FILING DATE: 21-FEB-1994
; APPLICATION NUMBER: PM0284 (AU)
; FILING DATE: 23-DEC-1994
; APPLICATION NUMBER: US 08/388,353
; FILING DATE: 14-FEB-1995
; APPLICATION NUMBER: PM3021/95
; FILING DATE: 17-MAY-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: FRANK S. DIGIGLIO
; REFERENCE/DOCKET NUMBER: 9606Z
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; INFORMATION FOR SEQ ID NO: 516:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; US-08-488-551B-516

Query Match      18.8% Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 18;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1749 CATCATTC 1757
Db      9 CATCATTC 1

RESULT 29
US-08-488-833/c
; Sequence 833, Application US/08488551B
; Patent No. 6015661
; GENERAL INFORMATION:
; APPLICANT: Nicholas J. Deacon
; APPLICANT: Dale A. McPhee
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 841
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
; STREET: 400 GARDEN CITY PLAZA
; CITY: GARDEN CITY
; STATE: NEW YORK
; COUNTRY: U.S.A.
; ZIP: 11530-0299
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
```

```

; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/488,551B
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PM3864 (AU)
; FILING DATE: 14-FEB-1994
; APPLICATION NUMBER: PM4002 (AU)
; FILING DATE: 21-FEB-1994
; APPLICATION NUMBER: PM0284 (AU)
; FILING DATE: 23-DEC-1994
; APPLICATION NUMBER: US 08/388,353
; FILING DATE: 14-FEB-1995
; APPLICATION NUMBER: PM3021/95
; FILING DATE: 17-MAY-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: FRANK S. DIGIGLIO
; REFERENCE/DOCKET NUMBER: 9606Z
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; INFORMATION FOR SEQ ID NO: 833:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; US-08-488-551B-833

Query Match      18.8% Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 18;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1749 CATCATTC 1757
Db      10 CATCATTC 2

RESULT 30
US-08-488-551B-834/c
; Sequence 834, Application US/08488551B
; Patent No. 6015661
; GENERAL INFORMATION:
; APPLICANT: Nicholas J. Deacon
; APPLICANT: Dale A. McPhee
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 841
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
; STREET: 400 GARDEN CITY PLAZA
; CITY: GARDEN CITY
; STATE: NEW YORK
; COUNTRY: U.S.A.
; ZIP: 11530-0299
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/488,551B
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PM3864 (AU)
; FILING DATE: 14-FEB-1994
; APPLICATION NUMBER: PM4002 (AU)
; FILING DATE: 21-FEB-1994
; APPLICATION NUMBER: PM0284 (AU)
; FILING DATE: 23-DEC-1994
; APPLICATION NUMBER: US 08/388,353
; FILING DATE: 14-FEB-1995
; APPLICATION NUMBER: PM3021/95
```

FILING DATE: 17-MAY-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: FRANK S. DIGIGLIO  
REFERENCE/DOCKET NUMBER: 96062  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (516) 742-4343  
TELEFAX: (516) 742-4366  
INFORMATION FOR SEQ ID NO: 834:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 10 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA  
US-08-488-551B-834

Query Match 18.8%; Score 9; DB 1; Length 10;  
Best Local Similarity 100.0%; Pred. No. 18;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 CATCATTC 1757  
Db 9 CATCATTC 1

RESULT 31  
US-08-618-834C-17/c  
Sequence 17, Application US/08618834C  
Patent No. 6361937  
GENERAL INFORMATION:  
APPLICANT: Stryer, Lubert  
TITLE OF INVENTION: Computer-Aided Nucleic Acid  
TITLE OF INVENTION: Sequencing  
NUMBER OF SEQUENCES: 54  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Rittler, Van Pelt & Yi LLP  
STREET: 4906 El Camino Real, Suite 205  
CITY: Los Altos  
STATE: CA  
COUNTRY: USA  
ZIP: 94022  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/618,834C  
FILING DATE: 19-MAR-1996  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER:  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: Rittler, Michael J.  
REGISTRATION NUMBER: 36,653  
REFERENCE/DOCKET NUMBER: AFYP002  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 650-903-3500  
TELEFAX: 650-903-3501  
INFORMATION FOR SEQ ID NO: 17:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 10 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-618-834C-17

Query Match 18.8%; Score 9; DB 1; Length 10;  
Best Local Similarity 100.0%; Pred. No. 18;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1720 TGATGTTGA 1728

Db 9 TGATGTTGA 1

RESULT 32  
US-08-618-834C-54/c  
Sequence 54, Application US/08618834C  
Patent No. 6361937  
GENERAL INFORMATION:  
APPLICANT: Stryer, Lubert  
TITLE OF INVENTION: Computer-Aided Nucleic Acid  
TITLE OF INVENTION: Sequencing  
NUMBER OF SEQUENCES: 54  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Rittler, Van Pelt & Yi LLP  
STREET: 4906 El Camino Real, Suite 205  
CITY: Los Altos  
STATE: CA  
COUNTRY: USA  
ZIP: 94022  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/618,834C  
FILING DATE: 19-MAR-1996  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER:  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: Rittler, Michael J.  
REGISTRATION NUMBER: 36,653  
REFERENCE/DOCKET NUMBER: AFYP002  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 650-903-3501  
TELEFAX: 650-903-3501  
INFORMATION FOR SEQ ID NO: 54:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 10 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-618-834C-54

Query Match 18.8%; Score 9; DB 1; Length 10;  
Best Local Similarity 100.0%; Pred. No. 18;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1720 TGATGTTGA 1728  
Db 10 TGATGTTGA 2

RESULT 33  
US-09-508-753B-21/c  
Sequence 21, Application US/09508753B  
Patent No. 6544736  
GENERAL INFORMATION:  
APPLICANT: Akira SHIMAMOTO  
APPLICANT: Yasuhiro FURUICHI  
APPLICANT: Yuko SHIBATA  
APPLICANT: Hiroko FUNAKI  
APPLICANT: Eiji OHARA  
APPLICANT: Masanori WATAHITI  
TITLE OF INVENTION: Method for Synthesizing cDNA from mRNA sample  
FILE REFERENCE: 00162/HG  
CURRENT APPLICATION NUMBER: US/09/508,753B  
CURRENT FILING DATE: 2000-06-16  
PRIOR APPLICATION NUMBER: JP 9/270324  
PRIOR FILING DATE: 1997-09-18

NUMBER OF SEQ ID NOS: 472  
; SEQ ID NO 21  
; LENGTH: 10  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Primer  
US-09-508-753B-21

Query Match 18.8%; Score 9; DB 1; Length 10;  
Best Local Similarity 100.0%; Pred. No. 18;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1738 CAGAGAAA 1746  
|||||  
Db 9 CAGAGAAA 1

RESULT 34  
US-08-192-942-8  
; Sequence 8, Application US/08192942  
; Patent No. 5989906  
; GENERAL INFORMATION:  
; APPLICANT: JAMES D. THOMPSON  
; TITLE OF INVENTION: METHOD AND REAGENT FOR  
; TITLE OF INVENTION: INHIBITING P-GLYCOPROTEIN mdr-  
; NUMBER OF SEQUENCES: 1 GENE  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 611 West Sixth Street  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: USA  
; ZIP: 90017  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb storage  
; COMPUTER: IBM COMPATIBLE  
; OPERATING SYSTEM: IBM P.C. DOS (Version 5.0)  
; SOFTWARE: WordPerfect (Version 5.1)  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/192,942  
; FILING DATE:  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/07/882,885  
; FILING DATE:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard J.  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 197/173  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 8:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 11  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; US-08-192-942-8  
Query Match 18.8%; Score 9; DB 1; Length 11;  
Best Local Similarity 88.9%; Pred. No. 20;  
Matches 8; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
QY 1740 GGAGAAATG 1748  
|||||  
Db 1 GGAGAAATG 9  
RESULT 35

US-08-646-695-15  
; Sequence 15, Application US/08646695  
; Patent No. 6168943  
; GENERAL INFORMATION:  
; APPLICANT: Rose, John K.  
; TITLE OF INVENTION: RECOMBINANT VESICULOVIRUSES AND THEIR  
; NUMBER OF SEQUENCES: 44  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: PENNIE & EDMONDS  
; STREET: 1155 Avenue of the Americas  
; CITY: New York  
; STATE: New York  
; COUNTRY: USA  
; ZIP: 10036-2711  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/646,695  
; FILING DATE: On Even Date Herewith  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Mastrock, S. Leslie  
; REGISTRATION NUMBER: 18,872  
; REFERENCE/DOCKET NUMBER: 6523-008  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (212) 790-9090  
; TELEFAX: (212) 869-9741/8864  
; TELEX: 66141 PENNIE  
; INFORMATION FOR SEQ ID NO: 15:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 11 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: unknown  
; MOLECULE TYPE: RNA  
; US-08-646-695-15

Query Match 18.8%; Score 9; DB 1; Length 11;  
Best Local Similarity 100.0%; Pred. No. 20;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1738 CAGAGAAA 1746  
|||||  
Db 2 CAGAGAAA 10

RESULT 36  
PCT-US96-06053-15  
; Sequence 15, Application PC/TUS9606053  
; GENERAL INFORMATION:  
; APPLICANT: Yale University  
; TITLE OF INVENTION: RECOMBINANT VESICULOVIRUSES AND THEIR  
; NUMBER OF SEQUENCES: 41  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: PENNIE & EDMONDS  
; STREET: 1155 Avenue of the Americas  
; CITY: New York  
; STATE: New York  
; COUNTRY: USA  
; ZIP: 10036-2711  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: PCT/US96/06053  
; FILING DATE: 01-MAY-1996

```
/ CLASSIFICATION:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Mistrock, S. Leslie
/ REGISTRATION NUMBER: 18,872
/ REFERENCE/DOCKET NUMBER: 6523-009-228
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (212) 790-9090
/ TELEFAX: (212) 869-9741/8864
/ TELEK: 66141 PENNIE
/ INFORMATION FOR SEQ ID NO: 15:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 11 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: unknown
/ MOLECULE TYPE: RNA
/ PCT-US96-06053-15

Query Match      18.8%; Score 9; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1738 CAGCAGAAA 1746
Db      2 CAGCAGAAA 10

RESULT 37
US-08-173-489C-256/C
/ Sequence 256, Application US/08173489C
/ Patent No. 5861244
/ GENERAL INFORMATION:
/ APPLICANT: WANG, C. -G.
/ APPLICANT: HERBURN, A. G.
/ TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
/ TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
/ NUMBER OF SEQUENCES: 365
/ CORRESPONDENCE ADDRESSES:
/ ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
/ STREET: 510 EAST 73RD STREET,
/ CITY: NEW YORK
/ STATE: NEW YORK
/ COUNTRY: USA
/ ZIP: 10021.
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5 inch, 1.44mb storage
/ OPERATING SYSTEM: MS-DOS version 6.2
/ SOFTWARE: Wordperfect Version 5.1
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/173,489C
/ FILING DATE: 22 DEC 1993
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 07/968,436
/ FILING DATE: 29 OCT 1992
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Handelman, Joseph H.
/ REGISTRATION NUMBER: 26,179
/ REFERENCE/DOCKET NUMBER: U9518-6
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (attorney) (212) 708-1880
/ TELEFAX: (attorney) (212) 246-8959
/ INFORMATION FOR SEQ ID NO: 256:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 12 bases
/ TYPE: nucleic acid
/ STRANDEDNESS: single stranded
/ TOPOLOGY: linear
/ MOLECULE TYPE: other nucleic acid
/ DESCRIPTION: third strand derived from M. luteus
/ DESCRIPTION: 238 region in Seq ID No. 5861244255
/ HYPOTHETICAL: Yes
```

```
/ ANTI-SENSE: NO
/ PUBLICATION INFORMATION:
/ RELEVANT RESIDUES IN SEQ ID NO: 256 :FROM 1 TO 12
US-08-173-489C-256

Query Match      18.8%; Score 9; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1736 GACAGAGA 1744
Db      9 GACAGAGA 1

RESULT 38
US-08-507-032-14
/ Sequence 14, Application US/08507032
/ Patent No. 5989810
/ GENERAL INFORMATION:
/ APPLICANT: Flanagan, William A.
/ APPLICANT: Crabtree, Gerald R.
/ TITLE OF INVENTION: Screening Methods for Immunosuppressive
/ TITLE OF INVENTION: Agents
/ NUMBER OF SEQUENCES: 19
/ CORRESPONDENCE ADDRESSES:
/ ADDRESSEE: William M. Smith
/ STREET: One Market Plaza, Steuart Tower, Suite 2000
/ CITY: San Francisco
/ STATE: California
/ COUNTRY: USA
/ ZIP: 94105
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: floppy disk
/ OPERATING SYSTEM: IBM PC compatible
/ SOFTWARE: PatentIn Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/507,032
/ FILING DATE:
/ CLASSIFICATION:
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US/08/228,944
/ FILING DATE:
/ APPLICATION NUMBER: US 07/749,385
/ FILING DATE: 22-AUG-1991
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Smith, William M.
/ REGISTRATION NUMBER: 30,223
/ REFERENCE/DOCKET NUMBER: 5490A-89
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 415-326-2400
/ TELEFAX: 415-326-2422
/ INFORMATION FOR SEQ ID NO: 14:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 12 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)
/ US-08-507-032-14

Query Match      18.8%; Score 9; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1738 CAGCAGAAA 1746
Db      1 CAGCAGAAA 9

RESULT 39
US-08-862-431-22
/ Sequence 22, Application US/08862431
```

Patent No. 6120994  
GENERAL INFORMATION:  
APPLICANT: TAM, SHUI-PANG  
TITLE OF INVENTION: ANTIOXIDANT RESPONSIVE ELEMENT  
NUMBER OF SEQUENCES: 51  
CORRESPONDENCE ADDRESSES:  
ADDRESSEE: STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.  
STREET: 1100 NEW YORK AVENUE, SUITE 600  
CITY: WASHINGTON  
STATE: DC  
COUNTRY: US  
ZIP: 20005-3934  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/862,431  
FILING DATE: 23-MAY-1997  
CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: Kim, Judith U.  
REGISTRATION NUMBER: 40,679  
REFERENCE/DOCKET NUMBER: 1669, 0020000  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202) 371-2500  
TELEFAX: (202) 371-2540  
INFORMATION FOR SEQ ID NO: 22:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 12 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-862-431-22

Query Match 18.8%; Score 9; DB 1; Length 12;  
Best Local Similarity 100.0%; Pred. No. 21;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1729 GGGAAACAGA 1737  
Db 1 GGGAAACAGA 9

RESULT 40  
US-08-244-087-12/c  
Sequence 12, Application US/08244087  
Patent No. 6610294  
GENERAL INFORMATION:  
APPLICANT: Lederman, Seth  
APPLICANT: Chess, Leonard  
APPLICANT: Yellin, Michael J.  
TITLE OF INVENTION: MURINE MONOCLONAL ANTIBODY (5c8)  
TITLE OF INVENTION: RECOGNIZES A HUMAN GLYCOPROTEIN ON THE SURFACE OF  
TITLE OF INVENTION: T-LIMPHOCYTES, COMPOSITIONS CONTAINING SAME AND METHODS  
TITLE OF INVENTION: OF USE  
NUMBER OF SEQUENCES: 16  
CORRESPONDENCE ADDRESSES:  
ADDRESSEE: Cooper & Dunham  
STREET: 30 Rockefeller Plaza  
CITY: New York  
STATE: New York  
COUNTRY: United States of America  
ZIP: 10112  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/244,087  
FILING DATE:

CLASSIFICATION: 424  
ATTORNEY/AGENT INFORMATION:  
NAME: White, John P.  
REGISTRATION NUMBER: 28,678  
REFERENCE/DOCKET NUMBER: 0575/39757-A-PCT  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (212) 977-9550  
TELEFAX: (212) 664-0525  
TELEX: 422523 COOP UT  
INFORMATION FOR SEQ ID NO: 12:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 12 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: cDNA  
HYPOTHETICAL: NO  
ANTI-SENSE: NO  
US-08-244-087-12

Query Match 18.8%; Score 9; DB 1; Length 12;  
Best Local Similarity 100.0%; Pred. No. 21;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1714 GCTGACTGA 1722  
Db 12 GCTGACTGA 4

RESULT 41  
PCT-US92-09955-12/c  
Sequence 12, Application PC/TUS9209955  
GENERAL INFORMATION:  
APPLICANT: Lederman, Seth  
APPLICANT: Chess, Leonard  
APPLICANT: Yellin, Michael J.  
TITLE OF INVENTION: MURINE MONOCLONAL ANTIBODY (5c8)  
TITLE OF INVENTION: RECOGNIZES A HUMAN GLYCOPROTEIN ON THE SURFACE OF  
TITLE OF INVENTION: T-LIMPHOCYTES, COMPOSITIONS CONTAINING SAME AND METHODS OF  
TITLE OF INVENTION: USE  
NUMBER OF SEQUENCES: 16  
CORRESPONDENCE ADDRESSES:  
ADDRESSEE: Cooper & Dunham  
STREET: 30 Rockefeller Plaza  
CITY: New York  
STATE: New York  
COUNTRY: United States of America  
ZIP: 10112  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: PCT/US92/09955  
FILING DATE: 19921116  
CLASSIFICATION:  
ATTORNEY/AGENT INFORMATION:  
NAME: White, John P.  
REGISTRATION NUMBER: 28,678  
REFERENCE/DOCKET NUMBER: 0575/39757-A-PCT  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (212) 977-9550  
TELEFAX: (212) 664-0525  
TELEX: 422523 COOP UT  
INFORMATION FOR SEQ ID NO: 12:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 12 base pairs  
TYPE: NUCLEIC ACID  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: cDNA  
HYPOTHETICAL: NO

```
ANTI-SENSE: NO
PCT-US92-09955-12

Query Match      18.8%; Score 9; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1714 GCTGACTGA 1722
Db      12 GCTGACTGA 4

RESULT 42
US-09-081-646-601
; Sequence 601, Application US/09081646
; Patent No. 633152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 633152mal and
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081.646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FASTSEQ for Windows Version 3.0
; SEQ ID NO 601
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-601

Query Match      15.4%; Score 7.4; DB 1; Length 15;
Best Local Similarity 88.9%; Pred. No. 41;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1749 CATGCATTC 1757
Db      1 CATGCATTC 9

RESULT 43
US-09-866-108A-8341
; Sequence 8341, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A60MICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
```

```
PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecmca Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8341
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8341

Query Match      14.6%; Score 7; DB 1; Length 17;
Best Local Similarity 66.7%; Pred. No. 46;
Matches 10; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY      1728 AGGGAACAGACAGA 1742
Db      3 AGACATGAGTCAGCA 17

RESULT 44
US-09-866-108A-8342
; Sequence 8342, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A60MICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecmca Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8342
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8342
```

```
Query Match      14.6%; Score 7; DB 1; Length 17;
Best Local Similarity 66.7%; Pred. No. 46;
Matches 10; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY      1728 AGGAGACAGACAGA 1742
Db      2 AGACATCAGTCAGCA 16

RESULT 45
US-09-866-108A-8343
; Sequence 8343, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8343
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8343

Query Match      14.6%; Score 7; DB 1; Length 17;
Best Local Similarity 66.7%; Pred. No. 46;
Matches 10; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY      1728 AGGAGACAGACAGA 1742
Db      1 AGACATCAGTCAGCA 15

RESULT 46
US-09-866-108A-8344
; Sequence 8344, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664

QY      1732 AACAGACAGAGA 1742
Db      4 ATCAGTCAGCA 14

RESULT 47
US-09-866-108A-8345
; Sequence 8345, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
```

PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: Aecomica Sequence Listing Engine  
Patent No. 6686188  
SEQ ID NO 8345  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108A-8345

Query Match 12.9%; Score 6.2; DB 1; Length 17;  
Best Local Similarity 72.7%; Pred. No. 54;  
Matches 8; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1732 AACAGACAGA 1742  
| | | | |  
DB 3 ATCAGTCAGCA 13

RESULT 48  
US-08-388-353-515  
Sequence 515, Application US/08388353  
Patent No. 6010895

GENERAL INFORMATION:

APPLICANT: Deacon, Nicholas J.  
APPLICANT: Learmont, Jennifer C.  
APPLICANT: McPhee, Dale A.  
APPLICANT: Crowe, Suzanne  
APPLICANT: Cooper, David  
TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1  
NUMBER OF SEQUENCES: 800  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Scully, Scott, Murphy & Presser  
STREET: 400 Garden City Plaza  
CITY: Garden City  
STATE: New York  
COUNTRY: United States  
ZIP: 11530

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent in Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/388,353  
FILING DATE: 14-FEB-1995  
CLASSIFICATION: 424  
ATTORNEY/AGENT INFORMATION:  
NAME: Digiglio, Frank S.  
REGISTRATION NUMBER: 31,346  
REFERENCE/DOCKET NUMBER: 9606  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (516) 742-4343  
TELEFAX: (516) 742-4366  
TELEX: 230 901 SANS UR  
INFORMATION FOR SEQ ID NO: 515:

SEQUENCE CHARACTERISTICS:  
LENGTH: 10 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)  
US-08-388-353-515

Query Match 12.1%; Score 5.8; DB 1; Length 10;  
Best Local Similarity 77.8%; Pred. No. 56;  
Matches 7; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1743 GAAATGCAT 1751  
| | | | |  
DB 1 GGAATGCAT 9

RESULT 49  
US-08-488-551B-515

Sequence 515, Application US/08488551B  
Patent No. 6015661

GENERAL INFORMATION:

APPLICANT: Nicholas J. Deacon  
APPLICANT: Dale A. McPhee  
APPLICANT: David Cooper  
TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1  
NUMBER OF SEQUENCES: 841  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER  
STREET: 400 GARDEN CITY PLAZA  
CITY: GARDEN CITY  
STATE: NEW YORK  
COUNTRY: U.S.A.  
ZIP: 11530-0299

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent in Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/488,551B  
FILING DATE: 07-JUN-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: PM3864 (AU)  
FILING DATE: 14-FEB-1994  
APPLICATION NUMBER: PM4002 (AU)  
FILING DATE: 21-FEB-1994  
APPLICATION NUMBER: PM0284 (AU)  
FILING DATE: 23-DEC-1994

APPLICATION NUMBER: US 08/388,353  
FILING DATE: 14-FEB-1995  
APPLICATION NUMBER: PM3021/95  
FILING DATE: 17-MAY-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: FRANK S. DIGIGLIO  
REFERENCE/DOCKET NUMBER: 9606Z  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (516) 742-4343  
TELEFAX: (516) 742-4366  
INFORMATION FOR SEQ ID NO: 515:

SEQUENCE CHARACTERISTICS:

LENGTH: 10 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA  
US-08-488-551B-515

Query Match 12.1%; Score 5.8; DB 1; Length 10;  
Best Local Similarity 77.8%; Pred. No. 56;  
Matches 7; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1743 GAAATGCAT 1751  
| | | | |  
DB 1 GGAATGCAT 9

RESULT 50  
US-08-488-551B-833

Sequence 833, Application US/08488551B  
Patent No. 6015661

GENERAL INFORMATION:  
APPLICANT: Nicholas J. Deacon  
APPLICANT: Dale A. McPhee  
APPLICANT: David Cooper  
TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1  
NUMBER OF SEQUENCES: 841  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER  
STREET: 400 GARDEN CITY PLAZA  
CITY: GARDEN CITY  
STATE: NEW YORK  
COUNTRY: U.S.A.  
ZIP: 11530-0299  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent in Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/488,551B  
FILING DATE: 07-JUN-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: PM3864 (AU)  
FILING DATE: 14-FEB-1994  
APPLICATION NUMBER: PM4002 (AU)  
FILING DATE: 21-FEB-1994  
APPLICATION NUMBER: PM0284 (AU)  
FILING DATE: 23-DEC-1994  
APPLICATION NUMBER: US 08/388,353  
FILING DATE: 14-FEB-1995  
APPLICATION NUMBER: PM3021/95  
FILING DATE: 17-MAY-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: FRANK S. DIGIGLIO  
REFERENCE/DOCKET NUMBER: 9606Z  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (516) 742-4343  
TELEFAX: (516) 742-4366  
INFORMATION FOR SEQ ID NO: 833:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 10 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA  
US-08-488-551B-833

Query Match 12.1%; Score 5.8; DB 1; Length 10;  
Best Local Similarity 77.8%; Pred. No. 56;  
Matches 7; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1743 GAATGCAT 1751  
| | | | |  
| | | | |  
Db 1 GAATGCAT 9

Search completed: July 13, 2004, 11:05:04  
Job time: 0.001 secs

***This Page Blank (uspto)***

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: July 13, 2004, 11:06:28 ; Search time 0.001 Seconds

(without alignments)  
43.488 Million cell updates/sec

Title: us-10-000-213-3

Perfect score: 48  
Sequence: 1 ggctgctgactgattgtgag.....caggagaatgcatccatcc 48

Scoring table: IDENTITY\_NUC  
Gapop 10.0, Gapext 0.5

Searched: 27 seqs, 453 residues

Total number of hits satisfying chosen parameters: 54

Minimum DB seq length: 8  
Maximum DB seq length: 80

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 20 summaries

Database: rnpbdb.\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	20	41.7	20	1	US-10-000-213-53 Sequence 53, Appl
2	20	41.7	20	1	US-10-000-213-54 Sequence 54, Appl
3	20	41.7	20	1	US-10-000-213-55 Sequence 55, Appl
4	20	41.7	20	1	US-10-000-213-56 Sequence 56, Appl
5	14.4	30.0	17	1	US-10-138-674-7673 Sequence 7673, Ap
6	14.4	30.0	17	1	US-10-287-949A-7673 Sequence 23, Appl
7	14.4	30.0	18	1	US-10-327-805-23 Sequence 3026, Ap
8	13.8	28.7	17	1	US-09-740-332-3026 Sequence 3026, Ap
9	13.8	28.7	17	1	US-09-817-879-3026 Sequence 3026, Ap
10	13.8	28.7	17	1	US-10-138-674-7674 Sequence 7674, Ap
11	13.8	28.7	17	1	US-10-287-949A-7674 Sequence 7674, Ap
12	13.4	27.9	16	1	US-10-138-674-5840 Sequence 5840, Ap
13	13.4	27.9	16	1	US-10-287-949A-5840 Sequence 5840, Ap
14	13.4	27.1	17	1	US-09-866-108-8341 Sequence 8341, Ap
15	13.4	27.1	17	1	US-09-866-108-8342 Sequence 8342, Ap
16	13.4	27.1	17	1	US-09-866-108-8343 Sequence 8343, Ap
17	13.4	27.1	17	1	US-09-866-108-8344 Sequence 8344, Ap
18	13.4	27.1	17	1	US-09-866-108-8345 Sequence 8345, Ap
19	12.8	26.7	16	1	US-10-138-674-5841 Sequence 5841, Ap
20	12.8	26.7	16	1	US-10-287-949A-5841 Sequence 5841, Ap

## ALIGNMENTS

RESULT 1  
US-10-000-213-53/c  
; Sequence 53, Application US/10000213  
; Publication No. US20030125271A1  
; GENERAL INFORMATION:  
; APPLICANT: Brenda F. Baker  
; APPLICANT: Mark P. Roach  
; APPLICANT: Kenneth Doble

TITLE OF INVENTION: ANTISENSE MODULATION OF VITAMIN D NUCLEAR RECEPTOR EXPRESSION  
FILE REFERENCE: RTS-0327  
CURRENT APPLICATION NUMBER: US/10/000,213  
CURRENT FILING DATE: 2001-11-14  
NUMBER OF SEQ ID NOS: 94  
SEQ ID NO 53  
LENGTH: 20  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Antisense Oligonucleotide  
US-10-000-213-53

Query Match 41.7%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 3.2;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Db 1710 GGCTGCTGACTGATGTTGAG 1729  
20 GGCTGCTGACTGATGTTGAG 1

RESULT 2  
US-10-000-213-54/c  
; Sequence 54, Application US/10000213  
; Publication No. US20030125271A1  
; GENERAL INFORMATION:  
; APPLICANT: Brenda F. Baker  
; APPLICANT: Mark P. Roach  
; APPLICANT: Kenneth Doble  
TITLE OF INVENTION: ANTISENSE MODULATION OF VITAMIN D NUCLEAR RECEPTOR EXPRESSION  
FILE REFERENCE: RTS-0327  
CURRENT APPLICATION NUMBER: US/10/000,213  
CURRENT FILING DATE: 2001-11-14  
NUMBER OF SEQ ID NOS: 94  
SEQ ID NO 54  
LENGTH: 20  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Antisense Oligonucleotide  
US-10-000-213-54

Query Match 41.7%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 3.2;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1722 ATGTTGAGGGAACAGACAGG 1741  
Db 20 ATGTTGAGGGAACAGACAGG 1

RESULT 3  
US-10-000-213-55/c  
; Sequence 55, Application US/10000213  
; Publication No. US20030125271A1  
; GENERAL INFORMATION:  
; APPLICANT: Brenda F. Baker  
; APPLICANT: Mark P. Roach  
; APPLICANT: Kenneth Doble  
TITLE OF INVENTION: ANTISENSE MODULATION OF VITAMIN D NUCLEAR RECEPTOR EXPRESSION  
FILE REFERENCE: RTS-0327  
CURRENT APPLICATION NUMBER: US/10/000,213  
CURRENT FILING DATE: 2001-11-14  
NUMBER OF SEQ ID NOS: 94  
SEQ ID NO 55  
LENGTH: 20  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Antisense Oligonucleotide  
US-10-000-213-55

Query Match 41.7%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 3.2;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1730 GGACAGACGAGGAAATGC 1749  
DB 20 GGACAGACGAGGAAATGC 1

## RESULT 4

US-10-000-213-56/c  
; Sequence 56, Application US/10000213  
; Publication No. US20030125271A1  
; GENERAL INFORMATION:  
; APPLICANT: Brenda F. Baker  
; APPLICANT: Mark P. Roach  
; APPLICANT: Kenneth Doble  
; TITLE OF INVENTION: ANTISENSE MODULATION OF VITAMIN D NUCLEAR RECEPTOR EXPRESSION  
; FILE REFERENCE: RTS-0327  
; CURRENT APPLICATION NUMBER: US/10/000,213  
; CURRENT FILING DATE: 2001-11-14  
; NUMBER OF SEQ ID NOS: 94  
; SEQ ID NO 56  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-000-213-56

Query Match 41.7%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 3.2;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1738 CAGGAGAAATGCATCCATTC 1757  
DB 20 CAGGAGAAATGCATCCATTC 1

## RESULT 5

US-10-138-674-7673  
; Sequence 7673, Application US/10138674  
; Publication No. US20040077565A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Payco, Pam  
; APPLICANT: MCSwigen, Jim  
; APPLICANT: Scinchoomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to the Growth of Endothelial Cells  
; FILE REFERENCE: MHB00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/138,674  
; CURRENT FILING DATE: 2002-05-03  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: Patent version 3.0  
; SEQ ID NO 7673  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-138-674-7673

Query Match 30.0%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 62.5%; Pred. No. 9.1;  
Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 1715 CTGACTGATGTTGAGG 1730  
DB 2 CUGAGUGAUGUGAGG 17

RESULT 6  
US-10-287-949A-7673

; Sequence 7673, Application US/10287949A  
; Publication No. US20040102389A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Payco, Pam  
; APPLICANT: MCSwigen, Jim  
; APPLICANT: Scinchoomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to the Growth of Endothelial Cells  
; FILE REFERENCE: MHB00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/287,949A  
; CURRENT FILING DATE: 2003-04-11  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: Patent version 3.0  
; SEQ ID NO 7673  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-287-949A-7673

Query Match 30.0%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 62.5%; Pred. No. 9.1;  
Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 1715 CTGACTGATGTTGAGG 1730  
DB 2 CUGAGUGAUGUGAGG 17

## RESULT 7

US-10-327-805-23/c  
; Sequence 23, Application US/10327805  
; Publication No. US20030144241A1  
; GENERAL INFORMATION:  
; APPLICANT: Brett P. Monia  
; APPLICANT: Lex M. Cowser  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SMAD6 EXPRESSION  
; FILE REFERENCE: RTS-0045  
; CURRENT APPLICATION NUMBER: US/10/327,805  
; CURRENT FILING DATE: 2002-12-20  
; PRIOR APPLICATION NUMBER: US/09/679,298  
; PRIOR FILING DATE: 2001-03-05  
; NUMBER OF SEQ ID NOS: 47  
; SEQ ID NO 23  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-327-805-23

Query Match 30.0%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 10;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1723 TGTGAGGAGACGAC 1738  
DB 18 TGTGAGGAGACGAC 3

## RESULT 8

US-09-740-332-3026  
; Sequence 3026, Application US/09740332  
; Publication No. US20030125270A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Scinchoomb, Dan  
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to the Growth of Endothelial Cells  
; FILE REFERENCE: RPI 400/003  
; CURRENT APPLICATION NUMBER: US/09/740,332  
; CURRENT FILING DATE: 2001-03-26  
; NUMBER OF SEQ ID NOS: 9704

```
SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3026.
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-3026
```

```
Query Match      28.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 10;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1714 GCTGACTGATGTTGAGG 1730
DB      1 GCUGAGUGAGUGGUGAGG 17
```

```
RESULT 9
US-09-817-879-3026
; Sequence 3026, Application US/09817879
; Publication No. US2003017131A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MHB00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3026
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-3026
```

```
Query Match      28.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 10;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1714 GCTGACTGATGTTGAGG 1730
DB      1 GCUGAGUGAGUGGUGAGG 17
```

```
RESULT 10
US-10-138-674-7674
; Sequence 7674, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: MCSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7674
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
```

```
US-10-138-674-7674
```

```
Query Match      28.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 10;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1716 TGACTGATGTTGAGGA 1732
DB      1 UGAGUGAGUGUGAGGA 17
```

```
RESULT 11
US-10-287-949A-7674
; Sequence 7674, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: MCSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7674
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-7674
```

```
Query Match      28.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 10;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1716 TGACTGATGTTGAGGA 1732
DB      1 UGAGUGAGUGUGAGGA 17
```

```
RESULT 12
US-10-138-674-5840
; Sequence 5840, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: MCSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5840
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-5840
```

```
Query Match      27.9%; Score 13.4; DB 1; Length 16;
Best Local Similarity 60.0%; Pred. No. 10;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      1715 CTGACTGATGTTGAG 1729
DB      2 CUGAGUGAGUGUGAG 16
```

```
RESULT 13
US-10-287-949A-5840
; Sequence 5840, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: MCSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH900-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5840
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-5840

Query Match          27.9%; Score 13.4; DB 1; Length 16;
Best Local Similarity 60.0%; Pred. No. 10;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY      1715 CTGCTGACTGATGTGAG 1729
Db      2 CUGAGUGAUGUGUGAG 16
|||||:|:|:|:|:|:|
|:|:|:|:|:|:|:|:|

RESULT 14
US-09-866-108-8341/C
; Sequence 8341, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: UT, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David R.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
```

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8341
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8341

Query Match          27.1%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1713 TGCTGACTGATGT 1725
Db      17 TGCTGACTGATGT 5
|||||:|:|:|:|:|:|
|:|:|:|:|:|:|:|:|

RESULT 15
US-09-866-108-8342/C
; Sequence 8342, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: UT, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David R.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8342
```

LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108-8342

Query Match 27.1%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 13;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1713 TGCTGACTGATGT 1725  
Db 16 TGCTGACTGATGT 4

RESULT 15  
US-09-866-108-8343/C  
Sequence 8343, Application US/09866108  
Patent No. US20020048800A1  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharon G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: AEOMICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00662  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00661  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00670  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: US 60/234,687  
PRIOR FILING DATE: 2000-09-21  
PRIOR APPLICATION NUMBER: US 60/266,860  
PRIOR FILING DATE: 2001-02-05  
NUMBER OF SEQ ID NOS: 15752  
SOFTWARE: Aecmca Sequence Listing Engine  
SEQ ID NO 8343  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108-8343

Query Match 27.1%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 13;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1713 TGCTGACTGATGT 1725

Db 15 TGCTGACTGATGT 3

RESULT 17  
US-09-866-108-8344/C  
Sequence 8344, Application US/09866108  
Patent No. US20020048800A1  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharon G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: AEOMICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00662  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00661  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00670  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: US 60/234,687  
PRIOR FILING DATE: 2000-09-21  
PRIOR APPLICATION NUMBER: US 60/266,860  
PRIOR FILING DATE: 2001-02-05  
NUMBER OF SEQ ID NOS: 15752  
SOFTWARE: Aecmca Sequence Listing Engine  
SEQ ID NO 8344  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108-8344

Query Match 27.1%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 13;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1713 TGCTGACTGATGT 1725  
Db 14 TGCTGACTGATGT 2

RESULT 18  
US-09-866-108-8345/C  
Sequence 8345, Application US/09866108  
Patent No. US20020048800A1  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong

```
; APPLICANT: Ji, Yongsang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A60MICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 8345
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8345

Query Match      27.1%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1713 TCGTGACTGATGT 1725
DB      13   TCGTGACTGATGT 1

RESULT 19
US-10-138-674-5841
; Sequence 5841, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
```

```
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5841
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-5841

Query Match      26.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 62.5%; Pred. No. 12;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY      1717 GACTGATGTTGAGGGA 1732
DB      1   GAGUGAUGUUGAGGAA 16

RESULT 20
US-10-287-949A-5841
; Sequence 5841, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5841
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-5841

Query Match      26.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 62.5%; Pred. No. 12;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY      1717 GACTGATGTTGAGGGA 1732
DB      1   GAGUGAUGUUGAGGAA 16

Search completed: July 13, 2004, 11:06:29
Job time : 1 secs
```